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Abstract:  
Cancer is an abnormal chronic inflammation and still remains a significant cause of 
morbidity and mortality with more than 10 million new cases per year. Dietary 
neutraceuticals along with recent innovations in genetic engineering could be used as an 
alternative therapeutic strategy to overcome adverse side effects imposed by 
chemotherapeutics. 100% iron saturated multi-functional, anti-cancer bovine lactoferrin (Fe-
bLf) and dominant negative survivin (Sur R9-C84A) are such proteins which are recently 
proved to be anti-cancerous. Nevertheless, short plasma half lives of bio-molecules like these 
demand painful infusions over a short time periods, an issue was tried to address by using 
nanotechnology. Moreover, oral delivery of these therapeutic proteins could be made possible 
by using bio-degradable nanoformulations utilizing the advantages of bio ceramic/polymeric 
combinations. Also, nano structures could have better uptake in tumour vasculature based on 
the enhanced permeability and retention effect. Thus, the hypothesis examining the ability of 
these nanoformulations not only to conserve the native configuration of these bio-active 
proteins but to also entail their tumour specific delivery can therefore be studied.  
This study demonstrated the formulation of a novel alginate enclosed, chitosan coated 
ceramic anti-cancer nanocarriers (ACSC NCs) designed to aid as an additional protective 
system towards gastrointestinal sustainability of these fragile biomacromolecules. These NCs 
were loaded with Fe-bLf along with Sur R9-C84A in order to develop a novel platform to 
carry anti-cancer proteins and/or peptides for oral therapy.  Thus, ACSC NCs carrying Fe-
bLf, Sur R9-C84A or a combination of both were prepared by using nanoprecipitation and 
ionic gelation methods. Size, morphology, internalization, gastrointestinal sustainability 
profiles and in vitro protein release of the NCs under varying pH – were determined for all 
three combinations of NCs. Cytotoxicity of the Fe-bLf/Sur R9-C84A loaded NCs was studied 
in colon and breast cancer cell lines. Cellular uptake of these NCs in vitro in colon/breast 
cancer lines was analyzed, by measuring the endocytosis and transcytosis.  
Additionally, the study examined the enhanced anti-cancer efficacy, bio-activity and tissue 
distribution of orally fed nanoformulated Fe-bLf in vivo as an extension of a previous study 
performed in our lab.  A diet containing Fe-bLf loaded NCs was given to the experimental 
nude (C57BL 6 nu/nu) mice and the mice were subsequently challenged with xenogenic 
(human colon and breast cancer cells) tumours.  To be able to investigate the possible route 
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for the internalization of the NCs and their apoptotic efficacy, real time analysis of the genes 
involved in the internalization pathways and pro/anti-apoptotic mRNA were analyzed. 
Electron microscopy and dynamic light scattering (DLS) results showed sphericity of the 
NCs with a size of 205 ± 15 nm for the CSC inner core and increased to 322 ± 27.2 nm after 
enclosing with alginate in order to form a final ACSC NCs. SDS PAGE followed by Western 
blotting, using specific antibodies against bLf confirmed the structural integrity of the protein 
after the nanoformulation; X-ray diffraction studies indicated amorphous properties of the 
NCs. Confocal microscopy and Flow cytometry determined the qualitative and quantitative  
internalization of rhodamine labeled NCs, upon treating the two cancer cell lines. Entrapped 
protein in the NCs enhanced their cellular uptake by around 3 fold compared to control/void 
NCs without protein. For example, void NCs have showed 25.1 ± 3.7% internalization in 1 h 
where as Sur R9-C84A loaded [55.4 ± 1.6% (P<0.05)]; Fe-bLf alone loaded [58.6 ± 6.0% 
(P<0.05)] and a combination of Fe-bLf and Sur R9-C84A [64.3 ± 4.6% (P<0.05)] have 
shown increased uptake. In vitro cytotoxic and cell proliferation assays have established an 
improved anti-cancer efficacy of the proteins upon nano encapsulation. Transcytosis studies 
have shown that the NCs cross the membrane with no/minimal damage to the Caco-2 cell 
monolayer as a confirmation of endocytic and transcytotic mechanisms. 
Furthermore, superior anti-tumour efficiency and nano toxicity was measured in vivo in nude 
mice bearing xenogeneic tumours.  Mice pre-treated with a diet containing the NCs were 
observed to reject the tumours induced with colon and breast cancer cell lines (Caco-2 and 
MDA-MB-231) derived from human origin. Histopathological and immunohistochemical 
studies demonstrated the desired internalization of nanoparticles in tumour tissues without 
any nanotoxicity. Real time PCR analysis indicated an over expression of  transferrin 
receptors (Tfr) and low density lipoprotein binding  receptors (LRP) specific to lactoferrin 
along with transferrin receptors, as an indication of a possible route of internalization. Anti-
apoptotic genes such as survivin and B-cell lymphoma (Bcl) family of genes were found to 
be down regulated with treatment of the NCs, whereas up regulation of pro apoptotic Bax, 
FAS and the executors such as caspase 3 indicated promotion of apoptosis in the tumours by 
the NCs.   
Taken together, the data from this study suggest for the first time that the ACSC NCs system 
is efficient in encapsulation of the bio-molecular drugs Fe-bLf/SurR9-C84A by maintaining 
their bio-activity and significantly enhancing their anti-cancer efficacy. Nano encapsulation 
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of proteins further improved the cellular internalization of the NCs. Fe-bLf delivered as an 
oral nanoformulation offers enhanced anti-tumorigenicity. No signs of nanotoxicity or 
biodistribution in RES organs confirmed the biodegradability of the NCs. Herein, as a proof 
of concept, the NCs were successfully tested in colon and breast cancer neoplasms, this 
principle could be extended for other solid tumours. Nevertheless, the NCs could be used to 
extend for the cure of difficult to treat malignancies. Future experiments related to insights of 
up/down regulation of angiogenic mediators and inhibitors could suggest a clear mechanistic 
view of the anti-cancerous nature of these novel nanocarriers. 
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Chapter 1: Introduction  
1.1 Foundations and background of the proposed study   
A Greek physician, Hippocrates (460-370 BC), was the founder of the word “cancer”. He is 
regarded as the “Father of Medicine”; Greek words carcinos and carcinoma (literally 
meaning crab) were the original words used to describe cancer. Non- ulcer forming and ulcer 
forming tumours were named as carcinos, based on the similarity in their structure with the 
crab in having finger like, spreading projections. Later, a Roman physician Celsus (28-50 
BC), translated the Greek term into cancer, which was the Latin word for crab. The word 
oncos (swelling in Greek) was introduced by another Roman physician, Galen (Sung et al., 
2011). 
Carcinogenesis is a multi step process, caused by combination of environmental and genetic 
factors, leading to a series of changes occurring at various stages in the development and 
progression of the disease (Aznavoorian et al., 1993). Cancer cells arise from a single 
transformed cell, which has undergone genetic and epigenetic changes. Thus, the cancerous 
state is a result of several sequential events triggered by various factors including genetic 
predispositions, transformation by viruses, radiation and/or by certain chemicals. Many 
genetic and cytoplasmic events including de activation of tumour suppressor genes such as 
P53 or Rb, triggers various events leading to cancer (Harris and Levine, 2005). Tumour 
invasion and metastasis is one of the major causes of treatment failure in cancer patients. 
Tumour cells have a capacity to generate new blood vessels by using pre-existing 
endothelium and/or endothelial precursor cells, through a process known as angiogenesis 
(Folkman, 1995, Cavallaro and Christofori, 2000), which in turn involves implication of 
complex and diverse actions such as extracellular matrix degradation, proliferation and 
migration of endothelial cells and morphological differentiation of endothelial cells to form 
tubes. A range of factors including various growth factors, cytokines, lipid metabolites and 
cryptic fragments of homeostatic proteins are known to be involved in angiogenesis (Haas et 
al., 2000). 
Conventional and new generation chemotherapy for cancer treatment has its own 
disadvantages in eradicating the cancer.  Although chemotherapy improves disease-free and 
overall survival in cancer patients, it involves a number of side effects during the course of 
the treatment or after the completion (Love et al., 1989). The adverse effects such as 
neuropathy and fatigue that occur during the treatment are regarded to be short term effects 
whereas the long term effects include leukemia and cognitive dysfunction (Partridge et al., 
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2001, Shapiro and Recht, 2001). Chemotherapeutics that are derived from anthracyclines 
were reported to impose severe problems such as congestive heart failure, ventricular 
tachycardia, and sudden death (Broeyer et al., 2008). A majority of chemotherapeutics are 
poorly soluble in water due to hydrophobic properties and the solvents used in their 
formulation can induce toxic responses, such as hypersensitivity and peripheral neuropathy, 
as well as reducing the extent of drug delivery to tumour (Yamamoto et al., 2011). In this 
regard, bio macromolecular therapy has gained attention as a safe approach (Kanwar et al., 
2010b, Kanwar et al., 2011b). Also, use and demand of herbal extracts and natural 
supplements among the cancer patients is very high. Significant developments in the area of 
cancer chemoprevention have been carried out in the recent past over the identification and 
characterization of the anti-cancer properties of natural products (Johnson, 2011, Johnson et 
al., 2010). Complications of parenteral administration routes such as thrombophlebitis or 
tissue necrosis and patient compliance have stimulated the investigation of non-parenteral 
routes. Among non-parenteral routes, oral administration is usually preferred because it is 
non-invasive, most acceptable and convenient for the patient as it requires no skilled worker 
for injection of drugs (Ranade, 1991). In recent times, the use of nanotechnology was found 
to be capable of minimizing the drug-induced adverse effects in experimental animals as well 
as in clinical trials during a treatment regime. Nanotechnology allows the targeted delivery of 
the therapeutics to the cancer cells with lower dosages. More interestingly, besides its 
advantages such as sustained delivery, the use of nanotechnology also promises the 
administration of fragile drugs to the subjects via the oral route (Soares et al., 2007, Kanwar 
et al., 2011a). 
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1.2 Significance of the study - hypothesis and research question 
Previous reports have suggested a synergistic anti-tumour effect of 100% iron saturated bLf 
(Fe-bLf) fed orally along with the monotherapy of the chemotherapeutics or in a combination 
of two chemotherapeutics, to prevent tumorigenesis (Kanwar et al., 2008). Similarly, a 
dominant negative mutant form (Cys 84 to Ala in the BIR domain) of survivin was shown to 
block the endogenous levels of survivin function by competitive inhibition there by 
promoting apoptosis in cancer cells (Kanwar et al., 2001b). It has also been shown in the 
prostate and cervical cancer cells grown in 3D culture that, antagonism of wild type survivin 
function promotes the apoptosis (Cheung et al., 2010a). Lower half lives and rapid renal 
clearance of proteins imposes development of new strategies for enhanced bioavailability. In 
this regard, this study used the advances in nanotechnology to design an oral delivery 
platform for encapsulation of Fe-bLf/ Sur R9-C84A. 
The hypothesis of the study is that Fe-bLf or Sur R9-C84A will act more efficiently as anti-
cancerous agents in vitro at lower dosage in a nanoencapsulated form as compared to their 
native forms.  
The oral route remains to be most challenging but convenient route for drug administration, 
in terms of full control over administration by the patient and needle free, non-invasive 
therapy. Biologically sensitive proteins have been tried with nanotechnology to be able to 
achieve safe and effective delivery via the gastrointestinal tract. Recently, most acceptable 
oral delivery of bio-active protein molecules like insulin, heparin, budesonide, leuprolide and 
gastric enzymes have been tried using polymeric nanoparticles (Section 2.16). Limitations 
for these formulations include 
Furthermore, the feasibility of the most challenging oral delivery in vivo, in the xenograft 
cancer (nude mice) models could be possible by using bio-degradable NCs and Fe-bLf alone 
act as an anti-tumour agent irrespective of the chemotherapeutics used.   
i) Particles with higher sizes tend to settle in the blood vessels if entry in to the systemic 
circulation occurs – they could be more efficient if the size is reduced below 500nm.  
ii) There are less chances of protecting a drug moiety with only one polymeric layer around it 
- if the number of polymeric layers increased with varying chemistry, the polymers could 
protect the entrapped drug more efficiently. 
In this regard, the present study was aimed to develop an oral nanodelivery system using a 
combination of biodegradable ceramics and polymers encapsulating Fe-bLf/ SurR9-C84A. 
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Nanoprecipitation and ionic gelation techniques were used in order to form an alginate 
enclosed chitosan coated calcium phosphate ceramic nanocarriers (ACSC NCs) encapsulating 
these therapeutic proteins.  
Thus, the question arises regarding the bioactivity of anti-cancerous proteins (Fe-bLf/ Sur 
R9-C84A) after their entrapment in the calcium phosphate, chitosan and alginate using the 
aforementioned nanoformulation methods
To solve this puzzle, this study focused in understanding 3 possible fates of the NCs 
. 
1. Bio-activity of the encapsulated therapeutic Fe-bLf/ Sur R9-C84A proteins after the 
formulation procedure 
2. Enhancement of cellular internalization and/or anti-cancer efficacy of the NCs loaded 
with therapeutic proteins and 
3. Evaluation of the proposed in vivo anti-tumour efficacy, nanotoxicity and enhanced 
permeability and retention efficacy 
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1.3 Aims and objectives  
Targeting angiogenesis and further promotion of apoptosis in cancer could be an effective 
strategy for designing an ideal therapeutic for tumour inhibition. The two model proteins Fe-
bLf and Sur R9-C84A used in this study were investigated towards the inhibition of 
tumorigenesis. More importantly, multi functional nature of these proteins found to have no 
diverse effects in normal cell physiology, which would reduce the side effects.  
Specific intervention of Inhibitors of Apoptosis (IAP) family proteins has the ability to 
promote apoptosis and further cell death in cancer cells. Important members of the IAP 
family, livin and survivin are presented to the immune system in a similar mechanism, which 
further ads up to their possible synergistic control over the apoptotic inhibition (Yagihashi et 
al., 2005b). At the molecular level, survivin is a unique member of IAP family members that 
can protect the cells from death by inhibiting the caspases (Kanwar et al., 2001a). Thus, 
survivin inhibitors have grabbed attention of researchers as survivin expression is high in 
tumours and not detectable in normal differentiated tissues (Li, 2003). BIR motif mutant Sur 
R9-C84A has the unique ability amongst the different mutants of survivin in the sense that it 
has the ability to localize to the microtubule organizing centre, undistinguished from the wild 
type survivin (Li et al., 1998). This mutant has previously been studied to decrease the 
tumour growth in EL-4 thymic lymphoma cells and has implications in inducing apoptosis 
(Kanwar et al., 2001b) and also in prostate and cervical cancer cells (Cheung et al., 2010a). In 
the later study, authors have shown that SurR9-C84A act synergistically with the 
proapoptotic effects imposed by TNF α by enhancing caspase 8 activity. Nevertheless, these 
two studies have employed intra tumoural injections of plasmids or protein form of SurR9-
C84A, while in the present study an attempt was made to be able to make much desired oral 
therapy by incorporating the protein into the proposed ACSC NCs (Section 1.2).  
On the other hand, lactoferrin was found to act as anti-cancer agent by acting as an 
immunomodulatory, anti-angiogenic as well as anti-apoptotic agent (Kanwar and Kanwar, 
2011). In this regard, bLf was found to potentiate the expression of interleukins to increase 
NK, Tc cells for immunomodulation (Takakura et al., 2006). In combination with TNF, bLf 
decreases the αvβ3-dependent endothelial cell adhesion and survival and disrupts the tumour 
vasculature (Mader et al., 2006). It was shown that lactoferrin enhances anti-apoptotic 
activity by modulation of apoptosis related genes such as TNF-α, Bcl-2, Bcl-xL, Bax, Bid in 
the colon of azoxymethane treated rats (Fujita et al., 2004). When these studies were taken 
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together, similar lines could be drawn for the functional mechanism of action, in case of both 
Fe-bLf and Sur R9-C84A, in the inhibition of angiogenesis and target the endogenous wild 
type survivin. Hence, it is tempting to use a combination of both in eradicating tumours. 
Thus, in vitro anti-tumour efficacy of Sur R9-C84A and Fe-bLf was tested after 
encapsulating them in the ACSC NCs. 
The main aim of this thesis was to evaluate anti-tumour efficacy of nanoencapsulated Fe-bLf 
in vivo in the nude mice bearing tumours from human origin. Previous studies have shown 
that full occupancy of iron in the metal binding pockets in the N and C lobes of bLf 
determines the anti-tumour efficacy of the protein (Kanwar et al., 2008). This particular 
phenomenon was attributed to the bio-availability and increased resistance to degradation in 
the digestive tract in the case of Fe-bLf. Several studies have supported the resistibility of Fe-
bLf over 20% iron saturated Lf or the Apo (iron free) form of bLf in the digestive tract 
because of the iron content (Troost et al., 2001, Kanwar et al., 2008). However, to be able to 
reach the tumour site, Fe-bLf needs additional protection, which was addressed in this study 
by incorporating the therapeutic protein in to ACSC NCs. Thus, this hypothetical 
phenomenon of the nano-entrapping the therapeutic protein has shown a significant anti-
cancer efficacy in vitro and in vivo. Previous data based on the in vitro studies showed 
enhanced anti-cancer ability of these NCs with low doses of Fe-bLf, than that of the free 
protein (Mahidhara et al., 2011 ). When Fe-bLf alone was administered orally, it abrogated 
tumorigenesis by enhancing anti-tumour immunity via the production of IFN-γ and 
interleukin -18 (Kanwar et al., 2008). This attributed to the activation of CD4+ and CD8+ T 
cells and NK cells by IL-18 and the production of IFN-γ, which further acts as anti-tumour 
agent in combination with TNF. Consequently, Fe-bLf alone could act as an anti-cancer agent 
provided the structure was conserved during the gastro intestinal absorption. Therefore, the 
natural bLf, Sur R9-C84A, Fe-bLf proteins were made more bio-active by means of 
nanoencapsulation in the aforementioned ceramic NCs. Moreover, enhanced anti-tumour 
efficacy after the entrapment of the proteins in the NCs and the conservation of bio-
activeness of the protein was analyzed.    
Five sets of physicochemical and biological experimentation were conducted in order to 
achieve the aims of this research. An attempt was made to compile all these interesting results 
in 5 different chapters of this dissertation. In brief, 1st set of experiments (Chapter 3 in the 
dissertation) is the scope of the hypothesis, where formulation conditions for ACSC NCs 
were standardized. Chapters 4 and 5 demonstrate the in vitro basis for a most potential future 
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nanodrug design for cancer therapy.  The proof-of-concept of the hypothesis (in vivo anti-
tumour efficacy of nano Fe-bLf) was compiled in the sixth chapter, whereas chapter 7 
validates the same concepts in vitro and in the breast cancer xenograft model.    
1. Fundamental work that has been carried out in order to develop a novel nano delivery 
platform, to carry natural bLf, was discussed in this chapter (Chapter 3). To be able to protect 
the proteins, various biodegradable polymer layers were integrated onto the ceramic cores, 
which was confirmed by DLS spectrometry and SEM. In vitro protein release profiles over a 
time period and pH sustainability measurements were done in order to assess the native 
configuration of the protein after the formulation. TUNEL assay and trypan blue exclusion 
was done along with estimating Annexin-V positive cells in order to study anti-cancer 
efficacy of the bLf loaded NCs. Endocytosis and transcytosis studies of the NCs in colon 
cancer cell lines were done using flow cytometry and transcytosis studies.  
2.  Anti-cancer protein - Sur R9-C84A was adsorbed in calcium phosphate ceramic nanocores 
and biodegradable polymer layers were integrated on the top of it, as confirmed by DLS 
spectrometry and SEM. In vitro protein release profiles over 24 h time period were observed 
by analyzing the protein supernatants. Further, qualitative analysis for the conservation of 
tertiary protein structure, protein retardation analysis was carried out chromatographically 
using Western blotting with survivin specific antibodies. In addition, possible in vivo 
behavior of the NCs in intestinal milieu was analyzed by omnizyme treatment to assess the 
protection offered by alginate and chitosan to the Sur R9-C84A. The NCs were analyzed by 
flow cytometry for quantitative determination of the endocytosis and confocal microscopy for 
qualitative analysis. To analyze the functional mechanism of action for the NCs on the cancer 
cells, endogenous survivin levels were quantified after treatment by using quantitative real 
time PCR and Western blotting.  
3. In order to achieve a combinatorial platform carrying Fe-bLf and survivin R9-C84A, bio 
degradable chitosan and alginate were employed to integrate onto the ceramic cores. In vitro 
protein release profiles over a time period and Fourier transformed infra red (FTIR) 
spectroscopy were done to analyze controlled release of the protein and chemical bonding 
pattern, respectively, in the formulation. Differential scanning calorimetric and thermo 
gravimetric analysis were employed to find out the crystallization behavior of the NCs.  Size 
distribution and morphology of the NCs were further confirmed by DLS spectrometry and 
SEM. Rhodamine labeled NCs were incubated with the colon cancer cells in various time 
intervals starting from 1 h to 6 h in order to analyze quantitative endocytosis of the NCs by 
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flow cytometry along with qualitative determination using confocal microscopy. Finally, 
endocytosis studies and mitochondrial membrane depolarization studies for analysis of 
respective internalization profiles and apoptotic induction in colon cancer cell lines.   
4. To be able to further enhance anti-tumour efficacy and bioavailability of Fe-bLf, 
nanotechnology was used as an innovative tool. In order to protect the protein, ACSC-FebLf 
NCs were generated using various biodegradable polymer layers integrated onto the ceramic 
nanocores carrying Fe-bLf. Spectroscopic and transmission electron microscopic techniques 
were utilized to confirm sphericity and homogeneous size distribution of the NCs. 
Furthermore, X-ray diffraction was done to predict crystallographic structure and chemical 
bonding pattern among various polymeric layers was predicted by FTIR. As a proof of 
concept, ACSC-FebLf NCs were tested in colon cancer xenograft nude mice models. In vitro 
cytotoxicity for analyzing the potential of these NCs for enhanced and more efficient anti-
cancer activity was determined by MTT assays and in situ cell death detection assays. In 
order to endorse a safe and biocompatible nature of these NCs with respect to nano toxicity, 
in vivo in the xenograft model of nude mice, FTIR, body condition scoring and tissue 
pathology in various organs collected after sacrificing the mice were carried out. Bio-
distribution of the NCs was done by immunohistochemistry and Western blotting using 
antibodies specific to Fe-bLf; CD-31 and Prussian blue double staining was also employed as 
an additional means to observe the biodistribution pattern. Finally, quantitative real time PCR 
(qRT-PCR) analysis was carried out for isolated RNA from the tissues in order to predict 
up/down regulation of LRP receptors along with various pro and anti-apoptotic genes.    
5. After the success of NCs therapy in colon cancer bearing nude mice, the NCs were tested 
in a breast cancer model as a confirmation of proof of concept. ACSC NCs encapsulating the 
Fe-bLf with an overall size of 322 ± 27.2 nm were used for in vitro evaluation in the MDA-
MB-231 breast cancer cells. CyQUANT and MTT assays were used for validating cellular 
proliferation and cell death respectively. Flow cytometry and confocal microscopy were used 
for validating internalization efficacies were employed to observe the in vitro effects. Then 
the NCs were mixed in a diet in order to treat breast cancer bearing nude mice (C57BalbC 
nu/nu). Anti-tumour efficacy, bio distribution and tissue pathology after the NCs treatment 
were evaluated. Iron uptake studies were done using spectroscopic and immunohistochemical 
techniques to find the internalization of iron in various organs after treatment with NCs. 
Finally, possible mechanism of internalization for these NCs was investigated by studying the 
gene expression levels of LRP receptors. 
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Chapter 2: Literature review  
2.1 Preface 
Over the years outstanding research was done in order to understand and cure complex 
malignancies (Katzel et al., 2009). The past three decades have observed a profound 
knowledge of cancer genes, but this has not translated into equivalent benefits to cancer 
patients. Certainly, a vast majority of the cases of increased success mostly reflect early 
diagnosis or prevention, rather than improved treatment (Kanwar et al., 2010d). With the 
plateau of conventional cancer therapies such as chemotherapy and radiation therapy, in the 
treatment of many cancers including colon, prostate, ovarian, lung and cervical cancers, 
improvements must now come from fresh approaches (Altieri, 2008, Fonseca et al., 2009). 
Thus, in order to protect normal cells and organ function, tumour-targeted therapy should be 
aimed at eliminating cancer cells, while at the same time sparing the normal tissue. In this 
regard genetic engineering and molecular biology have come up with bio macromolecules 
that could serve the purpose of specific targeting (Gao et al., 2010, Kanwar et al., 2010b). 
However, short plasma lives of most of these bio macromolecules open new doors for further 
research in novel drug delivery platforms for prolonged sustainability and aid from the 
internal locale. 
Recent advances in nanotechnology have offered a new hope for the oral and systemic 
delivery of the fragile therapeutic molecules. Nanotechnology has the potential to offer 
solutions to several of the aforementioned obstacles (Lee and Wong, 2011). The 
physicochemical characteristics of the materials including polymers, metals, and 
semiconductors offer distinct advantages for in vivo applications. Altered properties could be 
increased surface area, optical, electronic, magnetic and structural properties as well as 
quantum effects dictated by the nanometer scale that are not available from individual 
molecules or bulk solids. Properties such as self-assembly, stability, specificity drug 
encapsulation and imaging contrast of the nanoparticles have already been used clinically to 
provide targeted cellular/tissue delivery of chemotherapeutics, to improve drug 
bioavailability, to sustain drug effect in target tissue and to diagnose disease (Gindy and 
Prud'homme, 2009).  
Pathological angiogenesis originates around the cancer tissue, with the help of pro-angiogenic 
mediators such as vascular endothelial growth factors that are secreted by the tumour tissue. 
This will further assist the cancer in using the blood supply offered by the porous and leaky 
vasculature having nanopores of about 500 nm around the malignant area for enhanced 
10 
 
nutritional and oxygen support. Thus, this widespread breakdown of vessel integrity within 
the tumour results in extensive leakage of bloodstream components. This could be exploited 
in making the NCs in the circulation to infiltrate inside the tumour tissue, which is known as 
enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986). Further, 
random drifting of the nano sized particles (Brownian momentum), in addition to the receptor 
mediated endocytosis collectively enhances anti-tumour efficacy of the loaded drug.   
Herein, an effort will be made to review the recent advances in bio-macromolecular research 
towards an ideal tumour suppressor, along with outstanding capabilities of polymeric 
nanocarriers that have been designed for the safe delivery of the therapeutic moieties. 
Furthermore, advances in the ceramic research in finding innovative bio-materials for the 
medical use will be discussed. 
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2.2 Is the cancerous state a chronic inflammation?  
Cancer is a lethal disorder caused by a group of mutated cells in the body which overcome 
the regular cell death/ apoptosis. On average, cancer contributes to 13% of all deaths. The 
mutations and epigenetic changes such as DNA methylation and altered patterns of histone 
modifications found in the cancer cell genome accumulate over the lifetime of cancer 
patients. A variety of exogenous factors including tobacco smoke, lifestyle factors chemical 
toxicity in various forms and a broad spectrum of radiation, such as ultraviolet light increase 
the rate of mutation. Exposure to these environmental and lifestyle factors over a threshold 
range is thus associated with increased risk rates of cancer (Grivennikov et al., 2010). Since, 
the inflammatory responses were also mediated by involvement of analogous factors, a strong 
relationship between inflammation and cancer was suggested (Grivennikov et al., 2010, 
Mantovani et al., 2008, Sung et al., 2011). Chronic inflammation is one of the substantial 
factors responsible for long term diseases such as cancer and it has been estimated that more 
than 15% of cancers are caused by infection or inflammation (Coussens and Werb, 2002). 
Proinflammatory cytokines including tumour necrosis factor (TNF), interleukins (IL-1, IL-6, 
IL-8) and chemokines were the substantial factors that contribute to chronic inflammation. 
Similarly, proinflammatory enzymes (cyclooxygenase-2 [COX-2], 5-lipoxygenase, matrix 
metalloproteinase [MMP] and urokinase plasminogen activator [uPA]), adhesion molecules 
(intercellular adhesion molecule-1 [ICAM-1], vascular cell adhesion molecule-1 and 
endothelial leukocyte adhesion molecule-1) and certain growth factors (epidermal growth 
factor [EGF] and platelet-derived growth factor [PDGF]) were also included in the long list 
of factors that contribute to inflammation and carcinogenesis (Aggarwal and Gehlot, 2009).  
As shown in Figure 2.1, cancer progression passes different stages, starting from initial 
aggressive growth, penetration to the adjacent healthy tissues and final metastatic state, after 
the formation of pathological angiogenic vasculature. The mutations and/or modifications in 
the key regulatory bio-molecules attributes to the inefficiency of cancer cells to die naturally. 
This is mainly pertaining to mutations in various factors involved in cell cycle arrest viz 
P53,Rb and some tyrosine kinases, which are regarded as cell cycle check points. These 
mutations lead the cell to overcome apoptosis (Kerr et al., 1972), a natural process by which 
aged and/or virally infected cells die.  
12 
 
 
Figure 2.1 Various stages in the development of malignant metastatic cancer. A metastatic tumour 
development is as difficult as development of therapeutic treatments for cancer cure. If the healthy 
cells escape the process of apoptosis by mutations in one of the various molecular events related to the 
programmed cell death, will form a group of cells, normally regarded as a dormant tumour. This 
tumour can then produce various angiogenic factors; a ratio between pro and anti-angiogenic factors 
decides the fate of tumour angiogenesis. Once the blood vessel formation occurs, the tumour will now 
be regarded as malignant tumour, which grows independent of the other tissues, by absorbing 
nutrients and oxygen required for its growth. Mutated cancer cells from this tissue can travel to 
various other healthy tissues via the established angiogenic network, before establishing themselves as 
solid tumours.[Figure was taken from (Kanwar et al., 2011b)]. 
 
 
 
 
 
 
 
 
 
13 
 
2.3 Apoptosis: a well planned suicide  
Mammalian cells undergo apoptosis by two mechanisms; (a) extrinsic pathway – mediated by 
Fas ligand and/or APO1/CD95 and several other proteins such as Fas associated death 
domain (FADD) (Krammer, 2000) and caspases 8-10 (Wajant, 2002) and (b) intrinsic 
pathway- mediated by B-cell lymphoma 2 (Bcl-2) family proteins (Zapata et al., 2001, 
Hockenbery et al., 1990). These pathways are modulated by definite set of genes which 
means apoptosis is a process with genetic intervention. Bcl-2 family members regulate 
apoptosis in response to various death-inducing stimuli and so far, more than 15 members of 
this family have been identified (Figure 2.2). Death antagonists and anti-apoptotic proteins 
include Bcl-2, Bcl-XL, myeloid leukemia cell differentiation protein 1 (Mcl-1), Bcl-W and 
A1, provide protection. Death agonist members, including Bcl-2-associated X protein (Bax), 
Bcl-2-associated death promoter (Bad), Bcl Xs, BH3 interacting domain death agonist (Bid), 
Bim, Bcl-2-interacting killer (Bik) and activator of apoptosis harakiri (Hrk), increase the 
sensitivity to death-inducing signals. The death agonist/antagonist signal ratio determines the 
susceptibility of the cell to death stimuli (Scaffidi et al., 1998). In addition, members of the 
inhibitor of apoptosis protein (IAP) protein family, including c-IAP1, c-IAP2, X-linked IAP 
(XIAP), neuronal apoptosis inhibitory protein (NAIP), survivin, apollon, melanoma inhibitor 
of apoptosis protein (ML-IAP), livin and insulin-like peptide 2 (ILP-2) function as 
endogenous inhibitors of caspases. Among the IAP members, survivin and livin are highly 
expressed in cancer cells and transformed cells, but show little or no expression in normal 
differentiated tissues (Li and Ling, 2006). Co-localization of survivin antibodies and livin 
antibodies has been reported in the sera of breast cancer patients (Yagihashi et al., 2005a, 
Yagihashi et al., 2005b). In this regard, it has been demonstrated earlier that, combinational 
therapy using antisense survivin and B7-1 immunogene therapy eradicated EL4 thymic 
lymphoma tumours (Kanwar et al., 2001b). There are a few reports in using human and/or 
murine survivin antagonists as anti-cancer vaccines (Jiang et al., 2006, Paduano et al., 2006, 
Kanwar et al., 2010a). Heat shock protein 90 (HSP90) is a molecular chaperone believed to 
be involved in survivin regulation; interestingly, it has been shown that the HSP inhibitors 
geldanamycin and 17-allylamino-17-demethoxygeldanamycin (17-AAG) increase survivin 
expression (Cheung et al., 2010a), which solicits dual inhibition of HSP90 and survivin for an 
effective therapy. 
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Figure 2.2 schematic representations outlining the mechanisms of apoptosis. The extrinsic pathway 
causes cell death by activation of FAS protein with specific ligand and subsequent activation of 
caspase-8, which in turn activates downstream caspases in a cascading manner. The intrinsic pathway 
happens in response to intra cellular pathogens, cytochrome C, a mitochondrial protein, triggers this 
pathway. Various Bcl families of pro and anti-apoptotic proteins regulate this pathway. Both these 
pathways share a common pathway at caspase 3 activation and subsequent cell death. Members of 
IAP family proteins such as survivin, XIAP etc inhibit apoptosis by preventing caspase activation 
and/or by other mechanisms. [Figure was taken from (Kanwar et al., 2011b)]. 
 
 
 
 
 
 
15 
 
2.4 Angiogenesis and tumour progression   
Angiogenesis is the formation of new blood vessels from pre existing blood vessels and/or 
from endothelial progenitor cells (Figure 2.3). It has implications in many physiological 
conditions such as embryo development, ovulation, wound healing and in some pathological 
conditions such as arthritis, diabetic retinopathy and in metastasis (Folkman, 1990). 
Angiogenesis, depending on different physiological processes in which it is involved, can be 
classified into three major types. 
1. De novo angiogenesis occurring in embryonic development and in female reproduction. 
2. Degenerative angiogenesis in tissue repair and 
3. Pathological angiogenesis occurring in certain disorders such as cancer and diabetic 
retinopathies - tumour vessels tend to break conventional rules of micro circulation 
(spreading without organization and changing vessel diameter, with some missing 
differentiation in arterioles, capillaries and venules) as a result of this. 
 
Metastasis continues to be a major hurdle for successful and complete treatment of malignant 
tumours, as portrayed in a number of basic research studies. It has been observed that some 
human tumour lines do not form visible tumours when inoculated into immune suppressed 
mice. Interestingly, when these cells are transfected with some pro-angiogenic factors such as 
vascular endothelial growth factor (VEGF), dormancy was found to be overcome by these 
microscopic tumours. It has been estimated that more than one third of women between the 
ages 40-50 carry in situ tumours in their breast tissue by observing autopsy data, but only 1% 
of them are diagnosed with breast cancer in later days. Same is the case with prostate cancer 
in men, thyroid cancer in certain individuals and patients with Down’s syndrome (Folkman 
and Kalluri, 2004). These examples clearly support the phenomenon of “angiogenic switch”, 
which is used to denote the close relationship between angiogenesis and tumour progression 
(Folkman, 1996). It has been shown that hypoxia induces angiogenesis; high proliferation of 
tumour cells creates hypoxic areas necessary for the induction of VEGF expression. Also, 
identification of Hypoxia inducing factor (HIF1) as the up regulator of VEGF under low 
oxygen conditions gave further insights into the mechanisms of tumour angiogenesis 
(Maxwell et al., 1997). Hypoxia also has shown to stimulate other angiogenesis supporting 
growth factors such as platelet derived growth factor (PGDF) and fibroblast growth factor 
(FGF) (Kuwabara et al., 1995). It has been reported that succession of micro metastasis to 
macro metastasis happens by activation of angiogenic switch. Embryonic progenitor cells 
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from bone marrow rather than pre existing endothelium were found to be the critical 
regulators of this angiogenic switch. Immobilization of endothelial progenitor cells (EPCs) by 
blocking the expression of transcription factor id1 leads to the inhibition of angiogenesis and 
further reduction in tumour progression (Naumov et al., 2006). The switch clearly involves 
more than simple up-regulation of angiogenic activity and thought to be an insubstantial 
balance of positive and negative regulators.  
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Figure 2.3 The process of angiogenesis is very much essential for embryogenesis; however, tumour 
cells misuse this process. Embryonic angiogenesis begins with formation of an angioblast from 
mesodermal precursor cells (yellow). Endothelial cells formed from these angioblasts subsequently 
form primary capillary plexus (PCP), by a process called vasculogenesis. By angiogenesis, the PCP 
forms mature blood vessels. [Figure was taken from (Kanwar et al., 2011b)]. 
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2.5 Modulators of angiogenesis  
Many factors that were found to have implications in the process of angiogenesis are termed 
as either positive regulators (angiogenic factors) or negative regulators (angiostatic factors) 
depending on their respective roles in stimulating or inhibiting angiogenesis. Integrins, 
VEGF, angiopoietins, FGF, transforming growth factor (TGF) and CXC chemokines are 
grouped under angiogenic factors, whereas inhibitors of angiogenesis including angiostatin, 
endostatin and thrombospondin comprise the group angiostatic factors. Some of the 
angiogenic modulators are described below. 
2.5.1. Angiogenic factors  
2.5.1.1 Integrins: integrins are heterodimeric combinations consisting one α and one β  -sub 
units each from 18  different α and β  trans membrane proteins. In one study, blocking 
integrins αvβ3 and  α1β1 by using specific antibodies  showed that  antagonists against 
integrin αv β3 inhibit pro-angiogenic effects of VEGF and probol esters while antagonists 
against that of  α1β1 abolish FGF2 and tumour necrosis factor (TNF) α stimulated sprouting 
of new vessels (Smyth and Patterson, 2002). Angiogenic endothelial cells were shown to 
undergo apoptosis compared to their resting counterparts, after the αvβ3  antibody 
administration (Brooks, 1996). Defective vascular network as a consequence of injecting 
αvβ3  antibodies in quail embryos shows the role of αvβ3  integrins in endothelial cell 
proliferation (Clark et al., 1996) and in angiogenesis.   
2.5.1.2. Vascular endothelial growth factor: This most important factor among angiogenic 
factors was discovered in 1989 by Ferrara and coworkers (Ferrara et al., 2003). It was found 
that, by disrupting a single VEGF allele in mice ~ 50% reduction in VEGF and ultimately 
embryonic death was observed. Six known members of the VEGF family have been 
discovered viz. VEGF-A, -B, -C, -D, and -E and the placental growth factor, found to be 
generated by alternative splicing of the VEGF gene (Ferrara et al., 2003). VEGF binds to 
VEGF receptors (VEGFR1, VEGFR2 and VEGFR3) expressed on endothelial 
cells/lymphatics. After binding to their ligand, VEGF receptors undergo dimerization 
resulting in mitotic, chemotactic and pro survival signals. Several growth factors such as 
EGF, TGFα, β FGF and PDGF and hormones such as estrogen induce VEGF expression.  
2.5.1.3 Angiopoietins: The angiopoietins (Ang-1–Ang-4) have been implicated in the 
development of vasculature in a wide variety of tumour types (Plank et al., 2004). Among the 
four known angiopoietins, Ang-1 and Ang-2 are the best characterized cytokines, both 
exerting their biological function through binding to the Tie-2 receptor (Maisonpierre et al., 
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1997). Ang-1 promotes endothelial cell survival and sprouting and stabilizes vascular 
networks by recruiting pericytes to immature vessel segments. In contrast, Ang-2, expressed 
at sites of vascular remodeling, causes the loss of pericytes and exposes endothelial cells to 
angiogenic factors.  
2.5.1.4 Fibroblast growth factors: FGFs are a family of heparin binding proteins. FGF-1 
(acidic) and FGF-2 (basic) are described as inductors of angiogenesis (Szebenyi and Fallon, 
1999). All FGFs bind to heparan sulphate proteoglycans (HLGAGs) of the extracellular 
matrix (ECM). FGFs can bind to four transmembrane-specific receptor tyrosine kinases 
inducing receptor dimerization and activation. FGF-1 and FGF-2 induce endothelial cell 
proliferation and differentiation of epiblast cells into endothelial cells. Furthermore, FGF-2 
stimulates the release of urinary plasminogen activator and collagenases in endothelial cells 
and acts as a chemo-attractant for these cells 
2.5.1.5 Transforming growth factorβ  (TGFβ): It has been proposed that TGFβ has auto 
and/or paracrine activity on endothelial cells as well as pericytes (Antonelli-Orlidge et al., 
1989). Two isoforms TGFβ1  and TGFβ2  have been identified, the former acts as pro 
angiogenic and the later act as pro angiogenic in low concentrations and oppositely in high 
concentrations. Dickson and coworkers found that knockout mice lacking TGF are unable to 
produce stable vessel walls as well as inadequate tube formation (Dickson et al., 1995). 
2.5.1.6 CXC-chemokines: CXC chemokines, that primarily modulate infiltration of 
monocyte/macrophages to the sites of inflammation, have been found to associate with 
modulation of angiogenesis (Salcedo et al., 2000). Although underlying mechanism of their 
involvement in angiogenesis hasn’t been fully validated, an indirect involvement by 
stimulating monocytes and macrophages, which intern directly produce angiogenic factors 
has been suggested (Isik et al., 1996). However, recent evidence of endothelial cells 
expressing of CCL2 receptor CCR2 shows a direct angiogenic modulation by CXC 
chemokines (Stamatovic et al., 2006, Weber et al., 1999).    
2.5.2. Angiostatic factors 
2.5.2.1 Angiostatin: Angiostatin is a 38 kDa plasminogen fragment, consisting of the first 
four triple disulfide-linked kringle domains of plasminogen. Systemic injection of angiostatin 
has been shown to inhibit tumour neovascularization and metastatic growth by inhibition of 
extra cellular matrix (ECM). More recent studies indicated that the angiostatin act on innate 
immune cells as key targets in inflammatory angiogenesis (Albini et al., 2009). Angiostatin 
induced inhibition of angiogenesis was shown to be reverted when blocking antibody for IL-
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12 was used in matrigel plugs treated with VEGF-TNFα or supernatants of Kaposi’s sarcoma 
cells. These results were further evident in vivo in the knockout models with gene-targeted 
deletions of either the IL-12 specific receptor subunit IL-12Rβ2 or the IL-12p40 subunit. 
Thus, angiostatin proves to be anti-angiogenic as an immune modulator rather than a direct 
anti-vascular agent (Albini et al., 2009). The combinatorial therapy of plasmids containing 
angiostatin gene with B7.1 immunogene therapy have reduced solid EL4 lymphomas in 
syngenic C57BalbC /6 mice, supports the use of angiostatin in combinatorial therapy (Sun et 
al., 2001). Nevertheless, EL-4 tumours established in mice rapidly develop resistance to 
angiostatin gene therapy by up regulating hypoxia-inducible pathways. Restored angiogenesis 
and rapid tumour growth were noticed in large EL-4 tumours by up regulation of HIF 1-α 
and its effector VEGF, in response to increased tumour hypoxia. However, this mechanism 
seems to be relapsed when antisense HIF-1 alpha was used indicating the circumvention of 
hypoxia induced resistance by the use of combination therapy (Sun et al., 2010).  
2.5.2.2 Thrombospondin-1: Thrombospondins belong to a family of ECM proteins. CD36 
(also known as GP88, GP IV, GPIIIb) is an important cellular receptor for TSP-1 on micro 
vascular endothelium and is necessary for its anti-angiogenic activity (Tonini et al., 2003). 
The anti-angiogenic activity of TSP-1 is contained in a structural domain known as the TSP 
type I repeat which plays a role in endothelial cell apoptosis (Sargiannidou et al., 2001). In 
addition to CD36-mediated anti-angiogenic effects, TSP-1 can potentially inhibit 
angiogenesis through an interaction with pro-MMP2/9, MMP-2/9 or induction of cell cycle 
arrest (Sounni and Noel, 2005). TSP-1 mediated inhibition of angiogenesis involves direct 
effects on endothelial cell migration and apoptosis, as well as effects on the bioavailability of 
VEGF. Interaction of TSP-1 with VEGF in down regulation of angiogenesis was reported to 
be caused either by inhibiting the activation of matrix metalloproteinase 9, by which release 
of VEGF from the extracellular matrix will be suppressed (Wang-Rodriguez et al., 2003), or 
TSP-1 binds directly to VEGF (Greenaway et al., 2007).  
2.5.2.3. Endostatin: It is the NC1 domain of the α1 chain of type XVIII collagen and an 
inhibitor of tumour angiogenesis and growth. Endostatin inhibits endothelial cell migration, 
induces endothelial cell apoptosis and cell cycle arrest and is encoded by COL18A1 gene at 
21q22.3. In one interesting study, the levels of endostatin were observed in the serum of the 
patients with Down syndrome along with normal controls. The results interestingly showed 
that elevated endostatin levels persist in patients with Down syndrome (Down syndrome is 
most commonly caused by trisomy of the 21st chromosome) (Shichiri and Hirata, 2001). It 
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has been shown that endostatin directly and specifically acts on endothelial cells in culture to 
produce intracellular signals such as influx of extracellular calcium inside the cells 
(Sargiannidou et al., 2001, Shichiri and Hirata, 2001).  Endostatin’s application down 
regulates gene expression during endothelial cell growth, and exhibited a potent anti 
migratory effect on endothelial cells in vitro, mediated through c-myc down regulation 
(Shichiri and Hirata, 2001). Inhibitory action by endostatin has been proposed to involve 
binding to the receptor α5β1 (Sudhakar et al., 2003). cDNA and antibody microarray 
technology uncovered the full set changes in gene expression following endostatin 
administration. Endostatin up regulated anti angiogenic thrombospondin, kininogen, ATIII 
and chromogranin A; while down regulating downstream regulators of anti-apoptotic genes 
(eg: Bcl2, COX2, cMyc and iNOS) such as HIF1α, NFkB, Ets-1, id1 and the STATs, leading 
to cell cycle arrest (Abdollahi et al., 2004). Therefore, taking together this evidence, one can 
articulate that endostatin acts upon one or more receptors present on endothelial cells, 
resulting in intracellular signaling which decreases their migratory capacity and/or 
proliferative ability preventing the vascularization. 
More recently, poly-N-vinyl pyrrolidone (PVP) formulated endostatin and angiostatin 
expression vectors were employed to treat primary EL-4 lymphomas. Simultaneous 
intramuscular delivery of both angiostatin and endostatin plasmids significantly prolonged 
the survival of mice after removal of primary tumours, which suggest a prophylactic cancer-
prevention strategy using both endostatin and angiostatin to prevent tumour angiogenesis 
(Sun et al., 2005). Further, in metastatic mice bearing 4T1 breast tumours, low dose 
metronomic (LDM) chemotherapy down regulated VEGF-2 receptor and up regulate anti-
angiogenic thrombospondin-1, which support application of LDM for advanced breast cancer 
treatment (Jiang et al., 2010). In another study, a combination of plasmids encoding 
interferon-γ along with endostatin was employed along with radiation therapy to successfully 
treat murine metastatic breast tumour model. Irradiation significantly enhanced IFN-γ and 
endostatin secretion from the transfected 4T1 cells and the mice receiving the combination 
therapy were shown maximum attenuation of tumour with reduced intratumoral microvessel 
density (Liu et al., 2009). This shows the role of endostatin as an angiogenic suppressor and 
its possible use in the neoadjuvant management of locally advanced breast cancer.     
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2.6 Need for alternative therapy in cancer cure 
Chemotherapy is the most followed therapeutic regime in cancer patients. Although it 
increases the overall survival rate in cancer patients, serious side effects like hair loss, loss of 
appetite, fatigue, neuropathy, leukemia and cognitive dysfunction seeks more research to 
offer better medication. Thus, usage of chemicals and/or fungal derivatives can be reduced 
and replaced with the bio-macromolecules which have fewer side effects. Targeting the 
specific proteins expressed excessively in tumours and/or angiogenic blood vessels is the key 
point in developing an anti-tumour drug. Bio-macro molecules used for this purpose could be 
distinguished by  
i) their capacity to discriminate between healthy and malignant forms of the proteins 
involved in signaling pathways;  
ii) quantifying the level of expression of the oncogenic forms, applicability in vitro and 
in vivo and;  
iii) blocking the activity of the oncogene product, to be able to use as therapeutics. 
Interestingly, it has been observed that, with the blockage of one particular growth 
factor, cancer can adopt other pro- angiogenic factors (Brunckhorst et al., 2010).  
Hence, combinational therapy using different molecules could overcome this problem. Anti-
angiogenic/anti-cancer peptides, DNA vaccines; oligomers such as miRNA and siRNA, 
which control the synthesis of gene product post transcriptionally and small oligomeric 
aptamers are promising agents in this regard. There are many anti-cancer, anti-angiogenic 
drugs approved and in phase II clinical trials (http://www.cancer.gov/CLINICALTRIALS). 
But most of them are chemical and/or fungal derivatives, mainly steroid containing 
compounds and these have many side effects, when metabolized i.e. after producing their 
secondary metabolites. Thus, biodegradable molecules are the best alternative for decreasing 
patient compliance. In this regard, micro ribonucleic acids (miRNAs) are the ideal 
candidates to consider. These non-coding RNAs are reported to have many implications in 
temporal and spatial regulation of genes in different organisms. It has been reported that they 
have tumour suppressing as well as oncogenic properties. Certain classes of micro RNAs, for 
instance Let7 family of miRNAs have been proved to have anti-tumour properties by 
inhibiting Rat sarcoma (RAS), a factor involved in cell proliferation. So it is tempting to use 
these tiny wonders for anti-tumour therapies. There were several reports related to the  
biodegradable anti-cancer biomacromolecules especially on use of micro RNA, aptamer 
biology, Von Hippel-Lindau (VHL) tumour suppressor in the cancer prevention 
(Aznavoorian et al., 1993, Cavallaro and Christofori, 2000, Folkman, 1995, Haas et al., 
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2000, Harris and Levine, 2005, Kerr et al., 1972, Knudson, 1971, O'Rourke and Ellem, 2000, 
Thompson, 1995, Zapata et al., 2001). Using the aforementioned molecules for the new 
generation medicines towards eradication of cancer could be possible by combinatorial 
therapy. Here the two most important molecules to be able to use for alternative therapy that 
received much attention in the recent past, Fe-bLf and dominant negative survivin, were 
discussed. 
2.7 Uses of micro RNAs in cancer therapy 
Micro ribonucleic acids (miRNAs) are the non-coding RNAs that act as post-translational 
regulators to their complimentary messenger RNAs (mRNA) (Kanwar et al., 2010b). Due to 
their specific gene silencing property, miRNAs have been implicated in a number of cellular 
and developmental processes, including cancer (Sayed and Abdellatif, 2011). The first 
evidence for the link between miRNA and cancer comes from the study that miR15 and 
miR16 are located at chromosome 13q14, a region deleted in more than half of B cell chronic 
lymphocytic leukemias (B-CLL) (Calin et al., 2002). Detailed deletion and expression 
analysis showed that miR15 and miR16 were located within a 30-kb region of loss in CLL, 
and that both genes were deleted or down-regulated in the majority (≈68%) of CLL cases 
(Cimmino et al., 2005). The expression of miR15a and miR16-1 has been inversely correlated 
to Bcl2 expression in CLL and that both micro RNAs negatively regulate Bcl2 at a post-
transcriptional level showing the tumour suppressor functions of miRNA. The data presented 
in this study is of considerable therapeutic significance, since miR-15 and miR-16 have 
natural anti-sense Bcl2 interactions that could be employed for therapy in tumours 
overexpressing Bcl2. An important group of miRNAs, the let-7 family (known to regulate 
RAS and/or MYC oncogene expressions at the translational level), often found down-
regulated in human colon tumours owing to its growth repression functions (Sureban et al., 
2009, Akao et al., 2006). Recent evidence suggests that miR143 and miR145 are consistently 
down-regulated in colorectal tumours (Michael et al., 2003). Also, it has been shown that 
down-regulation of these miRNAs is a common occurrence in breast carcinomas and breast 
tumour cell lines (Iorio et al., 2005). On the flip side, miRNAs acting as oncogenes have also 
been identified, owing to speculations about their role in tumorigenesis. B cell integration 
cluster (BIC) or miR155 was shown to accelerate MYC mediated lymphoma cells in a 
chicken model (Tam et al., 2002). Another cluster of 6 miRNAs has implications in the 
development of large B cell lymphoma and these 66 miRNAs can act as potential oncogenes 
(Ota et al., 2004). miR372 and miR373 were found to block RAS induced cellular senescence 
and potentiate RAS mediated cellular transformation (Voorhoeve et al., 2006). 
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Cancer cells have been proved to have different miRNA expression profiles, as compared to 
normal cells, suggesting miRNA expression could be used for diagnosis of cancer. miR-21 
expression was found to be upregulated in glioblastoma, as compared to normal brain 
autopsies (Chan et al., 2005). Takamizawa et al. (Takamizawa et al., 2004) have shown 
significant reduction in let7 miRNA in lung cancers by Northern blotting. When compared 
with let7 miRNA basal expression in normal lung tissue, as frequent as 43.8% of all lung 
cancer tissues showed  > 80% reduction in let7 miRNA levels, These reports suggest that 
over expression of miR 21(~100 fold increase of miR21, as indicated by Northern blotting 
and membrane array in the study) and/or under expression of let7 miRNA are more 
commonly observed in cancer tissues, thus can be used as potential biomarkers for 
glioblastoma and lung cancer, respectively (Takamizawa et al., 2004). Differential expression 
profiling of breast cancer and normal breast tissues revealed discrepancy in the expression of 
29 miRNAs. Both miR21 and 155 were found to be up regulated, whereas miR-10b, 
miR125b and miR-145 were down-regulated, suggesting that these miRNAs can be 
potentially used as diagnostic markers (Iorio et al., 2008). In a study on 17 poorly 
differentiated tumour samples, when both miRNA and mRNA microarrays were used in 
parallel, miRNA microarray was found to be more sensitive for classification of 12 of 17 
tumour types, whereas mRNA microarray could correctly classified only one sample (Lu et 
al., 2005), indicating the potential uses of miRNA over mRNA in future diagnostics. 
Recently, when miRNA expression profiles of 144 lung cancer and control tissue samples 
were determined by using 352 probes for miRNA, 43 miRNA expression profiles 
consistently differed from normal controls (Yanaihara et al., 2006). Out of these, 8 miRNAs 
viz. miRs-17-3p,-21,-93, -106a, -145, -155, let-7a-2 and let-7b were found to be survival 
prognosticators.  
Another study confirms that miRNA expression in peripheral blood could be used as a 
substitute of miRNA expression in the tumour biopsy. Tumour-derived exosomes are small 
membrane vesicles of endocytic origin released by the tumour and found in the peripheral 
circulation. There are reports which have been shown that exosomes could be an important 
resource of cell-free miRNA in serum or plasma (Hunter et al., 2008, Valadi et al., 2007, 
Taylor and Gercel-Taylor, 2008). More recently, in relation to evaluation of circulating levels 
of tumour exosomes, exosomal small RNAs in patients with and without lung 
adenocarcinoma, an increase in protein concentration in circulating exosomes has been 
reported (Rabinowits et al., 2009). The authors have tested the levels of 12 miRNAs that have 
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been reportedly modulated in lung cancers including miR21 and 155.  In all 4 lung 
adenocarcinoma cases, there was no significant difference in miRNA levels of paired tumour 
and plasma samples, and there was similarity  between circulating miRNAs of tumour-
derived exosomes and tumour miRNAs (Rabinowits et al., 2009). In another study (Zhu et 
al., 2009), based on detection of serum miRNA loads for breast cancer diagnosis, women 
with progesterone positive breast cancer showed predominance in miR 155, compared to 
controls,  while other miRNAs detected in this study including miR16 and 145 didn’t show 
any such variation. This approach therefore, can lead to the development of a noninvasive, 
blood-based detection test for breast cancer. Measuring the expression of specific circulating 
miRNAs in cancer patients can be a good substitute to  tumour tissue specific  miRNA 
expression, thereby initiates a new paradigm that will be useful not only for early diagnosis 
but also for prognostic and therapeutic decisions (Rosell et al., 2009). Thus, miRNA could be 
used as a significant therapeutic tool in order to diagnose, treat cancer or employ as a ligand 
to direct cancer therapeutics to a particular target site. 
Limitations of the therapeutic potential of miRNAs: In spite of the great deal of success in 
the application of miRNA in cancer cure, their uses are still hindered by several confines. 
Delivery of miRNA results in the development of innate immune responses from the host, in 
the form of cytotoxic T lymphocytes (Brunetti-Pierri et al., 2004). Another major concern for 
miRNA therapy is the off target effects (Jackson et al., 2003). Since the action of miRNA is 
based on the imperfect base pairing with the target sequence in most of the circumstances, the 
specificity will be lower as confirmed by micro array analysis. In addition to this, as one 
miRNA could target multiple genes and one gene could be controlled by multiple miRNAs, 
significant differentiation between target of interest is complicated (Miranda et al., 2006). 
These limitations could be overcome by using anti-cancer proteins as described in subsequent 
sections.   
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2.8 Survivin – a hot anti-cancer target  
With the advancements in biotechnology and genetic engineering research, a number of 
therapeutic proteins have recently been innovated (Yeung et al., 2010). Incidentally, survivin 
inhibitors have gained the attention of researchers since survivin expression is high in 
tumours and not detectable in normal differentiated tissues (Li, 2003). At the molecular level, 
survivin is a unique member of IAP family proteins that can protect the cells from death by 
inhibiting caspases (Altieri, 2010). X-ray crystallographic observations depicted the survivin 
structure as N-terminal Zinc binding baculovirus IAP repeat (BIR) domain consisting of a 
three-stranded anti-parallel β-sheet surrounded by four small α helices that are linked to a 65 
Ao amphipathic C-terminal α-helix (Verdecia et al., 2000). The importance of BIR domain’s 
role in prevention of apoptosis was determined by mutational studies. Apart from the wild 
type survivin, there exist different splice variants, based on the fact that survivin is encoded 
by 4 exons. Out of many combinations of the encoding exons, 14 splice variants have been 
reported so far, but only 4 (Sur 2α, Sur 2β, Sur Ex3, Sur 3B) were studied extensively with 
reference to their apoptotic actions and sub cellular localization (Caldas et al., 2005a, 
Mahotka et al., 2002). Out of all human splice variants, survivin-2B is generated by the 
insertion of an alternative exon; survinin-∆Ex-3 arises from the removal of exon 3; and 
survivin-3B results from the introduction of a novel exon 3B (Figure 2.4). Furthermore, 
common features to all splice forms at the amino terminus include the dimer interface and the 
BIR domain. Survivin-2B differs by the introduction of exon 2B but retains the ORF for the 
remainder of the C terminus. The BH2 domain and mitochondrial localization signal will be 
introduced in survivin-∆Ex3. A frame shift occurs in exon3 of survivin 3B causing a 
premature stop of the protein with a distinct C-terminus (Caldas et al., 2005b). 
Apart from the natural variants of wild type survivin, various mutant forms of survivin have 
been constructed, which have gained therapeutic significance in the treatment of 
malignancies. Point mutations such as D53A, C84A and a combination of T34A and C84A 
(Yan et al., 2006, Baratchi et al., 2010a) in the BIR domain prevents dimerization of survivin, 
as a consequence of loss of hydrophobicity producing a dominant-negative mutant that 
impedes anti-apoptotic function of native survivin (Baratchi et al., 2010a, Kanwar et al., 
2001b). It has been observed by others and in our lab that loss of function mutants of survivin 
can act as anti-cancer agents, by inhibition of native survivin action (Kanwar et al., 2001a, 
Kanwar et al., 2010d, Baratchi et al., 2010b). Recently, a cysteine to alanine (amino acid 
position 84 of the wild type survivin, abbreviated C84A) mutant of survivin was shown to 
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induce apoptosis in cervical and prostate cancer cells (Cheung et al., 2010b). Among all the 
IAP members, survivin and livin are highly expressed in cancer cells and transformed cells, 
but show little or no expression in normal differentiated tissues (Li, 2003). Co-localization of 
survivin antibodies and livin antibodies has been reported in sera of breast cancer patients 
(Yagihashi et al., 2005a, Yagihashi et al., 2005b). There are reports that cytotoxic T 
lymphocytes (CTLs) were induced by survivin-derived peptides and HLA-A24 in patients 
with breast cancer, colon cancer, esophageal cancer, and gastric cancer (Hirohashi et al., 
2002). In a similar tendency, surfaces of various cancer cells present livin-derived HLA-A2 
and -A3 restricted epitopes. In addition, serum survivin antigen was detected in melanoma 
patients (Reker et al., 2004, Andersen et al., 2004). By this, one can articulate that livin and 
survivin are presented to the immune system in a similar mechanism, which further ads up to 
their possible synergistic control over the apoptotic inhibition. On the other hand, increased 
levels of survivin were noticed when HSP 90 inhibitors were used, which demonstrated the 
over expression of survivin as an important factor that contributes to the induction of 
chemotherapeutic drug resistance. (Cheung et al., 2010a).   
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Figure 2.4: Figure showing (a) formation of different splice variants of survivin (b) survivin structure 
consists of an N-terminal Zn-binding BIR domain linked to an amphipathic C-terminal α-helix via a 
β-strand (β4) BIR domain consists of a 3-stranded anti-parallel β-sheet surrounded by 4 small α-
helices In tumours, the survivin expression is high and prevents normal cellular apoptosis. (c) 
Schematic illustration of loss of function dominant negative survivin mutant (Sur R9-C84A) blue- 
dimer interface, black – BIR domain, orange- c terminal α helix. Figure was adopted from 
Ideonexus.com/uploads/2009/05/survivin.  
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2.9 Natural anti-cancer molecules in alternative therapy  
As per the guide lines of  US National Cancer Institute, chemo preventive agent should be 
non-toxic to normal and healthy people, should have high efficacy against multiple sites, 
orally bioavailable, should have a known mechanism of action, easily accessible and 
acceptable to most of the human population (Sung et al., 2011). Various nutraceuticals appear 
to meet most of these requirements. A number of natural anti-cancer compounds including 
curcumin, capsaicin and neem extracts and matrine (Li et al., 2010) have been studied for 
their non-toxicity and specific effects on cancer cells (Basnet and Skalko-Basnet, 2011, 
Chakraborty et al., 2011). This evidence regarding dietary nutraceuticals is fascinating and 
warrants greater attention. Similarly, milk and milk based products were shown to contain 
components with reported anti-inflammatory and anti- carcinogenic activity (Gill and Cross, 
2000). In this regard, lactoferrin (Lf) has gained attention of the scientific world with its 
siderophilic (iron binding) ability and active role as a natural defense molecule (Tsuda et al., 
2000, Ward et al., 1999). 
 
2.9.1. Lactoferrin 
“Red protein” was the name given to lactoferrin (Lf), when it was discovered 60 years ago. 
Lf was subjected to intensive structural and functional research after its purification from 
human and bovine milk in 1960 (Montreuil et al., 1960). Besides its main function; iron 
absorption in the intestine, lactoferrin also plays a role in protection against infections, 
myelopoiesis and against autoimmunity. Lf is not only present in milk but also in the other 
bodily secretions such as saliva, tears, semen and mucosal secretions (Masson et al., 1966). 
Similar to transferrin, lactoferrin also binds to iron in its +3 oxidation state tightly but 
reversibly with a dissociation constant (KD) of 10-22M.  Lf releases the bound iron in much 
lower pH (3-4) compared to transferrin (pH 5-6) thus could be regarded as a better 
therapeutic protein (Baker and Baker, 2009). X-ray crystallographic studies have indicated a 
close homology of Lf with the transferrin protein. The amino acid sequences of Lf show that 
the mature protein comprises of ~690 amino acid residues and share 65-100% homology with 
transferrin. The structural studies indicated that a single polypeptide chain folds into two 
globular lobes representing its N (amino acid 1-333) and C (amino acid 345-691) terminal 
halves connected by a 10-15 amino acids containing polypeptide. Iron binding sites were 
located in the deep clefts residing in the domains that were designated as α and β domain. 
Thus, two different domains bind one Fe+3 ions with a catalytic site that comprises of YDH 
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amino acid triplet sequence (Figure 2.4). With the flexible polypeptide arm bridging the two 
lobes, apo-Lf without any metal ions assumes a flexible form whereas metal saturated holo-
Lf assumes a rigid configuration.  
Taking in to fact that cancer is an abnormal chronic inflammation, as discussed in the section 
2.2, Lf would be an ideal anti-tumour agent, as it could modulate the inflammatory molecules 
against tumorigenesis (Mulder et al., 2008). Increasing evidence indicates the anti-cancerous 
nature of bLf.  bLf was found to exert in vitro and in vivo anti-tumoral activity, through 
several suggested mechanisms such as inhibition of tumour cell proliferation (Iigo et al., 
2009), regulation of NK cells activity, inhibition of VEGF-mediated angiogenesis 
(Shimamura et al., 2004, Ward et al., 2005) and enhancement of apoptosis (Iigo et al., 2004). 
In addition to these studies, previous reports have shown that 100% iron saturated bovine 
lactoferrin (Fe-bLf) can augment the anti-tumour cytotoxicity of certain chemotherapeutics, 
in a wide range of tumours, by increasing cytokines produced by Th1 family, which includes 
IL18, IFNγ and TNFα, as well as nitric oxide (NO) that have been reported to sensitize 
tumours to chemotherapy. It was reported for the first time that iron content is a critical 
determinant in the anti-tumour activity of bLf. This study found 100% iron-saturated bLf act 
as a potent natural adjuvant and fortifying agent for augmenting cancer chemotherapy thus 
has broad utility in the treatment of cancer.  
Interestingly, Fe-bLf displayed enhanced anti-tumour activity in combination with major 
anti-cancer drugs (paclitaxel, doxorubicin, epirubicin, or fluorouracil), the combination being 
capable of completely eradicating large tumours (0.6 cm diameter) that was otherwise 
completely insensitive to chemotherapy. Fe-bLf fed mice bearing either EL-4, Lewis lung 
carcinoma or B16 melanoma tumours completely rejected their tumours within 3 weeks 
following a single injection of paclitaxel, doxorubicin, epirubicin or fluorouracil, whereas 
mice fed the control diet were resistant to chemotherapy. On the other hand, Apo-bLf (4% 
iron-saturated), natural bLf and 50% iron-saturated bLf were less effective at potentiating 
cancer chemotherapy, and did not cause tumour eradication. Importantly, Fe-bLf restored 
both red and white blood cell numbers depleted by chemotherapy, potentially fortifying the 
mice against cancer (Kanwar et al., 2008).  
Thus, metal saturated or the native lactoferrin could be used as a potential nutraceutic 
therapeutic agent in cancer prevention and/or treatment. Since survivin antagonists have been 
shown to augment cancer chemotherapy, Fe-bLf along with survivin antagonists can act as 
potential anti-cancer biomolecular therapeutics. 
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Figure 2.5: Lactoferrin (Lf) is a single-chain glycoprotein folded into two globular lobes (N- and C- 
lobes), each lobe forms two domains that encloses a deep cleft. Tertiary structure of lactoferrin lodges 
binding sites for the metal ions, ferric (Fe3+) and carbonate (CO32-) ions. (a) figure showing holo Lf 
with bound iron α and β domains were represented as N1 and N2 in the N-lobe; and C1 and C2 in the 
C lobe. (b) A flexible configuration of Apo-bLf was represented in the figure. Figures presented by 
(Baker and Baker, 2009) 
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2.10 Iron homeostasis and its sequestration by lactoferrin  
Almost all the forms of life require iron, including humans and most microbial species. Iron 
can be found in a wide variety of food sources because of its wide spread nature. Since, iron 
has the unusual flexibility to serve as both an electron donor and acceptor; it is regarded as an 
essential element (Chua et al., 2007). Based on this quality only, many of the key biological 
and cellular processes including electron transfer, oxygen transport, DNA synthesis, cell 
cycle progression and growth uses iron as an essential mediator (Le and Richardson, 2002). 
Since there was no established mechanism for the iron excretion in human systems, iron 
absorption from the diet is a tightly regulated process and is found to be influenced by many 
nutritional factors (Hallberg and Hulthen, 2000). Most of the absorbed iron will be utilized 
for erythropoiesis and the remnant of it is stored in the liver (Chua et al., 2007). Non heme 
and heme iron from the respective plant and animal sources will be taken up by different 
mechanisms. Further uptake of heme iron into metallo porphyrin complex is modulated by a 
heme transporter. Intestinal absorptive cells/ simple coloumnar epithelial cells (enterocytes) 
are the key cells involved in the absorption of both forms of the aforementioned dietary iron. 
Haem oxygenase regulates the breakdown of heme iron into iron and biliverdin which is 
rapidly converted in to bilirubin in the enterocytes (Raffin et al., 1974, Montellano, 2000). On 
the other hand, Divalent metal transporter 1 (DMT 1) regulates the uptake of iron form the 
non heme iron. Thus, the absorbed iron in both the instances is transcytosed from the 
basolateral membranes of enterocytes and is oxidized by hephaestin and binds to plasma 
transferrin. Transferrin receptors play an important role in the uptake of transferrin bound 
iron. Iron absorption is inversely regulated by body iron levels, increasing during iron 
deficiency and decreasing in conditions of iron excess (Chua et al., 2010). Iron metabolism is 
regulated by the hepatic hormone, hepcidin, and its expression is controlled by many factors 
including iron stores, hypoxia, inflammation, anaemia and erythropoiesis.  
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2.10.1 Does excessive iron causes toxicity? 
Iron can also be potentially toxic; it can also damage tissues by catalysing the conversion of 
hydrogen peroxide to free-radical ions (reactive oxygen species – ROS) that attack cellular 
membranes, proteins, and DNA. Since tumorigenesis was described to be a chronic 
inflammation (Section 2.2), and ROS play a potential role in modulation of inflammatory 
responses, it is interesting to see the effects of ROS during tumorigenesis. In the process of 
carcinogenesis, ROS have been shown to play crucial roles, which are contradictory 
according to various observations. The ROS created in the immune cells enable them to 
destroy engulfed bacteria along with potential cancer cells (Fossati et al., 2003, Dahlgren and 
Karlsson, 1999). ROS were shown to be critical initiators and mediators of apoptosis during 
carcinogenesis (Cowell et al., 2009). On the other hand, ROS were shown to mediate genetic 
instability and accumulation of mutations in the cells, prompting undesirable responses such 
as inflammation and enhanced proliferation finally leading to cancer (Giftson et al., 2010, 
Kekec et al., 2009, Reuter et al., 2010). Thus, ROS while generally perceived as harmful and 
potentially carcinogenic by their ability to damage macromolecules may actually be 
beneficial in their ability to trigger apoptosis in potential cancer cells. 
Iron, when present at high levels, generates ROS via the Haber-Weiss-Fenton reaction. This 
type of ROS can cause potential oxidative damage to lipids, nucleic acids or proteins (Kinzler 
and Vogelstein, 1996), which in turn couple DNA bases resulting in DNA lesions (Valko et 
al., 2006). Prolonged oxidative stress can result in mutation of proto oncogenes and tumour 
suppressor genes, along with deregulation in transcription, signal transduction and 
replication, all of which are associated with carcinogenesis (Turker et al., 1999). Also, at the 
molecular level, progression to malignancy is associated with sequential events that use the 
activation of key molecular pathways. In this regard, intermediate levels of ROS triggers the 
inflammatory responses through the activation of nuclear factor κ B (NF-κB) and activating 
protein -1. NF-κB has been related with the cellular apoptosis promotion; on the other hand it 
was also demonstrated to endorse cell proliferation in carcinogenesis (Gloire et al., 2006, 
Krishnaswamy et al., 2010). The inhibitor of NFκB kinase (IKKβ)/nuclear factor kappa B 
(NFκB) signaling pathway constitutes a key molecular link between inflammation and 
carcinogenesis. Genes that control cell proliferation, apoptosis, angiogenesis and metastasis 
were found to be regulated by NFκB signaling (Naugler and Karin, 2008). A direct 
stimulatory effect of iron on NFκB signaling has also been demonstrated in hepatic 
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macrophages. In an interesting study, inhibition of endotoxin-induced NFκB activation by 
iron chelators was analyzed in hepatic macrophages, suggesting a role for the intracellular 
chelatable pool of iron in NFκB activation (Xiong et al., 2003).  
2.10.2 Sequestration of iron by iron-binding proteins 
To prevent that kind of damage, all life forms that use iron bind the iron atoms to proteins. 
Thus, iron binding proteins sequester iron to reduce the threat of iron toxicity and the 
excessive generation of ROS. These proteins include plasma transferrin, lactoferrin, ferritin, 
hemosiderin and heme proteins. Under most circumstances iron remains tightly bound to one 
among the several of these aforementioned proteins. It was reported that in humans, Lf in 
tissues and secretions and transferrin in serum ensure that free iron does not exceed 10-18 M, 
thereby avoiding iron precipitation, microbial growth and formation of reactive oxygen 
species (Weinberg, 2009).  As discussed above, dietary iron is absorbed preferentially from 
the proximal part of the small intestine in the divalent form and is transferred to the 
circulation in which it is carried by transferrin (Goldenberg, 1997). Hemoglobin in the 
developing erythroid precursors and mature red cells halts most of the iron content in the 
body. Absorption of the dietary iron occurs in the enterocytes, after which apo transferrin (Tf) 
bind to two iron atoms (oxidized form of Fe+3) and mediates the hepatocyte / erythroid cell 
uptake of iron, based on the receptor-mediated endocytosis (Figure 2.6). Transferrin receptors 
(Tfr) on the surface of hepatocyte bind to its transferrin ligand, which is saturated with two 
Fe+3 atoms. This complex is then localized to the catherin coated pits and further internalized 
by the formation of endosomes. Divalent metal transporter1 (DMT1) then catalyzes the 
transport of iron across the endosomal membrane into the cytoplasm and is subsequently 
oxidized to Fe+2 form. The cytosolic iron is either localized in mitochondria to be 
incorporated into protoporphyrin to make heme or enters the circulation by incorporation on 
to the transferrin upon oxidation with ceruloplasmin (Chua et al., 2007, Andrews, 1999). 
Other members of the transferrin family have also been implicated in regulating iron 
homeostasis in mammals (Ward and Conneely, 2004) Whilst Tf is essential for iron delivery 
to erythroid cells, other iron uptake systems must exist in non erythroid cells (Wessling-
Resnick, 2000).  
As discussed in the previous section, Lf is a member of Tf family, which has the strong iron 
binding properties, high iron bioavailability and it is abundant in concentration in the breast 
milk. These observations suggested that this protein may play a role in intestinal iron 
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absorption in the neonate (Levay and Viljoen, 1995). Evidence for the importance of Lf’s role 
in iron homeostasis came from the observations on breast fed-infants delivered by women 
with good iron status benefit themselves from adequate iron status during the first 6 months 
of neonatal life (Scarino, 2007, Lonnerdal and Hernell, 1994). There was a long-standing 
controversy that existed as to the role of Lf in iron homeostasis. For instance, Lf knockout 
model of mice were reported that they haven’t develop iron deficient anemia, on such basis 
the authors ruled out Lf as a determinant factor in iron delivery during early neonatal life in 
the mouse. However observations like mild iron overload during the sucking period indicated 
that Lf regulated iron distribution within the body (Ward et al., 2003). In another study 
(Lopez et al., 2006), immunohistochemical localization of mouse Lf receptor (Lfr), DMT-1 
was done in the gestational days 13.5, 15.5, and 18.5 in order to validate the alternative 
transport pathway for iron homeostasis using Lfr. Lfr is expressed in fetal mice as early as 
gestational days (GD) 13.5, 15.5, and 18.5 whereas DMT-1 protein appeared to be 
mislocalized during late gestation, expressed at very low level during early neonatal life and 
predominantly expressed as immature form at PD 20. This expression pattern supported that 
until the development-dependent expression of DMT1 in the intestine is induced, mLfR may 
serve as an alternative iron uptake pathway. In addition, specific receptors for Lf have been 
identified on the small intestinal mucosal surface from many species including human, rhesus 
monkey, pig and mouse (Ward and Conneely, 2004). In vitro experiments have shown that 
Caco-2 intestinal cells transfected with hLfR have increased radiolabeled [59Fe] hLf uptake 
compared to the control cells (Suzuki et al., 2001). A recent clinical trial conducted on 
pregnant women affected by iron-deficient anemia has un covered the role of Lf in iron 
homeostasis (Paesano et al., 2010). Oral administration of 30% iron saturated bovine 
lactoferrin (bLf) in pregnant women suffering from iron deficiency and iron deficient 
anaemia significantly increased the number of red blood cells, hemoglobin, total serum iron 
and serum ferritin levels after 30 days of the treatment. This result appears very promising for 
the use of Lf in the iron homeostasis and the treatment of iron-deficient anemia.  
 
 
 
 
36 
 
 
 
 
Figure 2.6: Iron transport mechanism from enterocyte to hepatocyte. Non heme iron is transported 
across the brush border via DMT1 and heme iron is taken up via HCP1. FPN mediates the entry of 
iron in to the systemic circulation, where the iron is reduced and coupled to iron transport proteins 
like transferrin and lactoferrin. Further uptake of the iron in hepatocytes takes place based on the 
ligand receptor chemistry of the Tfr and carrier proteins. The so formed endosomes then acidified 
causing the release of iron, which will be either stored as ferritin or transported in reduced form after 
further coupling with iron transporter proteins. 
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2.11 Advantages of delivering anti-angiogenic/ anti-cancer molecules within 
nanocarriers 
Extremely short plasma half life of the therapeutics causes cancer patients to suffer harsh 
management of prolonged parenteral administration (Schoffski et al., 2004). In this regard, 
oral administration would be convenient, cost effective and reduce patient compliance 
(Gerrits et al., 1998b). Needle-free systemic delivery of protein drugs can be achieved by the 
oral route, which offers a convenient alternative for painful regime of targeting anti-cancer 
bio-macromolecules against cancer. At the nano scale, the fundamental and vital properties of 
matter such as solubility, diffusivity, blood circulation half life and immunogenicity and drug 
release characteristics can be altered (Nishiyama, 2007). Nanotechnology promises new hope 
and offers advantages such as controlled release, specific, targeted delivery, combinatorial 
therapy and many more (Zhang et al., 2008a). These imperative properties can be used for 
oral administration of bio-macromolecules for sustained delivery, which otherwise is a 
mounting task taking into account that the challenges from varying pH and enzymatic activity 
posed by the GI tract. 
Many delivery routes have been formulated for drug administration to be able to fight 
different diseases (Baratchi et al., 2009). A number of parenteral and non-parenteral 
administration routes for drug delivery has been developed and devised in the past for therapy 
(Kanwar et al., 2009b). However, complications such as thrombophlebitis or tissue necrosis 
and poor patient compliance have stimulated the investigation of non-parenteral routes (Xin 
Hua, 1994). Among non-parenteral routes, oral administration is usually preferred because it 
is non-invasive, most acceptable and convenient for the patient as well as no requirement for 
a skilled worker for drug injection. Oral bioavailability of these prodrugs or enzymes and 
peptide as well as protein drugs is generally very low, owing to the acidic conditions of the 
stomach, proteolytic activity of the gastrointestinal enzymes present in the intestinal tract and 
poor permeability across intestinal mucosa (Zhou and Li Wan Po, 1991a). Various 
approaches have been proposed to overcome the biopharmaceutical limitations associated 
with these drugs, such as inhibition of the enzymatic degradation (Morimoto et al., 1991), 
chemical modifications (Conradi et al., 1992), in situ gel systems (Shah and Paradkar, 2005), 
and the formulation of polymer or microsphere-based carrier systems (Torchilin et al., 1977). 
Application of nanocarriers for drug delivery, especially RNA, pDNA, prodrugs and 
bioactive drugs, is an expanding area of research that provided the design of biomaterials 
with controlled rates of drug release (Prokop et al., 2002). Recent advancements in 
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chemotherapy are using nano materials with a broad range of chemistry, including 
PEGylated, hydrophobically modified, glycol chitosan moieties and other poly esters (Table 
2.1). These nano wonders are reported to protect the drug from the extremities of the pH and 
enzymatic degradations. Drug delivery is one of the promising biomedical applications of 
nanotechnology. Several nano based cancer drugs for example Doxil and Abraxane are in 
clinical trials, to be able to use in cancer chemotherapy. Ideally speaking, a good nanocarrier 
will have minimal side effects and a greater hangover time in the blood. Nanocarriers made 
up of two or more different polymers can spontaneously assume various shapes in specific 
solvents and bring several advantages to the nanocore such as size, stability, drug loading and 
release efficiencies.  
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Table 2.1 Different types of nanocarriers  
Name Structure Composition Salient futures and uses  
1.Carbon nano 
tubes  
 
Made up of 
fullerenes (C60 
compounds) 
and/or carbon 
based hollow cage 
like structures. 
Increased internal volume and ease of 
functional modification of internal and 
external surfaces. Single walled nanotubes 
are used for drug and gene delivery. 
Double walled nanoparticles are found to 
have better implications for transfection 
(Martin and Kohli, 2003, Foley et al., 2002) 
2.Liposomes 
 
Amphipathic lipids Small unilamellar vesicles (SUVs) made up 
of single lipid bi layer, whereas large 
unilamellar vesicles (LUVs) consist of 
multiple layers. They alter the 
pharmacokinetic profile of loaded drug 
molecules (Rawat et al., 2006). 
3.Solid lipid 
nanoparticles   
 
Amphipathic lipids Made up of hydrophobic core (50-100nm 
in diameter);they can be used as effective 
adjuvant for vaccines and as non viral 
transfection agents(Cevc, 2004). 
4.Polymeric 
nanoparticles  
Biodegradable and 
biocompatible 
polymers. 
Nano capsules entrap the drug and nano 
spheres can be used for coating the drug 
on their surfaces. They allow for the 
greater control of pharmako kinetic 
behavior of the loaded drug, leading to 
more appropriate steady levels of the drug 
(Rawat et al., 2008, Mahidhara et al., 2011 
). 
5.Polymeric 
micelles 
 
Amphipathic lipids They are formed in hydrophobic 
environment. They are suitable for the 
delivery of water insoluble drugs because 
of their core shell structure (Torchilin et 
al., 2003). 
6.Dendrimers 
 
ABn type 
monomers 
They offer several advantages such as 
nanometer size range, ease of 
modification and ease of preparation. 
They can be used as coating agents for 
protection and delivery of drugs to various 
sites (Choi et al., 2005). 
7.Functionalized 
nanoparticles 
 
Inorganic metals 
such as Pt, Pd, Au 
and Ag.  
Fluorescent properties can be 
incorporated in them to be used as 
biosensors. They can be used as markers 
for research in molecular biology, targeted 
drug delivery and biosensing (Schneider et 
al., 2000). 
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Name Structure Composition Salient futures and uses  
8. 
Multifunctional 
nanoparticles  
 
Inorganic metals or 
ceramics with 
surface 
modification using 
biopolymers  
New generation of nanoparticles with 
theragnostic properties, with the 
integration of therapeutics, targeting 
ligands and imagine agents such as 
quantum dots. These offer sensitive 
diagnosis along sides acting as targeted 
therapeutic agnets (Liu et al., 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
41 
 
2.12 Uses of nanoparticles in cancer treatment           
Blood vessels in the tumour vasculature are found to be leaky and have pores in the range of 
10s and 100s of nano meters (Kanwar et al., 2009b). This fact can be exploited for drug 
delivery to the tumour site, using nanocarrier of the diameter 1-100nm, which was named as 
enhanced permeability retention (EPR) effect (Matsumura and Maeda, 1986) (Peer et al., 
2007). Of late, natural and synthetic polymers are used as drug delivery vectors. Table 2 
summarizes some different types of nanocarriers. Other nanocarriers used along with polymer 
conjugates include polymeric nanoparticles, lipid based carriers such as liposomes and 
micelles, dendrimers, carbon nanotubes and inorganic nanoparticles. There has been 
increased attention towards the development of biodegradable, polymeric nanoparticles for 
the diagnosis and treatment of cancer, in the scientific field. As mentioned above, anti-cancer 
biomolecules targeted along with nanocarriers especially polymeric nanoparticles and 
dendrimers is being done at pace. In the recent past, some formulations have been tested by 
using chemotherapeutic drugs, along with polymeric nanoparticles (Table 2.2). A formulation 
with two distinct layers of biodegradable polymers with inner nucleus containing anti-tumour 
agent, doxorubicin and the pegylated outer envelope with anti-angiogenic agent has been 
successfully tested (Sengupta et al., 2005). In another development, nanoparticles that co-
deliver paciltaxil and ceramide to overcome multi drug resistance in tumours, using the same 
formulation, developed PEO-PCL nanoparticles with tamoxifen and paciltaxil encapsulated 
with poly ethelene oxide modified poly-ε-caprolactone, to overcome multi drug resistance 
(MDR) in breast cancer cell lines (Devalapally et al., 2008). Anti-cancer drug nutlin-3a has 
been actively targeted using EpCAM antibodies, loaded on to poly (lactide-co-glycolide) and 
successfully tested (Das and Sahoo, 2010).  Lodamin was the mPEG-PLA modification of 
TNP-470, using methylated poly ethylene glycol (PEG) and poly lactic acid (PLA), which 
have fewer side effects compared to its counterpart, TNP. It was tested successfully in 
melanoma and LLC cell lines (Benny et al., 2008) and was reported to be a promising oral 
administrative, for anti-angiogenic therapy. In addition, there were some polymer conjugates 
which are under clinical use such as zinostatin, stimalmer, oncaspar and neulasta for cancer 
treatment (Duncan, 2006). To develop an oral administrative, careful design of the core and 
exterior coat is required. Recent developments in bone marrow tissue engineering, dentistry, 
orthopedics and plastic surgery are making use of these kinds of composites in the macro 
scale; utilizing the same principles in the nanoscale will ensure more promising drug 
development (Kanwar et al., 2009b). 
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Table 2.2 various polymeric nano drug formulations tested against cancer angiogenesis. 
S/No. & Name Formulation Outcome Cell lines 
tested 
Reference 
1.Nano cell Nucleus with 
doxorubicin and 
pegylated lipid 
envelop over 
this 
Chemo therapeutic 
agent in the nucleus 
disrupt the solid 
tumour and  the anti-
angiogenic agent 
disrupt tumour 
vasculature 
Melanoma 
and  LLC 
(Sengupta 
et al., 2005) 
 
2.PEO-PCL 
nanoparticles 
Tamoxifen and 
paciltaxil 
encapsulated 
with poly 
ethylene oxide 
modified Poly 
ε caprolactone 
Combination therapy of 
temoxifen and paciltaxil 
nanoparticles can 
overcome Multidrug 
resistance (MDR) 
Breast 
cancer  
(Devalapally 
et al., 2008) 
 
3.Folate-
SPION-DOX 
micelles 
Doxorubicin, 
Fe2O3 in 
copolymer of 
PEG and Poly 
ε caprolactone 
with folate as 
targeting ligand.  
Used for both 
diagnostic as well as 
therapeutic purposes, 
as Fe2O3 can be 
detected with MRI 
Hepatic 
carcinoma 
(Hong et al., 
2008) 
4.Lodamin TNP-470 with 
mPEG-PLA co 
polymer 
Tumour vasculature 
gets reduced  with 
fewer side effects of 
TNP-470 
Melanoma 
and LLC 
(Benny et 
al., 2008) 
 
5.PEC micelles VEGF siRNA 
with Poly 
ethylene glycol 
and poly 
ethylene imine 
Inhibition of VEGF 
mediated angiogenesis 
Prostrate 
carcinoma 
cell lines 
(Kim et al., 
2008b) 
6.PECM siRNA-PEG-
Fusogenic 
peptide(KALA) 
VEGF gene silencing  Prostrate 
carcinoma 
cell lines 
(Lee et al., 
2007) 
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2.13 Use of inorganic biomaterials in medicine  
Various definitions have been allotted to the term ‘‘biomaterials’’. The major consents are ‘a 
nontoxic material that is biologically active’ and ‘a material that provokes a reaction with the 
body which is appropriate to the medical purpose’. Biomaterial is a substance that has been 
engineered to take a form which, alone or as part of a complex system, is used to direct, by 
control of interactions with components of living systems, the course of any therapeutic or 
diagnostic procedure in human or veterinary medicine (Williams, 2009). In a broad sense, 
biomaterials are designed to treat disorders of a biological system, which perform their 
function by interfering with the system, without disturbing its anatomical and/or 
physiological integrity. The major difference of biomaterials from other classes of materials 
is their ability to remain in a biological environment without damaging the surroundings and 
without being damaged in that process. Thus, biomaterials are solely associated with the 
health care domain and must have an interface with tissues or tissue components (Dorozhkin, 
2010, Jandt, 2007). The previous 3-4 decades represent the scientific advancement in 
innovative use of ceramics in biomedical applications such as skeletal repair and 
construction. Ceramics can be defined as solid compounds that are formed by a chemical 
reaction between a metal and a non-metallic elemental solid or between non-metal and non-
metallic elemental solids (Cevc, 2004, Duncan, 2006, Foley et al., 2002, Martin and Kohli, 
2003, Rawat et al., 2006, Rawat et al., 2008, Mahidhara et al., 2011 , Benny et al., 2008). The 
materials within this class of medical implant are often referred to as “Bioceramics” (Best et 
al., 2008).  As the bioceramics have enhanced bio compatibility and biodegradation, they can 
be used as versatile agents in drug delivery for fiddly diseases such as cancer and 
neurodegenerative diseases.  
2.14 Bio-ceramics used in medical applications  
Most ceramics used in medical applications such as dentistry and orthopedics are based on 
calcium phosphates. Various forms of calcium phosphate ceramics are being used for the last 
4 decades, which include hydroxyapatite, beta tri calcium phosphate, biphasic calcium 
phosphate amorphous calcium phosphate, carbonated appetite and calcium deficient 
hydroxyapatite (Rawat et al., 2006). Bio-ceramics with microporous and mesoporous surface 
architecture have been developed. The list includes i) Crystalline ceramics ii) Bio glasses and 
iii) Ceramic hybrids. 
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i) Crystalline ceramics have been widely employed in the areas of orthopedics and dentistry. 
These include synthetic apatites like hydroxyapatite, substituted apatites, biphasic mixtures of 
calcium phosphates and calcium phosphate cements.  
Structural and chemical analogue of bone mineral component, which has hexagonal 
symmetry to be able to use as biomaterial is hydroxyapatite (OHyAp), Ca10 (PO4)6(OH)2 
(Salinas and Vallet-Regí, 2007). Applications of liquid mix technique, precipitation of 
aqueous solutions and aerosol synthetic techniques are widely used for production of sub 
micrometric particles of OHyAp (Vallet-Regí and González-Calbet, 2004, Guzmán Vázquez 
et al., 2005). However, these synthetic apatites don’t exactly mimic bone mineral in all 
aspects, especially in the carbonate content in sub lattice arrangement. Synthetic procedures 
cannot incorporate carbonate ions in OHyAp in lower amounts than seen in bone mineral 
(Doi et al., 1998). Ions such as Na+, K+, Mg2+, Sr2+, Cl-, F-, [HPO4] 2-, etc. can be substituted 
in sub lattices of OHyAp (Zapanta-Legeros, 1965). This improves tissue growth as younger 
tissues can develop and grow faster while storing other minerals that the body requires during 
growth. These ionic substitutions can vary surface integrity of OHyAp and with positive 
outcomes on the material in the biological milieu.  In addition, the presence of ions such as 
carbonate and strontium aid dissolution of apatite for its bio degradation. Bioactive responses, 
mechanical strength and porocity of the ceramic could be improved by doping silicates into 
the structure (Alauzun et al., 2005, Okamoto et al., 2005).   
Biphasic mixtures of OHyAp and β-tricalcium phosphate (β-TCP) have been used to 
synthesize mineral components of bones. These two different phases (stable OHyAp and 
resorbable β-TCP) form carbonate hydroxyl apatite under physiological conditions. Released 
carbonate and phosphate ions from these biphasic mixtures helps in bone regrowth. Solid 
state treatment of natural bone, combustion precipitation and blending of different calcium 
phosphate are the various techniques employed in the preparation of these mixtures (Ragel et 
al., 2002, Padilla et al., 2006). Calcium, phosphate, carbonate and sulphate salt based cements 
attracted much consideration in bone tissue engineering and dentistry owing to their excellent 
biocompatibility and bone repair properties (Hoexter, 2002). They consist of powder phase 
calcium and/or phosphate salts together with an aqueous phase that reacts at room or body 
temperature and forms a calcium phosphate crystal that sets by entanglement of crystals. 
These cements are easy to handle and can be manipulated by varying  different constituents 
as per the choice of the required physicochemical characteristics (Nilsson et al., 2002).  
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ii) Bio glasses: usually these are used for assisting bone matrix regeneration and bone growth. 
Bioactive glasses are typically composed of SiO2, Na2O, CaO and P2O5 and are prepared by 
sol-gel process, because of which, key properties such as composition and texture could be 
modified as per the necessities. Also, due to their bioactivity, bio glasses are eligible for use 
as bioactivity accelerators of mineral apatites or as bioactivity inductors of magnetic 
materials for hyperthermia treatments of osseous tumours. Growth factors and polypeptides 
can be included in bioglasses to be able to achieve controlled release profiles. Bio-active 
glasses could be classic melt glasses, used in fillings. In vitro tests in simulated body fluid 
(SBF) have demonstrated the formation of carbonate hydroxyapatite (CHA) nano crystals, 
which shows the bioactivity of melt glasses (Jones et al., 2006). Sol-gel glasses are formed by 
ternary CaO-P2O5-SiO2 or binary CaO- SiO2 system, which is more time consuming than that 
of traditional melt glasses (Salinas et al., 2002). Network modifiers such as Mg or Zn can be 
used to dope in to this system to enhance mechanical and/or resorption capacities 
(Balamurugan et al., 2007). It has been observed that in ternary system, formation of Si-OH 
groups hinders formation of amorphous calcium phosphate, which means CHA 
crystallization requires more time in ternary systems compared to binary systems (Salinas and 
Vallet-Regí, 2007). These glasses were shown to have excellent biocompatibility in vitro as 
well as in vivo (Olmo et al., 2003). Because of this property, mixed materials have been 
produced, in which glass component provides bioactivity. Sol-gel glass- polymer-drug 
hybrids (Meseguer-Olmo et al., 2006) can be used for obtaining sustained therapeutic action; 
sol-gel glass-magnetic component-OHyAp based materials for hyperthermia treatments in 
bone tumours (Singh et al., 2009, Ebisawa et al., 1997).  
iii) Mixed ceramic hybrids: Polymeric organic components could be inserted in cereamic/ 
sol-gel glass component to form organic-inorganic hybrids, which have improved mechanical 
strength, elasticity and biodegradation. Varying formulations of polymers and inorganic 
components have been tested with wide range of performances in SBF with respect to bio 
activity. The mixed ceramic hybrids can be broadly classified into two classes out of which, 
class I hybrids have weak interactions between organic and inorganic components. Polyvinyl 
alcohol (PVA) or poly hydroxyethyl methacrylate (pHEMA) have been reported to form 
hybrids of type I (Luciani et al., 2008).  Type II hybrids are classified as hybrids formed by 
strong chemical linkage such as covalent or ionic covalent linkage. Polymethyl methacrylate 
(PMMA), poly ε caprolactone (PCL), gelatin or acetyl cellulose along with silica were 
observed to form type II hybrids (Tanaka and Kozuka, 2005). Mesoporous materials have 
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pore sizes in the range of 2-50 nm with different geometries. Ordered mesoporous materials 
have been reported to have advanced applications in controlled delivery of bio 
macromolecules (Yang et al., 2009). Improved biomedical applications of these materials 
could be the result of increased surface silane groups, which in turn improves the formation 
of CHA for an enhanced bioactive response (Slowing et al., 2008). Also, stargels, which are 
comprised of organic core and inorganic overhangs, were reported to have intermediate 
mechanical behavior between glasses and rubbers. Thus, these materials may well be used as 
good candidates in orthopedics, dentistry or drug delivery with little modification to their 
bioactivity. In order to produce bioceramics with improved bio-activity and porosity (hybrid 
character of sol-gel glass and mesoporous materials), template glasses have been synthesized. 
These template glasses showed high bioactivity, homogeneity and biodegradability compared 
to either sol-gel glasses or mesoporous materials (Xia and Chang, 2006).  
 2.15 Uses of bioceramics as nanoparticles  
Improving the therapeutic index while reducing the side effects of the bio-macromolecular 
formulations could be achieved by designing relatively inert and non-toxic carriers for in vivo 
delivery represents an optimistic approach. Astonishing efforts in the field of nano 
biotechnology have been made towards improving slow/controlled release, target specificity, 
improved efficiency, lower side effects and ease of delivery of drugs and pharmaceuticals by 
developing novel nanotechnology platforms. 
The chemistry of inorganic nanoparticles has been reported to be advanced for cellular 
uptake, compared to other formulations. Thus, many classes of inorganic nanoparticles have 
been used as carriers (Chowdhury and Akaike, 2005, Farokhzad and Langer, 2006, Bourgeat-
Lami, 2002). The tested inorganic materials for macromolecular delivery include 
biodegradable calcium phosphate, carbon nanotubes, silica, gold, magnetite, quantum dots, 
strontium phosphate, magnesium phosphate, manganese phosphate, and double hydroxides 
(anionic clays). Inorganic nanoparticles possess some outstanding characteristics such as 
resistance to microbial attack, ease of preparation, low toxicity, and good storage stability. 
Ceramic nanoparticles as drug delivery systems:  These are the nanoparticles made up of 
inorganic – ceramic compounds such as calcium phosphates; silica, titania and alumina have 
been found to have wide applicability in terms of macromolecular delivery (Table 2.3). 
Ceramic nanoparticles have a size less than 50 nm, which helps them invading 
reticuloendothelial system (RES) of body and exploit the enhanced permeability and 
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retention (EPR) effect posed by pathological angiogenic vasculature (Matsumura and Maeda, 
1986). As discussed above, changes in porosity and/or surface modifications are insignificant 
with variations in pH, temperature and enzyme actions, thus making these particles ideal 
candidates for delivery of macro molecular drugs such as proteins and enzymes (Bhattarai et 
al., 2008).  Moreover, because of their enhanced biocompatibility and surface modifications, 
these ceramic particles could have implications in effective targeting (Badley et al., 1990). 
Silica nanoparticles have been prepared by well conventional sol-gel methods (Ulrich, 1990). 
A three component transfection system has been developed for efficient DNA transfection as 
the first successful step towards this modular synthetic DNA delivery system (Luo et al., 
2004). Cationic surface modifications have been observed in efficient binding, condensation 
and protection of the DNA (Luo et al., 2004). Silica nanoparticles along with DNA having a 
size range of 10-100 nm modified with sodium chloride have been reported to show about 
70% of transfection efficiency in vitro and in vivo (Chen et al., 2003). In yet another 
interesting study, mesoporous silica nanoparticles were covalently modified with polyamido 
amine dendrimers. DNA combined with these nanoparticles, showed maximum transfection 
efficiency in neuroglia, human cervical cancer and CHO cells compared to commercial 
reagents (Radu et al., 2004). Increase in uptake of DNA with the aid of silica nanoparticles 
could be attributed to an increase in sedimentation because of a high density and also to the 
possible exertion of mechanical pressure on the cell membrane (Shen et al., 2004).  
Calcium phosphates (CaP) being an important constituent in bones and other hard tissues 
have been used in nanoparticulate form for transfection of bio macromolecules. It has been 
studied that calcium phosphate occurs in carbonate hydroxyapatite (CHA) form as 
nanoparticles, with the exception of enamel (Fratzl et al., 2004). This lessens any concerns 
regarding biocompatibility, when calcium phosphate nanoparticles are used as external 
therapeutic aid. In one study, CaP nano particles with varying ratios of Ca: P have been 
developed and studied for transfection efficiencies in HeLa and MC3T3-E1 cell lines. It has 
been observed that nanoparticles with 25-50 nm size and Ca/P ratio between 100 and 300 
showed maximum transfection efficiency (Olton et al., 2007). DNA loaded CaP nanoparticles 
have been successfully tested for transfection in CNE-2 cells  (Liu et al., 2005). In an 
interesting development, Kakizava et.al have used block co-polymer, poly ethylene glycol-
block- poly (methacrylate) modified CaP- siRNA nanoparticles for obtaining high 
transfection efficacy, tolerability in the biological medium, and low toxicity (Kakizawa et al., 
2006). Rapid precipitation and immediate surface fictionalization techniques have been 
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employed in preparation of 80 nm CaP nanoparticles baring either DNA or oligonucleotides 
(Sokolova et al., 2007). Improved transfection efficiencies because of enhanced protection 
from intracellular degradation was observed for oligonucleotides protected in the core of CaP 
(Sokolova et al., 2007). Taken together, bioceramics could act as ideal carriers for nucleic 
acid and/or biomolecular delivery. 
Table 2.3 some of the nanodrug formulations made up of ceramic materials. 
 
 
 
S.No Ceramic used Size 
range 
Formulation Comments 
1. Calcium 
phosphate 
 
400 nm Alginate, chitosan and 
calcium phosphate 
Controlled release of 
serratiopeptidase (STP) 
(Rawat et al., 2008) 
2. Hydroxyapatite 200 nm-
1 µm 
Hydroxyapatite and 
alginate 
Controlled release of insulin 
was successfully tested in SIF 
(Paul and Sharma, 2006) 
3. Calcium 
phosphate 
350 nm Alginate, chitosan 
Lactoferrin and calcium 
phosphate  
In vitro and in vivo efficacy, 
intoxicity and controlled 
release of anti-cancer proteins 
(Mahidhara et al., 2011 ) 
4. Calcium 
phosphate 
25-50 
nm 
Calcium and phosphate Transfection of DNA in HeLa 
and MC3T3 cells was studied 
(Liu et al., 2005) 
5. Silica  225 nm Silica nanoparticles Enhanced transfection of 
DNA in COS-7 cells (Luo et 
al., 2004) 
6. Silica 100 nm NaOH modified silica Enhanced DNA transfection 
in HT 1080 cells (Chen et al., 
2003)  
7. Silica 250 nm Silica and poly amido 
amine  
DNA transfection in CHO 
cells (Radu et al., 2004) 
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2.16 Oral delivery of anti-cancer therapeutics  
To develop an oral administrative, careful design of the core and exterior coat is required. 
Recent developments in bone marrow tissue engineering, dentistry, orthopedics and plastic 
surgery are making use of these kinds of composites in the macro scale; utilizing the same 
principle in the nano scale will ensure more promising drug development (Kanwar et al., 
2009b). Ceramic nanoparticles are being designed in order to assist protein absorption on 
them and various layers of biodegradable polymers are then coated on their surface as 
discussed below, in order to protect them from lytic or gastrointestinal enzymes and for 
obtaining sustained release kinetics of the loaded drug. Although there is an increasing list of 
publications on DNA transfection using ceramic nanoparticles, only a few studies have been 
done with respect to protein loading.  The oral route remains to be most challenging but 
convenient route for drug administration, in terms of full control over administration by the 
patient and needle free or non-invasive therapy. Biologically sensitive proteins have been 
tried with nanotechnology to be able to achieve safe and effective delivery via the 
gastrointestinal tract.  In this regard, acceptable oral delivery of bio-active molecules like 
insulin, heparin, budesonide, leuprolide and gastric enzymes has been tried using polymeric 
nanoparticles (Zhang et al., 2010, Iqbal et al., 2011, Kanwar et al., 2011a, Luong-Van et al., 
2006, Rawat et al., 2008, El-Sherbiny, 2010). Brief summary of these findings are given 
below 
1. Insulin was protected by forming complexes with cationic  β  cyclodextrin polymers, 
which were synthesized from β cyclodextrin, epichlorohydrin and choline chloride. 
Because of electrostatic interactions, it has been shown that insulin is protected from 
simulated gastro intestinal fluid (Zhang et al., 2010). 
2. In another study, gastric enzyme, STP was entrapped in a chitosan, alginate matrix 
and was shown to release the enzyme in a controlled fashion in gastric and intestinal 
pH (Rawat et al., 2008).  
3. Heparin is an anti coagulant that has wide applications in controlling vascular smooth 
muscle cell (VSMC) proliferation. Polycaprolactone  nanofibers loaded with heparin 
were shown to decrease inflammatory response by decreasing the proliferation of 
VSMCs (Luong-Van et al., 2006). 
4.  Microspheres with pH responsive character were prepared using ionotropically-
crosslinked mixture of sodium alginate and chemically modified carboxymethyl 
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chitosan. These microspheres were characterized and in vitro evaluated as potential 
carriers for oral delivery of protein drugs (El-Sherbiny, 2010). 
5. In an interesting study, using a novel one-step spray-drying process - uncoated and 
Eudragit 100 coated chitosan–Ca–alginate microparticles efficiently loaded with anti 
inflammatory drug budesonide (BDS) were prepared. With enhanced bio-adhesive 
and controlled release properties in GIT, these microparticles were proposed to be 
useful for local treatment of inflammatory bowel diseases (Simonoska Crcarevska et 
al., 2008). 
Limitations: Major disadvantages that are involved in using microspheres include difficulty 
of large scale manufacturing, maintaining the stability of the entrapped drug and poor control 
over drug release rates (Varde and Pack, 2004). Moreover, particles with higher sizes tend to 
settle in the blood vessel, if they were administered into the systemic circulation. There are 
less chances of protecting a drug moiety from the insults that were experienced from the 
interior milieu with only one polymeric layer around it. However, these limitations could be 
addressed if the size is reduced below 500 nm and the number of polymeric layers increased 
with varying chemistry will help in protecting the entrapped drug by various polymeric layers 
more efficiently.  
In a similar approach, with increase in genetic engineering and bio technological research, 
there has been vast improvement of anti-cancer drugs, which could act on various angiogenic 
and apoptotic targets, for eliminating tumours. Nanotechnology could be the best possible 
option for safe and bio-active delivery of these molecules. Oral delivery of various anti-
cancerous agents has been tried in the recent past: 
1. Fumagillin derivative TNP-470, an anti-angiogenic agent was tested with 
nanoformulation to be able to reduce the side effects. Lodamin, having TNP-470 in 
mPEG-PLA nanoparticles was proved to efficiently reduce the side effects with 
enhanced anti-tumour activity (Benny et al., 2008). 
2. PLA-TPGS-MMT nanoparticles carrying anti-cancer drugs made to take advantages 
of TPGS and MMT in nanoparticle technology such as high emulsification effects and 
high drug encapsulation efficiency (Feng et al., 2009). 
3. In an attempt to treat hormone-responsive cancers such as prostate or breast cancer, 
leuprolide based on poly-acrylic acid (PAA) nanoparticles were developed. It has 
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been shown that relative oral bioavailability of leuprolide could be increased by 
nanoparticulate tablets up to 4.2-fold (Iqbal et al., 2011). 
4. Hyaluronic acid–coupled chitosan nanoparticles bearing oxaliplatin (L-OHP) 
encapsulated in Eudragit S100–coated pellets were developed for effective delivery to 
colon tumours. These drug delivery systems show relatively high local drug 
concentration in the colonic milieu and colonic tumours with prolonged exposure time 
and enhanced anti-tumour activity (Jain et al., 2010). 
5. An anti-tumour drug, 10-hydroxycamptothecin, was encapsulated into nanoparticles 
made of biodegradable poly (caprolactone-co-lactide)-PEG-poly (caprolactone-co-
lactide) by a novel two-step nano-precipitation method. Chitosan surface modified 
nanoparticles have shown an increase in transcytosis across a Caco-2 cell monolayer 
(Zhang et al., 2006). 
6.  More recently, anti-angiogenic anti-cancer therapy using nanoplatforms carrying 
various bio-macromolecules, such as cell permeable peptides, natural anti-cancer 
proteins like Fe-bLf and genetically engineered dominant negative survivin have been 
encapsulated in polymeric nanoformulation as to develop an oral nutraceutic therapy 
(Kanwar et al., 2011b).  
Limitations: Chemotherapeutic drugs are mainly steroid derivatives thus could pose serious 
side effects when incompletely metabolized in the body. It has been observed that 
anthracyclines, such as doxorubicin cause serious cardiac side-effects, at high doses these 
may lead to acute tachy-arrhythmias and acute heart failure (Elberry et al., 2010). 
Nevertheless, due to the changed dosage- schemes these reactions are now rare but, the sub-
acute or chronic cardiac effects of anthracyclines remain a clinical problem. Several 
explanations account for the anthracyclin cardiotoxicity, like free radical production, calcium 
overloading, mitochondrial dysfunction and peroxynitrite formation have been proposed 
(Shuai et al., 2007). Clinically, anthracyclin- induced cardiotoxicity evident itself as left 
ventricular failure which develops as a chronic disorder over months to years after 
completion of the anthracyclin-based chemotherapy and may result in congestive heart failure 
(Minotti et al., 2004). A promising anti-cancer pharmaceutical could be achieved if these 
compounds can be replaced by efficient anti-cancer bio-macromolecules such as anti-cancer 
proteins, siRNA and/or miRNA, with the aid of nanotechnology.  
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2.17 Scope for using multi layered polymer encapsulated ceramic nanocarriers 
Taken together, the aforementioned innovative ideas and their possible limitations (Section 
2.14), along with the advancements of ceramic and polymeric nanotechnology as listed in 
sections 2.8, 2.10, 2.12; it is alluring to use bioceramics along with polymers for 
nanodelivery of therapeutics. Combination of bioceramics with polymers could improve the 
stability, bioactivity and biodegradation of the nanoformulations. In this regard, readily 
available biodegradable polymers such as chitosan, alginate and cyclodextrins (Kanwar et al., 
2011a) advance cost effectiveness of the polymeric nanomedicine compared to the use of 
conventional synthetic polymers. In an interesting study, protein drug delivery has been 
tested with porous hydroxyapatite nanoparticles entrapped in an alginate matrix. Oral 
administration of insulin via these ceramic nanoparticles suggests more efficient and 
controlled release (Paul and Sharma, 2006). Hence, for the above mentioned 
nanoformulations (Section 2.13), in vitro assessment of serratiopeptidase (Rawat et al., 2006, 
Rawat et al., 2008) could be modified with the addition of polymeric layers to meet the 
possible challenges that might be encountered in vivo. To the best of the knowledge, no 
previous work has reported on the use of this alginate encapsulated nanocarriers for plasmid 
DNA (pDNA) or RNA interference (RNAi) delivery for gene targeting in any disease in 
vitro/in vivo or in human clinical trials.  Furthermore, it is tempting to expand the utility of 
these nanocarriers for the delivery of therapeutic biomolecules, by further modifying their 
physicochemical characteristic such as size and thermal stability. Since, particles larger than 
20 μm are prone to be washed out, being inefficient for mucosal absorption (Lameiro et al., 
2006) and to maintain the native structures (Cleland, 1997), particles below 0.5 μm are better 
alternatives. Innovative techniques, as discussed above have put forward the use of ceramics 
in high-tech applications like delivering chemicals and biologicals effectively in vitro and in 
vivo (Cherian et al., 2000).  
In our lab, recently for the first time, the covalently cross-linked cell permeable peptides 
(CPP - R9 and Tat peptides) complexed with survivin siRNA were found to abrogate the 
expression of survivin, which is otherwise reported to be over expressed in tumours and 
inflammation (unpublished observations). ACSC nanoformulation was used for effective 
loading and protection of these active acid-labile and alkaline-labile bio macromolecules for 
oral administration. These loaded targeted nanocarriers have been successfully tested in 
human colon cancer cells (Caco-2 and HT-29) in transwell assays as an attempt towards 
increasing the bio-availability, sustained release, mucoadhesiveness and conformational 
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stability. The prolonged activity was obtained due to slow release of the protein or RNA from 
the ACSC and the intact structure without denaturation or dehydration during delivery and 
storage (Mahidhara et al., 2011 ). The encouraging results obtained in this study could 
propose the use of ACSC for future in vivo studies, especially in the delivery of biomolecular 
drugs including RNA, DNA, protein and peptides. These nanocarriers were further found to 
be promising in terms of exhibiting special qualities like better therapeutic effect and 
enhanced protection of the drug. Further studies in relation to pharmacokinetics, toxicology, 
and animal studies are required for validating clinical utility of the formulation. More 
recently, cell permeable SurR9-C84A (Bawa, 2009, Cheung et al., 2006, Kanwar et al., 2010 
, Baratchi et al., 2011) and HSP-90 antagonists, shepherdin have been tested to induce 
apoptosis and disintegrate the  mitochondria of colon and breast cancer cells (but not normal 
control cells) more efficiently, using in vitro cell based assays. In addition to covalently cross 
linked CPP with siRNA or SurR9-C84A protein only, non-covalently cross-linked CPP 
coupled siRNAs for survivin and siRNA for oncogenic microRNA-27a (as-miR-27a) on NCs 
and transferred to human breast cancer MDA-MB-231 and MCF-7 cell lines. The results 
show that both R9 and Tat CPP peptides covalently complexed with anti-sense miRNA-27a 
(as-miR-27a) loaded NCs exhibits oncogenic activity (unpublished data). Suppression of 
miR-27a inhibits breast cancer cell growth and invasion. Simultaneously, down regulation of 
the genes important for cell survival and angiogenesis such as survivin splice variants, 
vascular endothelial growth factor (VEGF), and VEGF receptor1(VEGFR1) was observed in 
more efficient manner in comparison to monotherapy.   
Therefore, using natural anti-cancer molecules like Fe-bLf along with bio macromolecules 
such as SurR9-C84A, miRNA, siRNA could thus be employed as an alternative therapeutic 
strategy to eradicate tumours. Furthermore, encapsulation of these anti-cancer agents in novel 
platforms made out of multilayered polymeric material with biodegradable ceramics 
enhances their stability in the interior milieu as represented in the Figure 3.9. Thus, natural 
polymers and ceramics make the system more bio-degradable and bio-available. 
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Chapter 3: Preparation and characterization of ACSC NCs with natural bLf (ACSC-Lf 
NCs) 
3.1 Introduction  
Side effects of present day anti-cancer chemotherapeutics can be readily overcome by using 
anti-cancer bio-macromolecules, such as siRNA ,miRNA and/or  anti-cancer proteins (Zeng 
et al., 2006). Proceedings in biotechnology and genetic engineering have led to an increased 
curiosity in the use of these biomolecules. As reported in the section 2.9.1, bLf, a single 
chain iron binding glycoprotein, present in bodily fluids was proved to be efficient in 
abrogation of tumorigenesis (Kanwar et al., 2008).  The study reported that apo-bLf (4% 
iron-saturated), natural bLf (`15% iron saturated) and 50% iron-saturated bLf were less 
effective in potentiating cancer chemotherapy, and did not cause tumour eradication. High 
anti-tumour efficacy of Fe-bLf was assigned to the 100% metal saturation levels, which 
increases in vivo stability, whereas Apo form of bLf and other forms used in this study are 
less stable against protease degradation. Thus, delivery of these molecules to the target site, 
maintaining their structural integrity poses predicaments from the tough conditions in 
gastrointestinal tract. 
Recent advances in nanotechnology can be explored to protect the active biological 
conformation and structure of macromolecules to overcome the sturdy barriers offered by the 
gastro intestinal epithelium (Kim et al., 2008a, Kumar Malik et al., 2007, Jain and Jain, 2008, 
Zhou and Li Wan Po, 1991b). Nanotechnology offer benefits like slow/controlled release, 
target specificity, improved efficiency, lower side effects and ease of delivery. Use of 
polymeric nanocarriers include safe and effective delivery of anti-cancer bio 
macromolecules, in addition to the above benefits along with improving biodegradability of 
the nanoformulation, after a time period (Duncan, 2006, Sanhai et al., 2008, Liam, 2009 , 
Zhang et al., 2008a). Due to their size, these nanocarriers can transport the cargo via very 
small pores- this property could offer additional benefits for blood brain barrier drug delivery 
(Kanwar et al., 2009b) and in cancer therapy, by exploiting enhanced permeability retention 
effect (EPR) offered by pathological- angiogenic vasculature in the cancer and 
neurodegenerative diseases  (Sarapa et al., 2003, Duncan, 2006). Modern developments in 
polymeric nanoformulations for the treatment of cancer have reported a number of homo and 
co-polymer combinations, for sustained and controlled delivery of anti-cancer agents (Hwang 
et al., 2008, Kim et al., 2008a, Balakrishnan et al., 2009, Wang and Li, 2008, Howard et al., 
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2008, Yadav et al., 2009, Zhang et al., 2008b). Nanocarrier based oral formulation for anti-
cancer drug delivery has attracted considerable interest recently (Benny et al., 2008, Zhang et 
al., 2006). Of late, NCs of size ranges between 100-1000 nm have also been prepared based 
on natural proteins, especially by salting out silk fibroin (Lammel et al., 2008, Slotta et al., 
2008). This scheme can be implicated in preparation of anti-cancer NCs for the efficient 
delivery of the particles through biological barriers.  
Taking all the above reported studies into consideration, the present study deals with the 
development of chitosan coated calcium phosphate - lactoferrin nanocarriers (CSC-Lf NCs) 
for the effective delivery of anti-cancer proteins. For better protection, in the GI tract, these 
nanocarriers were further encapsulated in alginate gel (termed as ACSC-Lf NCs). Nano 
encapsulation of the natural bLf was tested using the novel NCs that were hypothesized to 
stabilize the entrapped cargo. Thus, an attempt towards increasing the anti-cancer efficacy of 
natural bLf was done by enhancing its stability in the ACSC NCs. All of the constituents 
chosen for the formulation are biocompatible and bio-degradable; calcium phosphate is a 
natural chemical present in bone, chitosan and alginate offer low immunogenicity and 
enhanced biocompatibility. Preparation and further investigation of the physicochemical 
profiles, internalization in vitro and transcytosis of these NCs in colon cancer cells was 
carried out. Promising outcomes with respect to internalization, enhanced apoptosis to the 
cancer cells and in vitro transcytosis studies have been identified and thus this formulation 
might become a promising oral delivery system for the administration of anti-cancer drugs, to 
be able to develop an effective nutraceutical therapy. 
Methodology: A detailed description of methodology involved in the formulation and in 
vitro evaluation of NCs was given in chapter 8 (page no.183 - 201). Methodology that 
corresponds to each specific result sections has been mentioned in the text.  
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3.2 Results  
3.2.1 Standardization of formulation conditions for ACSC Lf NCs   
 
                                
Figure 3.1: Schematic representation of alginate enclosed nanocarriers (NCs) were shown in the 
figure.  Natural bLf loaded calcium phosphate ceramic cores were surface coated with chitosan. 
Biocompatible NCs were made upon treatment with sodium tripolyphosphate (STPP) cross linker. 
Alginate was used as an additional polymer to make an orally available nano system. CaCl2 was used 
to make an alginate gel by cross linking alginate monomers on the top of chitosan coated ceramic 
nanocores porous hybrid structures. 
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Different formulation conditions have been tested before standardizing the specific protocol 
to synthesize ACSC NCs, as shown in the Table 3.1. Initially, chitosan (10%w/w) was 
dissolved in acetic acid solution and was agitated along with calcium phosphate containing 
protein under investigation (natural bLf or Fe-bLf) for 30 min, resulting in slurry like 
substance. This method further was modified with reduction in chitosan to 5% which resulted 
in polymeric rods in micron range. The protocol then modified as follows to obtain 
nanoparticles of 350 nm sizes: bLf was filtered through a 100 nm filter to restrain the 
agglomerates and the free protein was adsorbed on to the ceramic calcium phosphate 
nanoparticles. The ceramic nanocarriers were then coated with a thin chitosan (0.1%w/v in 
acetic acid) film in a magnetic stirrer for a period of 2 h. A non toxic poly anion, STPP was 
used to make cross linkages between positively charged amine groups within the chitosan, 
with constant stirring for 24 h to be able to obtain a thin film. This standardization method is 
more evidently represented in Table 3.1.  Finally, the alginate layer was deposited on the 
chitosan coated ceramic nanocarriers by gelation of sodium alginate using calcium chloride. 
More detailed methodology for the preparation of ACSC NCs was given in chapter 8 
(Section 8.5 page 187) Moreover, with each different protein loaded NCs as reported in 
chapters 4, 5, 6 and chapter 7 the standardization procedures were modified to be able to 
reduce the final size of the ACSC NCs to 322 ± 27.2 nm, as represented in Table 6.1 
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Table 3.1: Standardization conditions for preparation of CSC Lf NCs 
S. No. Constituents 
(w/w)# 
Conditions Size Morphology E.E* 
 
 
1. bLf – 5% 
Chitosan – 10% 
STPP – 10% 
Agitation for 
30min 
> 1 µm 
 
Non 
particulate 
slurry 
60% 
2. bLf – 5% 
Chitosan – 1% 
STPP – 1% 
Stirring 6000gX 
30min 
> 1 µm 
 
Non 
particulate 
slurry 
60% 
3. bLf – 5% 
Chitosan – 1% 
STPP – 1% 
Stirring for 
6000gX 1h 
> 1 µm 
 
Rod like 
consistency 
73% 
4. bLf-10% 
Chitosan -1% 
STPP – 1% 
Stirring for 
6000gX 4h 
800nm
-1µm 
 
Non 
homogenous 
particles 
80% 
5.  bLf -10% 
Chitosan - 1% 
STPP – 1% 
Stirring 6000g 
X 6h 
400-
450nm 
 
Non 
homogenous 
particles 
80% 
6. bLf – 10% 
Chitosan -0.1% 
STPP - 0.1% 
Stirring 6000g 
X 6 h 
250-
300nm 
 
Spherical 
particles 
80% 
7. bLf-10% 
Chitosan-
0.01% 
STPP-0.02% 
Stirring 
6000gX12 h 
200-
250nm 
 
Spherical 
particles 
80% 
(# w/w= with respect to CaP core   *E.E=encapsulation efficiency) 
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3.2.2 Physical characterization of ACSC Lf NCs  
ACSC NCs entrapping either natural bLf (abbreviated as ACSC Lf NCs) or Fe-bLf 
(abbreviated as ACSC-Fe bLf NCs) were prepared as described above with modifications of 
the previous reports (Kossovsky et al., 1996, Yuan et al., 2007). Physical appearances of the 
NCs formed in various steps during the formation of ACSC NCs were observed, taking Fe-
bLf and Fe-bLf loaded NCs as an example. Figure 3.2 represents the physical appearance of 
Fe-bLf and various nanocarriers after the lyophilization of the sample. Cherry red color that 
is the characteristic of Fe (III) coordinate compounds was observed in case of Fe-bLf or CaP 
nanocores loaded with Fe-bLf. Chitosan coated NCs and alginate encapsulated NCs were 
transparent as the colour was masked by the polymeric layers.  
In order to observe the hydrodynamic diameter of the NCs after encapsulating the natural 
bLf, Dynamic light scattering spectrometry (DLS) was used. Detailed methodology for the 
physicochemical characterization was represented in chapter 8, (Section 8.6.1, page 188). 
The results indicated an increase in the size of NCs after layering with different polymers 
which includes chitosan and/or alginate. Ceramic cores were found to have a diameter of 
190.1 ± 23.3 nm and chitosan covering has increased the size up to 255.1 ± 20.1 nm. After 
complete formation of ACSC Lf NCs, the size was further increased up to 379 ± 27.3 nm 
(Figure 3.3b). Scanning electron microscopic (SEM) results further supported the DLS data 
and it also determined the spherical morphology of NCs (Figure 3.3a), which conveys their 
advantage in transporting the anti-cancer protein to the cancer tissue via mucosal, gastric 
barriers and subsequent systemic circulation.  
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Figure 3.2: Lyophilized powders of (a)Fe-bLf, (b) CaP-FebLf, (c)chitosan encapsulated CaP void 
NCs (CSC NCs) (d) Fe-bLf loaded CSC NCs (e) alginate encapsulated CSC-Fe-bLf NCs and (f) void 
ACSC NCs. The representative schematic diagrams were given in the inset of the corresponding 
image.  
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 Figure 3.3: The NCs were found to have spherical morphology when observed under SEM, for (a) 
CaP- Lf (CaP loaded with natural bLf – scale bar 200 nm), (b) CSC NCs (scale bar 200 nm), (c) 
CSC-Lf NCs (scale bar 300 nm); (d &e) ACSC Lf NCs (scale bar 300 nm) (f) DLS spectrometric 
observation of in various layers predicts the size of ceramic to ACSC Lf NCs increases from 100 to 
380 nm.   
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3.2.3 Analysis of the natural bLf configuration after the formulation  
As the native 3-dimentional configuration plays a crucial role in the function of protein, the 
NCs were analyzed for the presence of lactoferrin by using chromatographic techniques. 
ACSC Lf NCs were subjected to SDS PAGE gel retardation assay and Western blotting. 
Detailed methodologies for the chromatographic techniques were represented in chapter 8, 
(Section 8.7, page 189). Retardation of ACSC Lf NCs in the stacking gel was observed as 
represented by intense bands in the stacking gel, this was compared with positive control of 
bLf, where there were no specific bands observed in the stacking gel (Figure 3.4a, lane 1). 
This indicated the immobilization of bLf loaded in ACSC Lf NCs in the stacking gel. In 
addition to this, bLf specific bands in Western bots, developed by using antibodies specific to 
the bLf showed the integrity of the protein after the formulation procedure (Figure 3.4a). To 
investigate the stability of ACSC Lf NCs in the acidic pH in the stomach and alkaline pH in 
the intestine, ACSC Lf NCs were treated with HCl pH 1.2 and with phosphate buffered saline 
at pH 7.4, for different time intervals starting from 1 h to 6 h. The resultant samples were 
then analyzed by SDS PAGE, as it is shown in the left panel of Figure 3.4b; more intense 
bands were observed from 4 h of incubation time in alkaline medium (Figure 3.4b lane 6), 
representing the release of CSC NCs by dissolution of outer alginate covering. Whereas in 
acidic medium there were no significant bands until 6 h of incubation time, which means the 
protection to the protein offered by alginate gel in the acidic medium. Subsequently, Western 
blots indicate the clear bands of bLf confirming the findings observed by SDS-PAGE (Figure 
3.4b). 
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Figure 3.4: (a) Release of natural bLf from ACSC Lf NCs was observed by doing SDS PAGE gel 
retardation assay. Retarded bands in the stacking gel represent NCs; protein released from the gel was 
separated at 75 kDa region on the gel. Western blot shows clear bands that correspond to bLf. (b) 
Stability of NCs in pH 1.2 and 7.4 shows an increase of degradation starting from 2-4 h in alkaline 
media, whereas in acidic media the NCs were stable up to 6 h was represented in SDS gel as well as 
Western blots. Lane 1 - control, lanes 2,4,6,8 represent alkaline treatment in 1 h, 2 h, 4 h and 6 h; 
lanes 3,5,7,9 represent acidic treatment in 1 h, 2 h, 4 h and 6 h respectively.  
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3.2.4 Cell viability studies 
In order to determine the nature of cell death following treatment with different preparations 
of NCs and the difference between apoptosis and necrosis, annexin-V staining was used. 
Further, TUNEL assay was also performed using an in situ apoptosis detection kit from 
Roche, to confirm the results of annexin-V assay. Since, the ACSC Lf NCs were found to be 
dissolved in the intestinal pH releasing inner CSC Lf NCs, to proceed with these experiments, 
Caco-2 cells were treated with CSC NCs (3mg/ml or 1 x106 NCs) carrying natural bLf along 
with same concentration of void NCs without protein and the viability of the cells were 
measured compared to taxol (-ve control) and/or untreated cells (+ve control). 
Comprehensive methodology for the cell viability studies were represented in chapter 8, 
(Sections 8.9.2 and 8.9.4, page 193). As indicated in Figure 3.5a, a time dependent cell death 
by using natural bLf loaded NCs was observed. For example, an apoptotic index of 35.3 ± 4.0 
(P<0.005) was observed in case of CSC Lf NCs at the end of 12 h whereas up to 24 h the 
percentage was increased to 44.7 ± 5.7 (P<0.005). In addition to this, amount of FITC 
fluorescence that corresponds to TUNEL positive staining was increased in CSC Lf NCs 
treated cells (blue) were observed in comparison to control (red) or void NCs treated cells. 
Further analysis of apoptosis, confirmed the apoptotic index that was predicted by Annexin-V 
staining. For example, an apoptotic index of 28.2 ± 0.2 (P<0.005) was observed in case of 
CSC Lf NCs at the end of 12 h and at 24 h the percentage was increased to 45 ± 4.9 
(P<0.005), which is corresponding with the annexin –V staining. An index of 9.5 ± 1.3 in 
case of void NCs treated cells indicated the in toxicity of void NCs. So the same 
concentration was used for further in vitro experiments that were done to understand 
endogenous effects of CSC NCs.   
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Figure 3.5: (a) Viability of Caco-2 cells were measured by annexin V-PI staining after treatment 
with CSC-Lf NCs and void NCs, using 6 µM/ml of taxol as –ve control. Increase in cell death in case 
of CSC-Lf NCs was observed (b) TUNEL assay results obtained indicates there is no difference in the 
fluorescence of void NCs (green) compared to control (red).Increase in the fluorescence was observed 
that corresponds to apoptotic cells in CSC-Fe-bLf (blue) and taxol (purple) treated cells, as indicated 
by relative fluorescence observed using flow cytometry. Data represents mean ± SEM. Experiments 
were repeated 3 times independently with similar results. √√P<0.005 ACSC Lf NCs or taxol vs void 
NCs was considered as highly significant. 
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3.2.5 In vitro internalization studies of NCs in Caco-2 cells 
After analyzing the cytotoxicity of the natural bLf loaded NCs, the study focused in finding 
the functional mechanism of internalization. To be able to do this, rhodamine labeled CSC, 
CSC-Lf and ACSC Lf NCs were used for the quantification of endocytosis percentage of the 
NCs in Caco-2 cells, using flow cytometry (Figure 3.6a). Comprehensive methodology for 
the cellular internalization was represented in the chapter 8, (Section 8.10.2, page 194). The 
cancer cells were treated with rhodamine labeled NCs (2.8x105 NCs), for up to 12 h, starting 
from 1 h. Flow cytometric analysis showed an increase in cellular uptake of void CSC NCs 
from 16.6 ± 0.4 % in 1 h to 62.2 ± 2.4% by the end of 12 h whereas increase was observed to 
be prominent in CSC Lf NCs, which was 17.7 ± 1.2% initially in 1 h and increased to 72.2 ± 
7.2% (P<0.005) at the time period of 12 h. In case of ACSC Lf NCs the percentage of 
endocytosis was increased to 16.1 ± 0.7 % at the end of 12 h from 6 ± 0.3 % in 1 h (Figure 
3.6b). Furthermore, to confirm the flow cytometric findings and to assess internalization of 
CSC Lf NCs by chromatographic technique, Caco-2 cells were treated with CSC Lf NCs for 
different time periods ranging from 1 h to 72 h and lysed using RIPA buffer. The lysates were 
analyzed by 10% SDS PAGE, bands that correspond to 75kDa were observed in the 
acrylamide gels (Figure 3.6c). Detailed methodology for the chromatographic techniques was 
represented in chapter 8, (Section 8.7, page 189). Immunoblotting with bLf specific 
antibodies was done in order to confirm the bLf bands obtained in the SDS PAGE. Specific 
bands that represent bLf immunoreactivity were observed confirming the internalization of 
bLf loaded NCs. 
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Figure 3.6: (a) Flow cytometric analysis shows increased internalization profiles of fluorescently 
labeled NCs. (b) Internalization of the rhodamine labeled CSC Lf NCs with time up to 12 h; ACSC Lf 
NCs have not shown much increase compared to other combinations. Data represents mean ± SEM 
Experiments were repeated 3 times independently with similar results. √√P<0.005, CSC-Lf vs ACSC 
Lf NCs treatment. (c) Endocytosis of CSC-Lf NCs was analyzed by doing cell lysis after treatment 
with ACSC NCs for different time intervals. Subsequent probing with Lf specific antibody shows the 
internalization of NCs. 
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3.2.6 Internalization of NCs in Caco-2 cells – Confocal microscopic and 
immunocytochemical studies 
To determine qualitative endocytosis in order to further visualize the flow cytometric and 
chromatographic internalization observations, confocal microscopy was done using 
fluorescent NCs. Rhodamine labeled CSC NCs loaded with natural bLf or Fe-bLf were 
treated on to Caco-2 cell monolayers grown in 8 well chamber slides and incubated over a 
time period of 12 h. After the successful incubation, the slide was fixed in 4% 
paraformaldehyde (4%PF) and the cytoskeleton was stained with actin antibody, the nuclear 
staining was done with DAPI (Please refer to Section 8.10.2, page 194 for detailed 
methodology). Confocal microscopic data indicated the cytoplasmic as well as nuclear 
localization of the rhodamine labeled NCs (Figure 3.7a). Cells treated with rhodamine only 
were used as negative control and the absence of rhodamine specific fluorescence further 
proved the fluorescence that was observed in case of NCs treated cells was due to the 
internalization of the NCs. Furthermore, to confirm these results, immunocytochemical 
observation for bLf specific immunoreactivity was analyzed in Caco-2 cell monolayer after 
treatment with bLf loaded CSC NCs. Characteristic brown coloration was observed in 
cytoplasmic and nuclear regions in the cells after the probing the reactivity of the goat 
polyclonal bLf antibody using DAB substrate, which is specific for anti-goat HRP conjugated 
IgG as a secondary antibody (Figure 3.7b). These results confirmed the cytoplasmic and 
nuclear localization of the NCs. 
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Figure3.7: (a) Confocal microscopy shows the cytoplasmic and nuclear internalization of 
fluorescently labeled NCs (rhodamine-red) with nuclear (DAPI -nucleus) and cytoplasmic staining 
(actin –FITC green). Control cells (a-d) show no red fluorescence (scale bar represents 75 µm); 
Rhodamine loaded CSC NCs (e-h–scale bar -10 µm) and CSC- Fe-bLf NCs (i-l–scale bar -25 µm) 
shows fluorescence corresponding to the rhodamine. (b) Microscopic observation of 
immunocytochemistry using bLf specific antibodies shows +ve immune reactivity for bLf protein in 
cytoplasm and nucleus, images were observed under 100 X oil immersion objective.    
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3.2.7 In vitro transport of CSC NCs via Caco-2 cell monolayer  
After observing the endocytosis of NCs in the cells, the study focused on validating the 
additional transcytosis mechanism (refer to Figure 3.9). In order to proceed with the 
experiments, Caco-2 cells were grown in transwell plates for a time period of 24 days so as to 
form a monolayer and were treated with rhodamine labeled CSC, CSC Lf and ACSC Lf NCs 
(2.8x105 NCs), in different transwells. Comprehensive methodology for the in vitro transport 
was represented in the chapter 8, (Section 8.10.3, page 195) transepithelial electrical 
resistance (TEER) values were measured as a function of integrity of the Caco-2 monolayer 
after treating with different NCs. TEER was calculated at regular time intervals after the 
treatment for 2 h, 4 h, 6 h, 24 h, 48 h and 72 h; for any difference compared to initial 0 h 
treatment. The resistance values were found to be unaffected (Figure 3.8a) till 72 h, 
indicating that the NCs does not affect the integrity of the monolayer by opening tight 
junctions. However, there has been a slight decrease in TEER values in monolayers treated 
with CSC, CSC Lf NCs was observed at 72 h of treatment, whereas monolayers treated with 
ACSC Lf NCs have not shown any decrease in TEER values even after 72 h. Amount of 
relative fluorescence units were measured at both apical and basolateral sides, as a function 
of transcytosis. As shown in Figure 3.8b there has been increase in transcytosis in CSC-Lf 
NCs and CSC NCs from 2 h to 72 h compared to ACSC NCs, indicating an improved 
transcytosis with chitosan covering as well as decrease in size of the NCs.  
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Figure 3.8: (a) TEER measurements were noticed to be the same when Caco-2 cell monolayer was 
treated with ACSC-NCs, from 0 h after treatment to 72 h. From the graph it can be observed that there 
is a slight decrease in the TEER in case of monolayers treated with CSC and CSC Lf NCs at the end 
of 72 h.  Right panel (b) shows transcytosis profiles of CSC NCs, CSC Lf NCs and ACSC Lf NCs for 
a time period of 2 h to 72 h. The graph indicates the decrease in relative fluorescence units in apical 
side (represented as api) compared to the basolateral side (bl) with progression of time. Data 
represents mean ± SEM. Experiments were repeated 3 times independently with similar results. 
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3.3 Discussion  
 Using anti-cancer proteins/peptides to target solid tumours is a better approach, in order to 
overcome the side effects of present-day medications. To date, a number of anti-cancer 
and/or angiogenic proteins/peptides have been identified and tested successfully for the 
development of an effective anti-cancer drug. Various tumour suppressor proteins such as 
survivin antagonists and other anti-angiogenic proteins such as RGD peptide have been 
effectively shown to perk up anti-angiogenic and/or anti-apoptotic tumour therapy (Ryan et 
al., 2009, Pasqualini et al., 1997). However, these peptides show rapid renal clearance in 
rodents and humans (Haubner et al., 1999, Sivolapenko et al., 1998). Nanocarrier based anti-
cancer protein delivery is a promising strategy for better protection and controlled delivery of 
the protein/peptide in the target site (Peer et al., 2007). In recent studies, protein drug 
targeting to the tumour by using polymeric nanocarriers has been practiced (Kim et al., 
2008a). Nevertheless, many of the studies aimed at development of a parenteral 
administration, which are invasive procedures and imposes painful regime. There are some 
studies designed for oral administration of anti-cancer chemotherapeutics that could have 
serious side effects. Therefore the strategy in the present study was aimed at developing a 
nano platform that can carry a combination of anti-cancer proteins for oral administration, so 
that patient compliances against the painful intravenous infusions in clinic can be effectively 
reduced. This study demonstrated the preparation of alginate enclosed chitosan coated 
lactoferrin ceramic nanoparticles comprising calcium phosphate, for protection against pH 
variations and increased uptake in intestine. 
Natural polymers such as biodegradable alginate and chitosan were used because of their 
ready availability, inexpensiveness, low toxicity, and mucoadhesiveness and above all they 
have low immunogenicity. Calcium phosphate, a naturally occurring ceramic in bones and 
teeth have good biocompatibility and biodegradability to be able to use as an inner ceramic 
core. Natural bovine lactoferrin was incorporated into the NCs to improve oral 
bioavailability. Lf, a natural secretory-defence protein present in bodily fluids is a single 
chain 78kDa metal binding glycoprotein (Gupta et al., 2009). It is a multi functional protein 
and plays a key role in iron absorption in the intestine, promotes intestinal cell growth and 
protects against microbial infections, along sides acting as an anti-cancerous agent (Section 
2.9.1). Thus, when coupled to NCs, bLf could help in increased intestinal absorption of the 
inner core comprising CSC Lf NC – released after degradation of alginate outer layer, in the 
intestinal alkaline pH. In addition to this, augmentation of chemotherapy has been reported 
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when 100% iron saturated Fe-bLf was administered parallel prior to chemo therapy (Kanwar 
et al., 2008).  However, 20% iron saturated or Apo form of bLf were shown to be ineffective 
in eradicating the tumours owing to their high degradation compared to metal saturated 
protein. Thus, this study aimed at incorporation of natural bLf with around 15-20% saturation 
of metal ions. In total, the designed platform can carry natural bLf protein, embedded in the 
core formed by ceramic calcium phosphate and encapsulated by chitosan and alginate for 
improved gastrointestinal protection. DLS spectrometric data represents the formation of 
layers one over the other throughout the process of final ACSC formation. The range of bLf 
and/or Fe-bLf loaded NCs was found to increase from 200 nm for ceramic core to 400 nm 
after the formation of final ACSC NCs. SEM indicated a stable spherical morphology of 
ACSC NCs. Although there was a debate regarding the dimensions for the nanotechnology to 
be within 1-100 nm (Zhang et al., 2008a), particles of the sizes ranging from 200 nm up to 
400 nm, such as Abraxane were also tested. In the recent past, many reports were published, 
in relation to the threshold limit for polymeric nanoparticles ranging up to several hundred 
(~400 nm) of nanometres to show EPR effect (Peer et al., 2007). In this regard, when the size 
of the ACSC NCs in the range of 400 nm were used, there could be possible queries to 
qualify them as traditional NCs but when the alginate layer is dissolved in the intestinal 
milieu, the released CSC NCs could well under the nano range. However, this bigger size was 
further trimmed, as will be discussed in the subsequent chapters, with modification in the 
formulation procedure (Table 3). Therefore, taking into consideration that size effect cellular 
internalization profiles, in the subsequent chapters the NCs were analyzed for their uptake 
starting from 1 h instead of 12 h as done in this study. In addition, alginate and chitosan being 
biodegradable polymers solubilised in aqueous environment and release the loaded bLf in a 
controlled way as indicated by SDS PAGE observations. Retardation of NCs in the stacking 
gel could be attributed to the large molecular weight of the NCs compared to proteins as well 
as their net positive surface charge.  Presence of bLf specific bands in immunoblot using 
specific antibodies indicates the protection of the protein conformation during the 
formulation procedure. The controlled release experiments using SDS PAGE gel retardation 
assays and subsequent immunoblots indicated the controlled release of bLf from ACSC Lf 
NCs.   
Residence time of a drug through the gastrointestinal tract is predicted to be in between 9-12 
h. Taking into consideration that maximum transit time of a drug in stomach and intestine is 4 
h, therefore, the stability of ACSC Lf NCs in acidic media (HCl pH1.6) and alkaline media 
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(PBS pH 7.4) for a time period of 6 h was determined. The results indicate the release of CSC 
Lf nano cores from ACSC from 4 h to 6 h in alkaline medium, which is predominant in the 
intestine. So for further experiments of internalization and transcytosis of NCs, CSC Lf NCs 
were used. Absence of prominent bands in HCl treated NCs for a time period of 1-4 h 
indicates the intactness of ACSC Lf NCs in acidic media. Discrete bands after 4 h show 
release of CSC Lf NCs from ACSC after 4 h, when this phenomenon is applied to in vivo 
conditions, NCs will not be degraded as such because by the time NCs would have escaped 
from acidic environment in the stomach. Further, in vitro endocytosis assay for CSC Lf 
uptake by Caco-2 cells showed internalization of NCs from 1 h up to 12 h. Flow cytometric 
analysis indicates increase in uptake of the CSC Lf NCs by cells compared to void CSC NCs 
or ACSC Lf NCs; this can be because of the surface coating with Lf, which helps in 
improved endocytosis. It has been suggested that nanocarrier size plays a key role in the 
adhesion and uptake of NCs by cells (Chen and Langer, 1998), this can be attributed to the 
reason why ACSC Lf NCs were taken less compared to other nanoformulations. However, 
decreased uptake of ACSC Lf NCs shall not affect the overall uptake of NCs by cells and/or 
through intestine, since the motto of using alginate layer is to protect the inner core from 
getting degraded in the GI tract and alginate itself gets degraded in the process, releasing 
CSC inner core. The pool of CSC NCs will be abundant in a total population of NCs that 
have reached their final destination. Thus, minimal uptake of ACSC Lf NCs as reported in 
flow cytometric results adds up to the total internalization of NCs. Confocal microscopy 
indicates internalization of CSC-Lf NCs in Caco-2 cells. Interestingly, nuclear localization of 
the NCs was observed in addition to cytoplasmic localization. Immunocytochemical 
observation also indicates nuclear localization of Lf specific reactive bands, representing 
nuclear permeability of the NCs carrying Lf. This is a very interesting observation because 
unpublished reports in our lab show that bLf, by itself cross the nuclear membrane after 12 h; 
whereas the uptake time was decreased with the nanoformulation. So this particular 
phenomenon can be implemented in targeting an anti-cancer agent that cannot cross nuclear 
membrane. Induction of apoptosis in the cancer cells in vitro was further investigated by 
measuring apoptotic index after treatment with natural bLf loaded NCs. Compared to the 
amount of free bLf (1000 µg per ml), lower doses (100 µg per ml) of the nano entrapped 
protein was sufficient to produce equal amount of a cytotoxic response. This 10 fold increase 
in sensitivity could be contributed by the improved protection and sustained release of the 
protein offered by the NCs and their nuclear translocation, as exemplified in the confocal 
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microscopic investigations. Increase in apoptotic index using protein loaded NCs indicates 
the potential of these NCs to be used as anti-cancer therapeutics. Since the 100% saturated 
Fe-bLf was shown to be more anti-cancerous compared to natural bLf, an increase in the 
cytotoxicity could be observed when loaded in to these NCs, which was addressed in the 
subsequent chapters 6 and 7. 
It has been reported that surface modification can enhance the uptake of NCs by cells 
(Kanwar et al., 2009b). This study has demonstrated the increase in transcytosis of NCs 
containing chitosan and bLf. In order to mimic the in vivo conditions, Caco-2 cells were 
grown in the millicell tissue culture inserts, with the help of which, they can access media 
from both their apical and basolateral sides, unlike the other plastic culture plates. After 
various treatments with the NCs, the confluence of the cellular monolayer was quickly 
determined by observing for any change in TEER at successive time intervals. Herein, there 
was no significant difference in TEER of the monolayer before and after treatment with NCs 
until 72 h. In a previous study, it was noticed that there was a decrease in TEER values after 
treatment of Caco-2 cell monolayer with chitosan NCs (Zhang et al., 2006). Further the 
authors attributed the decrease in TEER values was because of opening of tight junctions by 
chitosan. However, results in this study indicated a different scenario, which can be possibly 
because of a different nanoformulation used in the preparation of these NCs. In this study, 
chitosan film was primed over the nanocore by using a poly anion, STPP, which would react 
with amine groups of chitosan, because of which these NC open the tight junctions in a 
reversible manner causing minimal damage to the cell membrane, as reported previously 
(Sonaje et al., 2009). Thus the NCs could enter the blood circulation without effecting or with 
very little damage to the epithelial cell layer. The NCs were hypothesized to reach the 
intestine after being delivered orally, protecting the anti-cancer proteins loaded in them from 
variations in pH and enzyme activity. The alginate covering get degraded in the intestinal 
alkaline pH, releasing CSC-Lf NCs to invade blood stream. Infiltration of these NCs into the 
tumour occurs upon encountering with tumour angiogenic vasculature, based on the EPR 
effect and Brownian movement of the NCs inside the tumour. The finally formed CSC Lf 
containing endosomes form endolysosomes, which upon further degradation releases the 
contents inside the cell (Figure 3.9). This hypothetical phenomenon was successfully 
addressed by in vivo investigation in nude mice bearing xenograft tumours from human 
origin. The novel anti-tumour efficacy of nano entrapped Fe-bLf protein was shown to 
completely abrogate tumorigenesis as will be discussed in chapter 6 and 7 of this 
76 
 
dissertation. 
 
Figure 3.9: Schematic illustration of the proposed mechanism of alginate enclosed chitosan coated 
calcium phosphate bioceramic nanoparticle internalization. (a) The alginate coating gets degraded in 
the alkaline and enzymatic environment in the intestine and the (b) chitosan coated ceramic particles 
released in the intestinal milieu to enter the blood circulation via endocytosis and/or transcytosis. (c) 
Passive delivery of these ceramic cores at the cancer site happens by utilizing the EPR effect. (d) 
Further uptake of the NCs in to the cancer cells would be based on oligosaccharide receptor mediated 
endocytosis. Ceramic core further helps in the controlled release and biodegradation of the 
formulation. [Figure was taken from (Kanwar et al., 2011b)]. 
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Chapter 4: Validation of bio-availability of the Sur R9-C84A after encapsulation in 
ACSC NCs                                       
4.1. Introduction 
Polymeric nanocarriers made of carbohydrate and/or carbohydrate derivatives are important 
in anti-cancer and oral drug delivery, as they can be efficiently taken by mucosal membranes 
in the intestine. Naturally occurring polysaccharides like sodium alginate and chitosan have 
received much attention in drug delivery system for their excellent biocompatibility. Chitosan 
is a weak cationic homo polysaccharide, with a repeating units of 2-amino-2- deoxy-β-d-
glucan in a 1,4 linkage and could be subjected to chemical modification in order to obtain a 
derivative with the desired characteristics (Alves and Mano, 2008). Chitosan was shown to be 
used as pharmaceutical excipient. It has been successfully tested as wound dressing agent, 
ingredient in food and also it was shown to reduce cholesterol levels (Tapola et al., 2008). 
Chitosan was successfully used in some weight loss drugs. More interestingly, in human 
volunteers chitosan haven’t shown side effects when taken in high amounts (Gades and Stern, 
2005). Although there were some reports about toxicity of chitosan in solution form and 
chitosan derivatives, with additional care in maintaining some aspects such as pH, salt free 
form could provide health benefits (Baldrick, 2010). Alginic acid is a linear copolymer of (1, 
4) linked-D-mannuronic and -l-guluronic acid residues with properties such as an aqueous 
matrix environment, high gel porosity and biocompatibility, and approved by the US Food 
and Drug Administration (FDA) for oral use (Tugcu-Demiroz et al., 2007). Amino groups in 
the chitosan molecule and carboxyl groups in the alginate molecule are pH-sensitive and can 
be therefore used as drug carrier materials. The interactions between alginate and chitosan 
were scientifically investigated (Becheran-Maron et al., 2004). Their polyelectrolyte complex 
was widely used to obtain devices for the controlled release of the drugs (Murata et al., 
2004).  
As discussed in the section 2.8, survivin inhibitors (inhibitors of IAP) have grabbed the 
attention of researchers as survivin expression is high in tumours and not detectable in normal 
differentiated tissues (Li, 2003). In addition to this, It has been noticed that the increased 
levels of survivin with the use of HSP 90 inhibitors, which demonstrated the over expression 
of survivin as an important factor that contributes to the induction of chemotherapeutic drug 
resistance (Cheung et al., 2010a). Baculovirus IAP repeat (BIR) domain is a predominant part 
of the IAP protein structure consisting of a three-stranded anti-parallel β-sheet surrounded by 
four small α helices (Verdecia et al., 2000). Importance of BIR domain’s role in prevention of 
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apoptosis was determined by mutational studies. Therefore, point mutations such as D53A, 
C84A and a combination of T34A and C84A (Yan et al., 2006) in the BIR domain prevents 
dimerization of survivin as a consequence of loss of hydrophobicity, producing a dominant-
negative mutant that impedes anti-apoptotic function of native survivin  (Baratchi et al., 
2010a, Kanwar et al., 2001b). It was observed by others and in our lab that loss of function 
mutants of survivin can act as anti-cancer agents, by inhibition of native survivin action 
(Shen et al., 2009, Kanwar et al., 2010d). Intracellular delivery of macromolecules could be 
enhanced by conjugation to the cell penetrating peptides (CPPs). The most frequently used 
CPPs are penetratin (pAntp), Tat and 9-mer of L-arginine (R9) (Deshayes et al., 2005). Since, 
R9 peptide was shown to be superior to Tat peptide (Wender et al., 2000), this study utilized 
R9 cell-permeable peptide carrier fused to the C84A survivin mutant.  Recently, it was shown 
that a cysteine to alanine (amino acid position 84 of the wild type survivin, SurR9-C84A) 
mutant of survivin, induces apoptosis in cervical and prostate cancer cells (Cheung et al., 
2010b). Although R9 CPP carrier makes the protein more permeable in the cancer cells, bio-
availability of the protein could be increased by nano encapsulation.  
In theory, delivery of labile SurR9-C84A to the target site can be further improved by using 
the ACSC NCs as described in the previous chapter. Thus, the ACSC NCs was further loaded 
with SurR9-C84A mutant of survivin, to test its in vitro anti-tumour activity on Caco-2 cell 
lines. The SurR9-C84A – ACSC NCs were characterized with respect to their morphology, 
particle size, size distribution and release profiles of SurR9-C84A. Further, in vivo behavior 
of the NCs in intestinal milieu was analyzed by creating the intestinal microcosm with 
omnizyme treatment to assess the protection offered by alginate and chitosan to the Sur R9-
C84A. Quantitative and qualitative determination of the endocytosis was analyzed by flow 
cytometric and confocal microscopic techniques. Real time PCR and Western blotting were 
done to investigate endogenous survivin levels after NCs treatment, in order to analyze the 
functional mechanism of action for the NCs on the cancer cells.  
Methodology: A detailed description of methodology involved in bio-availability of the Sur 
R9-C84A after encapsulation in ACSC NCs was given in chapter 8, pages 183-201. 
Methodology that corresponds to each specific result sections has been mentioned in the text. 
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4.2. Results 
4.2.1. Sur R9-C84A loaded NCs show spherical morphology with 330nm size  
For the preparation of Sur R9-C84A loaded ACSC NCs, slight modification of the protocol 
from the preparation of ACSC Lf NCs (Section 3.2.1), was carried out. SurR9-C84A 
(purified protein with 16 kDa MW for monomer and 32 kDa for dimer as given in section 
8.4) was filtered through a 100 nm filter to sieve the aggregates and adsorbed on to the 
ceramic calcium phosphate. The ceramic nanocarriers were then coated with a thin chitosan 
(0.01%w/w in acetate buffer) film. A non toxic poly anion, STPP was used to make cross 
linkages between positively charged amine groups within the chitosan, as was done 
previously (Refer to section 8.5, page 187 for detailed methodology). Hydrodynamic 
diameter analysis using the DLS spectrometry indicated an increase in the size of NCs after 
coating with chitosan and/or alginate, from 226 ± 23.5 nm for ceramic cores to 322.1± 22.6 
nm after complete formation of ACSC NCs (Figure 4.1a). SEM results further supported the 
DLS data and it also determined the spherical morphology of the NCs (Figure 4.1b), which 
conveys their advantage in transporting the anti-cancer protein to the cancer tissue via 
mucosal, gastric and subsequent systemic circulation as illustrated in Figure 3.7.  
Incorporation of SurR9-C84A into ACSC nano platforms did not affected the size of the NCs 
as shown in Figure 4.1c. 
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Figure 4.1: Synthesis of ACSC Sur NCs and characterization: (a) DLS spectrometric observation of 
various layers predicts the size of ceramic calcium phosphate (CaP) to ACSC NCs increases from 
100-322 nm. Sizes of CaP (blue), CSC- Sur (red) and ACSC Sur NCs (green) were represented as 
according to light intensity and size of the NCs. Lower panel shows the surface morphology of (b) 
CSC-Sur NCs, (c) ACSC Sur NCs respectively. The NCs were found to have spherical morphology 
when observed under SEM, scale bars indicates 200 nm. 
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4.2.2 ACSC Sur NCs show controlled release profiles of the encapsulated protein  
Controlled release of SurR9-C84A encapsulated in the ACSC NCs was analyzed in PBS pH 
7.2, using spectrophotometrical analysis of SurR9-C84A released from the NCs (Please refer 
to section 8.8, page 191 for a detailed methodology). The results show a sustained release up 
to 24 h (Figure 4.2a). In order to visualize qualitatively, SDS PAGE gel retardation assay, for 
ACSC Sur NCs was carried out (Figure 4.2b). Absence of SurR9-C84A specific bands (in the 
resolving gel) indicates immobilization of ACSC Sur NCs in the stacking gel. Further, 
retardation of ACSC Sur NCs was indicated by intense bands in stacking gel as well as 
SurR9-C84A specific bands in the Western bots (Figure 4.2b), the corresponding position (32 
kDa) to that of the positive control (observed as dimerized SurR9-C84A) in SDS-PAGE. Use 
of SurR9-C84A specific mouse monoclonal antibodies indicated the preservation of native 
protein configuration during the formulation (inset Figure 4.2c). To investigate the fate of 
ACSC Sur NCs in the enzymatic milieu in the digestive tract, ACSC Sur NCs and CSC Sur 
NCs were mixed with commercially available enzyme tablet cocktail mixture, omnizyme, for 
a period of 6 h at 370C. The resultant samples were then analyzed by SDS PAGE, as it is 
shown in Figure 4.2b; no intense bands were observed from 4 h of incubation time in case of 
CSC Sur NCs, indicating the degradation of SurR9-C84A in the core of CSC nanocarriers 
starts at that time. In the case of ACSC-Sur NCs, there were no potential bands till 6 h of 
incubation time, indicating the release of CSC inner core only after 6 h. Successive Western 
blots indicate the clear bands of SurR9-C84A at 32 kDa confirm the findings observed by 
SDS-PAGE (Figure 4.2d). 
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Figure 4.2: Controlled release of ACSC-Sur NCs. (a) Controlled release of SurR9-C84A from NCs 
as observed under PBS pH 7.2; inset showing SDS PAGE gel retardation assay (c) and Western blots 
(b) indicate the integrity of the protein during the formulation process. Thick bands in the stacking gel 
indicate SurR9-C84A immobilized on the NC, this is evident from the Western blots. (d) Stability of 
NCs in enzymatic milieu was observed by treating with Omnizyme for different time periods. 
Intensity of the retarded bands in 10% SDS PAGE and immunoblots confirm an increase of 
degradation starting from 2-4 h, in case of CSC NCs [lane 1- control; lane 2 – 2 h, lane 3 – 4 h and 
lane 4 – 6 h treatments in SDS-PAGE]; [lane 1- control; lane 2 – 4 h, lane 3 – 6 h treatments in 
Western blots] . (e) In case of ACSC NCs, alginate layer get degraded and release CSC inner core by 
6h [lane 1- control; lane 2 – 2 h, lane 3 – 4 h and lane 4 – 6 h treatments in SDS PAGE; lane 1- 
control; lane 2 – 4 h in Western blots]   
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4.2.3 Cell apoptotic studies shows maximum cell death when treated with 
nanoformulated SurR9-C84A  
In order to find out an answer for the research question i.e. to investigate the retention of anti-
cancer efficacy for SurR9-C84A after its nanoencapsulation, this section of the dissertation  
addressed the extent of apoptosis in Caco-2 cells after incubation with CSC NCs carrying 
SurR9-C84A (3mg/ml or 1x106 NCs). Cells treated with the same amount of void NCs, non 
nanoformulated SurR9-C84A protein were used as controls to test the cell viability by doing 
TUNEL assay (for a comprehensive methodology please refer to section 8.9.2, page 193).  
Caco-2 cells were treated for 10 and 20 h time intervals, fixed using 4% PF and incubated in 
TUNEL reaction solution containing label solution and enzyme solution, following 
permeabilization. Confocal microscopic observations for TUNEL positive cells indicated 
increase in cell death in the case of cells treated with SurR9-C84A protein only and CSC-Sur 
NCs (Figure 4.3a). These results were further confirmed by flow cytometry, using FITC 
detector. As indicated in Figure 4.3b, there was no difference in the amount of fluorescent 
signal observed in void CSC NCs treated cells in comparison to control, which indicates 
lessened cyto-toxicity of void CSC NCs. Thus, protein loaded NCs shows maximum cell 
death compared to the void NCs. For example, SurR9-C84A and CSC-Sur NCs showed an 
apoptotic index of 53.4 ± 6.8 and 54.9 ± 0.6 respectively (P<0.05) compared to void CSC 
NCs, which was 15.5 ± 0.4 at the end of 10 h treatment. At the end of 20 h, SurR9-C84A 
(61.1 ± 0.8) and CSC-Sur NCs (64.8±0.2) showed high apoptotic index compared to 16.7 ± 
2.9 for void CSC NCs.  
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Figure 4.3: (a) Cell apoptotic studies of Caco-2 cells were measured by TUNEL assay after 
treatment with ACSC Sur NCs, void CSC NCs, CSC-Sur NCs. SurR9-C84A was used as a positive 
control. Qualitative indication for TUNEL assay, as observed under confocal microscopy. Green 
(FITC nucleotides), blue (DAPI for nucleus) and bright field (permeabilized cells). (b) No difference 
in fluorescence between void ACSC (violet) or CSC (blue) compared to un treated control (red) was 
observed but FITC fluorescence was increased in SurR9-C84A loaded CSC NCs (green) and SurR9-
C84A (yellow) treated cells, as indicated by relative fluorescence observed using flow cytometry. (c) 
Apoptotic index, as measured by confocal microscopy was plotted against different treatments. Data 
represents mean ± SEM. Experiments were repeated 3 times independently with similar results. 
√√P<0.005, CSC-Sur vs CSC control.   
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4.2.4 Cellular uptake of CSC Lf NCs by Caco-2 cell monolayer (quantitative study)  
In the previous chapter, endocytosis of the NCs was observed to be increased after 4 h of 
incubation, which was attributed to their bigger size. Sizes of the NCs were further trimmed 
by modification in the formulation procedure in this study. Thus, taking the smaller sizes of 
CSC-Sur NCs in to consideration, the internalization profiles of rhodamine loaded NCs 
starting from 1 h was studied. Caco-2 cells were treated with rhodamine loaded NCs (2.8x105 
NCs) and analyzed for the increased fluorescence for up to 6 h (detailed methodology was 
presented in the section 8.10.2, page 194). Flow cytometric analysis showed an increase in 
cellular uptake of CSC NCs from 25.1 ± 3.8% in 1 h to 37.8 ± 5.3% in 6 h whereas increase 
was observed to be prominent in CSC-Sur NCs, which was 55.4 ± 4.6 % initially in 1 h and 
increased to a massive 82 ± 2.7% at the end of 6 h (Figure 4.4b). In case of ACSC sur NCs 
the percentage of endocytosis was almost same till 6 h as compared 1 h maintaining at 5.7 ± 
0.6%. 
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Figure 4.4: (a) Flow cytometric analysis shows an increase in the internalization of rhodamine 
loaded CSC-Sur NCs from 50% to 80% with time, up to 6 h. (b) Bar diagram shows internalization 
profiles of various NCs as measured by flow cytometry. Data represents mean ± SEM. Experiments 
were repeated 3 times independently with similar results √√ P<0.005, CSC-Sur vs ACSC Sur.  
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4.2.5 Cellular uptake of CSC NCs by Caco-2 cell monolayer (qualitative study) 
To determine endocytosis through morphological identification, rhodamine labeled CSC NCs 
and CSC-Sur NCs were treated on to Caco-2 cell monolayers grown in 8 well chamber slides 
(Please refer to section 8.10.2, page 194 for detailed methodology). Cytoskeleton was stained 
with tubulin anti-body and nuclear staining was done with DAPI (Figure 4.5). The confocal 
microscopic images confirm the result of flow cytometric observations. The micrographs 
indicate cytoplasmic and nuclear localization of CSC-Sur NCs. In case of CSC-Sur NCs, cell 
layer was found to be damaged compared to void CSC NC treatment and/or rhodamine 
treated control cells. 
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Figure 4.5: In order to validate the endocytosis of the CSC-Sur NCs in comparison to void NCs, 
confocal microscopic analysis was done. Fluorescence images shows the cytoplasmic and nuclear 
internalization of rhodamine labeled CSC-Sur NC (k-o) and CSC (void) NCs (f-j), in comparison with 
rhodamine only treated NCs (a-e). Bright field- cells, green-tubulin filaments, red-NCs and blue-
nucleus. Scale bars75 µm, 25 µm and 100 µm respectively for control, void and CSC-Sur NCs.  
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4.2.6 Down regulation of endogenous survivin expression after treatment with NCs  
As discussed above in the introduction (Section 4.1), survivin plays a crucial role in cellular 
growth, cancer progression and metastasis. Inhibition of survivin could be regarded as a 
crucial factor in promoting the apoptosis in cancer cells. Thus, up/down regulation of 
endogenous survivin was evaluated in gene and protein levels after the treatment with NCs. 
In order to observe the endogenous levels of survivin expression, Caco-2 cells were treated 
with various nanocarrier combinations such as CSC-Sur NCs, CSC Lf NCs and void NCs 
(2.8x105 NCs), for a time period of 20 h. RNA and protein extraction was done after lysing 
the cells (Please refer to section 8.19, page 199 for detailed methodology). Quantification of 
the gene levels in various treatments was done after the subsequent formation of cDNA from 
the mRNA. The results indicated that the survivin levels were down regulated in treatments 
compared to control or void NCs treated cells (Figure 4.6a). For example, a decline of 1.9 ± 
0.02 fold of survivin gene was observed in Fe-bLf treated cells compared to control whereas 
the change was 5.46 ± 0.02 fold in case of SurR9-C84A treated cells. Similarly, 4.6 ± 0.01 
fold decrease in endogenous survivin was observed in CSC-Lf NCs treated cells, compared to 
void and the decrease was 4.8 ± 0.002 fold in case of CSC-Sur NCs treated cells. Further to 
observe the effect in the protein levels, the obtained lysates were analyzed by 10% SDS 
PAGE and Western blotting (Section 8.7, page 189 gives a detailed methodology) (Figure 
4.6b). Endogenous survivin expression seems to be diminished in the similar trend as 
observed in qRT PCR analysis. The phenomenon was predominant in case of cells treated 
with CSC-Sur and CSC- Lf or Fe-bLf. There was no prominent decrease in survivin 
expression in the lysates treated with void NCs compared to control untreated cells.  
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Figure 4.6: (a) Real time analysis of survivin mRNA with different treatments shows down 
regulation of survivin with therapeutic NCs. Data represents mean ± SEM Experiments were repeated 
3 times independently with similar results. √√ P<0.005, √ P<0.05. Agarose gel images shows 
qualitative analysis of the gene product. Lane 1-control; lane 2-void; lane 3 Fe-bLf; lane 4-SurR9-
C84A; lane 5-CSC-Fe-bLf; lane 6-CSC-Sur (b) Endogenous protein expression of survivin was 
analyzed in cell lysates collected after treatment with different NCs for 20 h. Subsequent probing with 
survivin specific antibody shows the down regulation of survivin, in the treatments, as represented 
based on the band densities calculated with reference to endogenous actin levels. Lane 1-control; lane 
2-void; lane 3 Fe-bLf; lane 4- CSC-Sur; lane 5- CSC-Fe-bLf; lane 6- SurR9-C84A. 
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4.3 Discussion  
Side effects of present-day medications can be expediently overcome by using anti-cancer 
and anti-angiogenic proteins/peptides. Various tumour suppressor proteins such as survivin 
antagonists and other anti-angiogenic peptides such as RGD peptide have been effectively 
shown to perk up anti-angiogenic and/or anti-apoptotic tumour therapy  (Kanwar et al., 
2001a, Pasqualini et al., 1997). In this regard, survivin is an important member of the 
inhibitor of apoptosis (IAP) gene family that effects cell survival at various points. IAPs have 
a much broader functions, encircling signaling pathways, cell division, metabolism and 
adaptation to unfavorable environments. These tasks rely on regulated interactions that 
involve survivin and its multiple protein partners, including tubulin and various chromosomal 
passenger proteins in the control of mitosis and other IAP family members to counteract 
apoptosis. This makes survivin, a sensible and a prominent target for cancer therapy. In the 
recent past, survivin mutants have been investigated to counteract survivin’s functions in 
carcinogenesis (Guha and Altieri, 2009). Considerable effort has been extended towards 
counteracting survivin, including development of antisense oligonucleotides (Kanwar et al., 
2001a), hammerhead ribozymes, RNA interference  (Jiang et al., 2006, Paduano et al., 2006), 
cancer vaccines (Pisarev et al., 2003) and dominant-negative mutants (Grossman et al., 
2001); These studies provoked us to use SurR9-C84A as anti-cancer protein. To protect these 
therapeutic proteins from the reticuloendothelial system, nano particle based cancer peptide 
delivery can be a promising strategy for the better protection and controlled delivery of the 
protein/peptide in the target site (Peer et al., 2007). Thus, in this study SurR9-C84A loaded 
on to the nanocarriers to observe the subsequent effects in vitro was examined. In the recent 
studies protein drug targeting for the tumour by using polymeric nanocarriers has been 
practiced (Kobayashi and Lin, 2006). Nevertheless, many of the studies aimed at 
development of a parenteral administration, which are invasive procedures and imposes 
painful regime. There are some studies designed for oral administration of anti-cancer 
chemotherapeutics that have many side effects. Therefore, this study aimed in developing a 
nano platform that can carry a combination of anti-cancer proteins for oral administration so 
that patient compliances against the continuous intravenous infusions in the clinic can be 
effectively reduced. Similar to the Fe-bLf encapsulation, SurR9-C84A, which was adsorbed 
on the ceramic core, was encapsulated in biodegradable alginate and chitosan polymers 
because of their ready availability, inexpensiveness, low toxicity, and mucoadhesiveness and 
above all their low immunogenicity. Calcium phosphate, a naturally occurring ceramic in 
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bones and teeth can have good biocompatibility and imparts overall biodegradability to the 
system, when used as an inner ceramic core. SurR9-C84A containing a R9 cell penetrating 
peptide was incorporated in the NCs to improve the bio-availability of the protein. In total, 
the designed NCs can carry anti-cancer protein, SurR9-C84A embedded in the core formed 
by ceramic calcium phosphate and chitosan. DLS spectrometric data represents the formation 
of layers one over other throughout the process of final ACSC formation. The range of 
SurR9-C84A loaded NCs was found to increase from 100 nm for ceramic core to 322 nm for 
the ACSC Sur NCs. SEM indicated a stable spherical morphology of ACSC Sur NCs. To find 
out the in vitro control release profiles of these NCs, they were suspended in phosphate buffer 
saline solution and observed for the controlled release of the protein spectrophotometrically, 
over a time period. Alginate and chitosan being biodegradable polymers, solubilises in 
aqueous environment and release the loaded SurR9-C84A in a controlled manner. Results 
(Figure 4.2a) suggest the controlled release of protein from the ACSC Sur NCs in the 
physiological pH up to 24 h. This controlled release phenomenon was further confirmed 
qualitatively by doing SDS PAGE and immunoblotting (Figure 4.2b). Net positive charge on 
the NCs and their size are the reasons for the retardation in the stalking gel. Presence of 
SurR9-C84A specific bands in immunoblot indicates the protection of the protein 
configuration during the formulation procedure.  
Residence time of a drug through the gastrointestinal tract is predicted to be in between 9-12 
h. Taking in to consideration that maximum transit time of a drug in stomach and intestine as 
4 h, we have determined the controlled release of ACSC Sur NCs in enzymatic locale by 
creating a microcosm of intestinal enzymes around NCs, by dispersing them in Omnizyme 
enzyme cocktail mixture. In case of ACSC Sur NCs, there were no prominent bands observed 
in SDS PAGE or Western blotting, up to 6 h, but after 6 h bands that correspond to CSC Sur 
NCs were observed, indicating the release of CSC Sur NCs from ACSC Sur NCs (Figure 
4.2c), by dissolution of Alginate outer layer. However, in case of CSC NCs, there were no 
enough bands in treatments other than 2 h treatment indicating the degradation of the NCs by 
end of 2 h. In our previous reports, we have shown the release of CSC-Lf nano cores from 
ACSC in a time period of 4 h to 6 h in alkaline medium, which is predominant in intestine 
(Mahidhara et al., 2011 ). Unpublished results in our lab have indicated an increase in the 
protection of Fe-bLf after loading in to the NCs in the enzymatic environment after the 
treatment with omnizyme. Up to some extent, metal saturation plays an important role in the 
protection of Fe-bLf from the gastrointestinal environment, which was further potentiated by 
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incorporating the protein in the NCs. Taken together, encapsulation of SurR9-C84A in the 
ACSC NCs increased the bio-activity of the protein in the gastric microcosm of digestive 
enzymes, making the fragile protein equally resistant as that of Fe-bLf. Thus, alginate 
covering protects the inner CSC nanocores till the intestinal absorption phase. So for further 
experiments of internalization and transcytosis, CSC-Sur NCs were used. In addition to the 
added protection in the GI tract, alginate outer covering seems to clean up the nanocarriers 
and make the system less polydisperse, as represented in the electron micrographs. Thus, 
alginate entrapment not only serves as a protective covering but could be exploited as a 
particle purification method. Carcinogenesis involves biological immortality of the cells by 
overcoming apoptosis and drug resistance. Since, IAPs along with several other proteins such 
as bcl-2 and bcl-xL plays key role in inhibiting apoptosis, their biological antagonists 
promote cancer progression (Mannhold et al., 2010). On the same basis, the de facto protein 
SurR9-C84A promotes the apoptosis by competitively inhibiting survivin. To evaluate this 
finding, terminal deoxynucleotidyl transferase- mediated dUTP nick end labeling (TUNEL) 
assay on the cancer cells, after treatment with SurR9-C84A loaded NCs along with other 
combinations was done. The results indicated an increase in cell cytotoxicity after treatment 
with CSC-Sur NCs compared to other combinations, which is important upshot for using 
these NCs as anti-cancer therapeutic. These results show that 1x106 SurR9-C84A loaded NCs 
is essential for showing in vitro cytotoxicity. Flow cytometric analysis indicates increase in 
uptake of the CSC-Sur NCs by cells compared to CSC NCs or ACSC Sur NCs; this may be 
because of the encapsulation with SurR9-C84A. This could also be attributed to the exposed 
epitopes present in the NCs, which helps in the improved endocytosis via cell permeable R9 
peptide, which is the key factor for this improved uptake of CSC- Sur NCs. It has been 
suggested that particle size plays a key role in the adhesion and uptake of NCs by cells (Chen 
and Langer, 1998), this can be attributed to the reason why ACSC NCs were internalized less, 
in a specified time of 6 h as compared to CSC NCs, based on their size difference. As 
discussed in the previous chapter (Section 3.2.5), a decrease in uptake of ACSC Sur NCs will 
not affect the overall internalization of the NCs by cells. Imagining the in vivo situation, the 
population of CSC Sur NCs will be abundant in the total cluster of NCs (ACSC+CSC) that 
have reached the tumour vasculature. Therefore, minimal uptake of ACSC Sur NCs as 
reported in flow cytometric results adds up the total internalization of NCs. Confocal 
microscopy indicates internalization of CSC-Sur NCs in Caco-2 cells. Rhodamine control 
well shows no specific fluorescence as compared to rhodamine labeled NC treatment, 
indicating the rhodamine fluorescence observed was due to the internalization of NC only. 
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Besides this other factors such as Z stack and merge of fluorescent channels in confocal 
microscope confirms the phenomenon of NCs internalization. Interestingly, nuclear 
localization of the NC was observed in addition to cytoplasmic localization. In the preceding 
chapter (Section 3.2.6), it was showed that, immunocytochemical observation as well as 
immune fluorescence confirms nuclear localization of CSC-Lf (Mahidhara et al., 2011 ). 
Further apoptotic cell membrane morphology in the cell layers that corresponds to SurR9-
C84A loaded CSC NCs treatments was observed, confirming the findings of cytotoxicity 
studies.  
Expression of IAPs especially survivin is a key factor in tumour development and 
progression. Survivin promotes cell cycle progression by inhibiting caspases and plays key 
role in cell cycle. Thus, anti-cancer proteins could antagonistically act on the biogenesis of 
survivin thereby promoting cellular death. It has been shown in our lab that Fe-bLf down 
regulates survivin expression in order to promote the apoptosis in colon cancer cells (un 
published results). Decrease in endogenous survivin level in CaCo-2 cells after treatment 
with NCs loaded with Sur R9-C84A and Fe-bLf indicates the molecular mechanism of action 
of these NCs. In the same experiment, void nano carrier treatment has shown no significant 
decrease of the survivin expression compared to control cells. Decrease in endogenous 
survivin was prominent in case of CSC-Sur or Fe-bLf loaded NCs as compared to Sur R9-
C84A or Fe-bLf alone, which indicates the benefit of using nanocarriers for the controlled 
release of the protein. Herein, the gene expression studies show the clear mechanistic action 
of the anti- cancer NCs compared to protein expression profile, which could perhaps because 
of the competition between exogenous Sur R9-C84A with the endogenous survivin for the 
antibody. Even though a monoclonal antibody was used; similar epitopes could result in the 
immunoreactivity. The clear mechanism behind the decrease in the endogenous expression of 
survivin with the use of either Fe-bLf or Sur R9-C84A mutant is not known clearly. 
However, further detailed insights in understanding this down regulation phenomenon needs 
to be elucidated. An attempt was made to further understand the mechanism of internalization 
and action of the ACSC NCs in colon cancer cells. This will be discussed in the upcoming 
chapter (chapter 5, sections 5.2.7 and 5.2.8). Increase in endosomal markers along with 
alteration of mitochondrial potential was observed with the treatments of the NCs. Taken 
together, based on these results a diagrammatic representation for mechanistic action of the 
NCs could thus be drawn (Figure 9.1), by which the therapeutic protein loaded NCs are 
effecting the intrinsic mitochondrial pathway for the promotion of apoptosis.    
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Chapter 5: Dual protein loaded nanocarriers for in vitro evaluation of anti-cancer 
efficacy  
5.1. Introduction  
Complex and heterogeneous course of cancer development and metastasis opened access to 
new strategies for using synergistic combinations of different anti-cancer biomolecules (Pang 
et al., 2010). Genetic engineering and biotechnological advancements have brought up many 
active anti-cancer molecules into light. Recently, survivin inhibitors have grabbed attention 
of researchers as survivin expression is high in tumours and not detectable in normal 
differentiated tissues (Li, 2003). Since, it was known that BIR domain plays an important role 
in action of IAP members (discussed in the section 2.8); mutational studies were conducted 
to understand the importance of BIR domain’s role in prevention of apoptosis. Therefore, 
point mutations such as D53A, C84A and a combination of T34A and C84A in the BIR 
domain results in the loss of hydrophobicity and prevents dimerization of survivin (Yan et al., 
2006, Baratchi et al., 2010a). Dominant-negative mutants of survivin were shown to obstruct 
the anti-apoptotic function of native survivin by preventing the ability of survivin to interfere 
with caspases (Ma et al., 2006). Cysteine to alanine (amino acid position 84 of the wild type 
survivin, abbreviated SurR9-C84A) mutant of survivin, with a carrier peptide was found to 
induce apoptosis in cervical and prostate cancer cells (Cheung et al., 2010b). In the chapter 3 
and 4 NCs with two anti-cancer proteins were prepared and tested. Thus, taking in to 
consideration of the possible benefits offered by both Fe-bLf and SurR9-C84A, this chapter 
study was aimed in encapsulating both of these proteins in combination, to validate the 
improved anti-cancer efficacy. 
However, delivery of these molecules in their native form certainly is an issue. Thus, these 
proteins were incorporated in ACSC NCs as reported in the previous chapters, to test the oral 
delivery efficacy (Zhang et al., 2008a), to make sure that the protein delivery through oral 
route, polymeric nanoparticles have shown interesting assure (des Rieux et al., 2006). 
Mucoadhesive particles which have the property to maintain contact with intestinal 
epithelium for extended periods have been extensively investigated. These particles thus will 
be taken up by microfold cell (M cells) of payers patches for endocytic as well as 
transcellular absorption (Borges et al., 2006). Polymeric nanoparticles made of carbohydrate 
and/or carbohydrate derivatives are important in anti-cancer and oral drug delivery, as they 
can be efficiently taken by mucosal membranes in the intestine, as well as by the cancerous 
tissues based on their surface oligosaccharide receptors. Naturally occurring polysaccharides 
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sodium alginate and chitosan have received much attention in drug delivery system for their 
excellent biocompatibility (Section 4.1).  
This chapter integrates the methods and approaches of the previous 2 chapters in using both 
Fe-bLf and SurR9-C84A for by the combinatorial therapy. Thus, a dual combination of 
SurR9-C84A along with Fe-bLf for improvement of cellular absorption and in vitro 
cytotoxicity after their encapsulation in ACSC NCs (ACSC FS NCs) was analyzed.  These 
NCs were further characterized for their size, surface morphology, control release, thermal 
stability, in vitro uptake mechanism and cytotoxicity profiles. Mechanism of uptake of the 
NCs by the cancer cells was determined by observation for elevation of markers involved in 
the endocytotic pathway. Mitochondrial depolarization studies were also done in order to 
understand the mechanism by which these NCs impose cytotoxicity in the colon cancer cells. 
Methodology: A detailed description of methodology involved in the in vitro anti-cancer 
efficacy of Sur R9-C84A and Fe-bLf combination after encapsulation in ACSC NCs was 
given in chapter 8, page 183 - 201. Methodology that corresponds to each specific result 
sections has been mentioned in the text. 
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5.2 Result 
5.2.1 Characterization of NCs   
Fe-bLf and SurR9-C84A in solution form were filtered and adsorbed on to the ceramic 
calcium phosphate. The ceramic NCs then were coated with a thin chitosan (0.01%w/v in 
acetate buffer) film. Poly anion, STPP was used to make cross linkages between positively 
charged amine groups within the chitosan, as was done previously (Please refer to section 
8.5, page 187 and section 8.6, page 188 for a detailed methodology). Increase in the 
hydrodynamic size of NCs after coating with chitosan and further encapsulation in alginate 
after complete formation of ACSC Fe-bLf –Sur R9-C84A NCs (ACSC FS NCs) was 
observed by DLS spectroscopy (Figure 5.1b). For example, protein loaded ceramic NCs 
obtained a size of 177.15 ± 12.5 nm whereas chitosan coated NCs obtained 237.6 ± 17.4 nm; 
the size was increased to 322.1 ± 52.6 nm with the addition of alginate. SEM results further 
supported the DLS data and it also determined spherical morphology of NCs (Figure 5.1a), 
which conveys their advantage in transporting the anti-cancer protein to the cancer tissue via 
mucosal, gastric and subsequent systemic circulation.  Incorporation of Fe-bLf and SurR9-
C84A into ACSC nano platforms doesn’t affect the size of the NCs as shown in Figure 5.1a 
and Figure 5.1c. 
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Figure 5.1: Synthesis of ACNC FS NCs and characterization. The NCs were found to have spherical 
morphology when observed under SEM, scale bars indicates 200 nm, upper panel shows the surface 
morphology of (a) CSC-FS NCs, (b) ACSC FS NCs respectively. (c) DLS spectrometric observation 
during the formation of various layers predicted the size of ceramic core to ACSC FS NCs increased 
from 177.2 nm - 322.1nm, respectively. Sizes of CaP-FS (blue), CSC- FS (red) and ACSC FS NCs 
(green) were represented as according to light intensity and size of the NCs respecticely. 
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5.2.2 Protein loaded NCs show controlled release profiles  
Controlled release of Sur R9-C84A as well as Fe-bLf from the nanocarriers was analyzed in 
PBS (pH7.2) till 24h for the proteins released from the NCs (Please refer to section 8.8, page 
191 for a detailed methodology). The results indicated that there was a sustained release up to 
24 h (Fig 5.2). Fe-bLf has shown an initial burst after 6 h, whereas SurR9-C84A has shown 
the release at the end of 7 h, thereafter the remaining entrapped proteins were released in a 
controlled manner. There was more sustained release of Sur R9-C84A up to 24 h compared to 
Fe-bLf. In order to visualize this, SDS PAGE gel retardation assay, for ACSC-FS NCs 
carrying Fe-bLf and Sur R9-C84A, has been carried out. Absence of SurR9-C84A specific 
bands in positive control (in the resolving gel) indicates immobilization of ACSC FS NCs in 
the stalking gel. Further, retardation of ACSC FS NCs in the stacking gel were confirmed by 
intense bands in stacking gel as well as Sur R9-C84A specific bands in Western bots, 
developed by using specific antibodies (inset of Figure 5.2).  
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Figure 5.2: Controlled release of ACSC FSNCs. (a) Controlled release of Fe-bLf and SurR9-C84A 
from ACSC FS NCs as observed in PBS (pH 7.2). Insert is the SDS PAGE (10%) gel retardation 
assay and immunoblots indicate the integrity of the protein during the formulation process. Thick 
bands in the stacking gel indicate Fe-bLf and SurR9-C84A immobilized on the NCs, this is evident 
from the immunoblots (Figure in inset). 
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5.2.3. Chemical bonding and the thermal stability assessment of the NCs 
In order to observe chemical bonding pattern in the interior of the NCs, Fourier transform 
infrared spectroscopy (FTIR) was performed (Please refer to section 8.6.3, page 189 for a 
detailed methodology). Characteristic peaks of free amide and OH groups corresponding to 
chitosan were observed in both CSC NCs as well as in pure chitosan. Amide group vibration 
can be seen at 1340 cm-1 in case of pure chitosan. Characteristic peak for phosphate group in 
free calcium phosphate was observed at 924.4 cm-1 and 1034 cm-1. There was a bridge peak 
corresponding to hydrogen bonding was observed in CSC NC at 1522 cm-1 proving the 
bonding of amino groups in the chitosan and phosphate group in the calcium phosphate. 
Furthermore, both phosphate and amino stretching vibrations were observed in ACSC NCs 
representing the ceramic core fit inside the alginate gel (Figure 5.3b). Differential scanning 
calorimetric (DSC) studies were employed to investigate the crystal transformation of the 
nanocarrier system (A comprehensive methodology was given in section 8.6.4, page 189). 
DSC thermograms of Fe-bLf protein, ACSC NCs loaded with protein, void NCs and CSC 
NCs were showed in the figure 5.3b. Fe-bLf gives rise to sharp peak at 272.170C, 
corresponding to the melting points of the crystalline regions. Void NCs shows a small 
relaxation peak at 87.490C, whereas it was found at 910C in case of CSC NCs loaded with Fe-
bLf. The same peak was shifted to 2650C in case of ACSC NCs. No notable melting point 
was observed in NCs as the polymers were amorphous. Moreover, the melting peaks of void 
and protein loaded NCs were similar indicating that the protein loading does not affect the 
polymer structure. In addition to this, characteristic peak of Fe-bLf was absent in the 
nanoformulaltion indicating the conversion of crystalline protein to the amorphous form 
(Figure 5.3b).  In addition to DSC, phase transformations in various polymer structures were 
observed by thermogravimetric analysis (TGA). No phase transitions were observed in case 
of void NCs, indicating the thermal stability at high temperature. An initial decrease in the 
onset of decomposition temperature corresponds to the loss of water, because the mass loss 
observed here is most pronounced up to 1000C. Relatively small mass loss is assigned to the 
removal of absorbed water between 80ºC and 120ºC.Three distinct regions of significant 
mass loss in case of polymer coated NCs were observed. A 10% mass loss was noticed 
between a temperature of 1050C, and 2470C in ACSC NCs, followed by significant mass loss 
between the temperatures 265-3300C and 330-7650C, indicating the presence of multiple 
polymeric layers in the nanocomposite. 
 
103 
 
 
  
Figure 5.3: (a) Schematic representation of the interactions among ceramic inner core, polymers and 
proteins in the NCs, where inner ceramic core is covered by chitosan and alginate respectively (b) 
FTIR spectroscopic observation for CSC NC, chitosan and CaP (c) DSC for NCs system (d) Thermo 
gravimetric analysis of NCs represents the arrangement of different layers one over the other during 
the formulation procedure to protect the encapsulated proteins.    
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5.2.4 Cell apoptosis assessment after treatment with dual protein loaded nanocarriers  
Further, to find out the improved anti-cancer efficacy of the dual protein loaded 
nanoformulation, this section of the dissertation addresses the degree of apoptosis by CSC 
NCs carrying the combination of Fe-bLf and SurR9-C84A (CSC-FS) at a concentration of 
1x106 NCs. Cells treated with same concentration of void NCs, native SurR9-C84A + Fe-bLf 
proteins were used as control to test the cell apoptosis by TUNEL assay (Methodology was 
given in the section 8.9.2, page 193). Caco-2 cells were treated for 10 h and 20 h time 
intervals, fixed using 4% PF and incubated in TUNEL reaction solution containing labeling 
and enzyme solutions, following permeabilization. Confocal microscopic observations for 
TUNEL positive cells indicated an increase in cell death in case of cells treated with the 
treatments such as protein combination and CSC-FS NCs (Figure 5.4a). As indicated in 
Figure 5.4 b, native protein combination and CSC-FS NCs showed an apoptotic index of 54.8 
± 0.3 and 51.5 ± 1.9 respectively (P<0.05) compared to void CSC NCs, which is 15.5 ± 0.4 at 
the end of 10 h treatment. At the end of 20 h, native protein combination (56.8 ± 1.9) and 
CSC-FS NCs (65.2±0.9) showed high apoptotic index compared to 16.7 ± 2.9 for void CSC 
NCs. Thus, protein loaded NCs showed increased cell death compared to the void NCs. 
These results were further confirmed by flow cytometry, using FITC detector. Increase in the 
fluorescent signal intensity in case of CSC-FS NCs confirmed confocal microscopic 
observations.  
 
 
 
 
 
 
 
 
 
105 
 
Figure 5.4: Cell apoptotic studies of CSC NCs. (a) Qualitative indication of TUNEL assay, as 
observed under confocal microscopy. Green (FITC nucleotides), blue (DAPI for nucleus). (b) 
Apoptotic index, as measured by confocal microscopy was plotted against different treatments. Data 
represents mean ± SEM. Experiments were repeated 3 times independently with similar results. 
√√P<0.005, CSC-FS, CSC-Fe-bLf vs void control. (c) Apoptosis of Caco2 cells were measured by 
TUNEL assay after treatment with ACSC- NCs, CSC NCs, CSC-FS NCs and Fe-bLf-SurR9-C84A 
combination. The results indicate that there is no difference in fluorescence of void NCs (red) 
compared to un treated control, but increase in cell death was noticed with CSC-FS NCs (violet) CSC-
Fe-bLf (dark green) Fe-bLf (light green) and SurR9-C84A (dark blue) treated cells, as indicated by 
relative fluorescence observed using flow cytometry.  
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5.2.5 In vitro internalization profiles of the NCs   
It was evident from the previous chapters that encapsulation of anti-cancer proteins improved 
the cellular uptake of the NCs compared to the void NCs. As of this section is concerned, 
advantage in incorporating both Fe-bLf and SurR9-C84A at a time in NCs was proposed to 
be much more advantageous compared to the encapsulation of either of the proteins alone. 
Thus, this section focused in addressing the internalization profiles of CSC-FS NCs. Flow 
cytometric analysis for the internalization of rhodamine labeled NCs (2.8x105 NCs) was 
analyzed using rhodamine alone treated cells as control (Please refer to  the section 8.10.2, 
page 194 for methodology). The results showed an increase in cellular uptake of CSC-FS 
NCs compared to the void CSC NCs. For example, an increased internalization of CSC-NCs 
from 25.1 ± 3.8% in 1 h to 37.8 ± 5.3% in 6 h was observed whereas increase was revealed to 
be prominent in CSC - FS NCs, which was 64.3 ± 4.7% initially in 1 h and had increased to 
83 ± 4.7 % at a time period of 4 h. However, slight decrease at the end of 6 h 78 ± 0.9% 
could be contributed to the increase in the cellular death by CSC-FS NCs (Figure 5.5). In case 
of ACSC FS NCs the percentage of endocytosis was almost the same from 1- 6 h (Figure 
5.5). Internalization efficacies of the CSC-FS NCs were following almost the same trend as 
that of SurR9-C84A alone loaded CSC NCs or CSC-Lf NCs. 
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Figure 5.5:  (a) Flow cytometric analysis shows an increase in the internalization of rhodamine 
loaded CSC-FS NCs from 20% to 83% with time, up to 6 h. (b) Graphical representation shows 
internalization profiles of various NCs, as measured by flow cytometry. Data represents mean ± SEM. 
Experiments were repeated 3 times independently with similar results. √√ P<0.005, CSC-FS, CSC-Fe-
bLf vs control. 
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5.2.6 Qualitative determination of NCs internalization in cancer cells  
To determine qualitative endocytosis, rhodamine labeled CSC NCs and CSC - FS NCs were 
treated on to the Caco-2 cell monolayers grown in 8 well chamber slides. Cytoskeleton was 
stained with FITC labeled phalloidin and the nuclear staining was done with DAPI (Please 
refer to section 8.10.2, page 194 for detailed methodology). Confocal microscopic 
observation using FITC, DAPI and TRITC channels revealed interesting observations in 
support of the flow cytometric analysis (Figure 5.6). The confocal microscopic images 
confirm the result of flow cytometric observations by the fact that there was an increased 
fluorescent signal in cells treated with rhodamine labeled NCs. Further cytoplasmic and 
nuclear localization of the NCs was observed by using Z stacking (Figure 5.6; u-x) in 
confocal microscope. In case of CSC - FS NCs, cell layer was found to get damaged with the 
progress in time (6 h) compared to rhodamine only treated control ones.  
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Figure 5.6: Visualization of the rhodamine loaded NCs compared to rhodamine only treated control 
confirms the endocytosis of the NCs. Specific fluorescence that corresponds to the NCs was observed 
by adjustment of Z position in case of CSC-FS NCs (u-x), whereas, absence of any rhodamine 
fluorescence that is corresponding to rhodamine in case of rhodamine only treated cells confirms the 
phenomenon of endocytosis of the fluorescent NCs. Cytoplasmic and nuclear internalization of 
rhodamine labeled CSC-FS NC was evident from the Confocal microscopic observations done in 
varying time periods starting from 1 h (a-d), 2 h (e-h), 4 h (m-p) 6 h (q-t) and Z max (u-x) indicates 
the highest resolution image among the images obtained in Z stacking. Green (FITC)-actin filaments 
labeled with phalloidin, red (rhodamine)-NCs and blue (DAPI)-nucleus. Scale bars 50 µm.  
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5.2.7 Determination of mitochondrial membrane potential (∆ψm) after the treatment  
The phenomenon of forming J-aggregates of the JC-1 complex that represents high 
membrane potential of healthy mitochondria was used to evaluate apoptotic state of the cell 
(Cossarizza et al., 1993). Thus, to clarify the mechanism underlying the apoptotic promotion 
in the NCs treated cells an early apoptotic event of mitochondrial transmembrane potential 
was evaluated (Section 8.10.4, page 196). As shown in Figure 5.7, J-aggregates were 
predominant in control as well as in treatments with void CSC and ACSC NC, as represented 
by high voltage in PI channel (Figure 5.7a). JC-1 monomers were predominant in case of 
SurR9-C84A treated cells. For example, CSC – Fe-bLf have shown a mitochondrial potential 
of 15.5 ± 4.1% in 10 h and 53.4 ± 2.1 % in 20 h whereas CSC – FS has shown 28.7 ± 1.1% in 
10 h and increased to 82.8 ± 0.1% in 20 h. However, more interestingly, void NCs treated 
cells have shown less FITC gain (9.2 ± 0.5% and 5.1±1.4%) that corresponds to the 
mitochondrial potential (Figure 5.7b). These results prove that the mitochondrial membrane 
depolarization, which is an indicator of intrinsic pathway of apoptosis, and prevalent in the 
case of cells treated with NCs carrying therapeutic proteins.  
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Figure 5.7: Measurement of mitochondrial membrane potential: flow cytometric observations that 
corresponding to the change in mitochondrial membrane potential was given in the upper panel. 
Compared to void NCs treated cells, all other combinations including combination of Fe-bLf + 
SurR9-C84A, CSC-Fe-bLf and CSC-FS have shown an increase in FITC signal that corresponds to 
mitochondrial membrane potential alteration. In the cells treated with Fe-bLf + SurR9-C84A and 
CSC- FS, there is a phenomenal change in FITC gain (represented by the graph in the bottom panel), 
corresponding to alteration of membrane potential was observed. Data represents mean ± SEM. 
Experiments were repeated 3 times independently with similar results. √√ P<0.005, CSC-FS, SurR9-
C84A + Fe-bLF, CSC-Fe-bLf vs CSC (void). 
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5.2.8 Endocytosis of CSC FS NCs   
Since, it was shown that the NCs loaded with Fe-bLf or SurR9-C84A have improved efficacy 
of the anti-cancer protein, in the previous chapters, this study was focused in the functional 
mechanism of internalization of the NCs. Thus, internalization of NCs was determined by 
using specific antibodies for early endosomal marker (EEA1) and lysosomal marker 
(LAMP1), along with Lf specific antibody for the Fe-bLf that was encapsulated inside the 
NCs (Section 8.10.4, page 196). Interesting results were obtained with respect to expression 
of early or late endosomal antibodies after the treatment with NCs. Cells treated with void 
NCs showed lower expression of EEA/LAMP compared to the ones treated with CSC- Fe-
bLf and CSC – FS (Figure 5.7).  For example, after the treatment with void NCs, cells have 
shown 14.4 ± 1.6 % ( 30 min); 17.6 ± 3.3% (2 h) of EEA1 expression whereas the expression 
was found to be 39.2 ± 2.8% (30 min) and 49.1 ± 2% (2 h) in case of CSC-Fe-bLf NCs 
treatment. The percentage of expression was equally significant in case of combinatorial 
treatment whereas in 30 min it was found to be 32.4 ± 0.3 % and gradually increased up to 
71.3 ± 3.2 % at the end of 2 h. Similarly, lysosomal markers have shown around 4 fold 
increase after treatment with protein loaded NCs. The void NCs treated cells were shown to 
have 30.8 ± 1.4% LAMP1 expression in 1 h and 29.1 ± 0.6 % in 4 h, whereas in case of CSC 
–Fe-bLf ( 31.4 ± 5% in 1 h and 67.1 ± 5.6 % in 4 h) and CSC-FS (24.6 ± 4.6% in 1 h and 
77.8 ± 0.6 % in 4 h) an obvious increment in LAMP expression was observed. 
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Figure 5.7: (a) Mechanism of endocytosis of NCs was analyzed by dot plots using flow cytometric 
observations. Co localization of EEA-1 and LAMP -1 with Fe-bLf was evident in CSC – Fe-bLf and 
CSC – FS NCs treated cells. In case of empty NCs, EEA-1 and LAMP- 1 expression was in moderate 
levels. (b) Bar diagram shows the quantitative representation of flow cytometric analysis, where 
combinatorial treatment was shown to be increase the EEA1 expression by 4.05 fold in case of CSC-
FS NCs treated cells compared to void NCs. A  2.5 fold elevation of LAMP levels in the CSC-FS NCs 
was observed in comparison to the void NCs.  Data represents mean ± SEM. Experiments were 
repeated 3 times independently with similar results. √√ P<0.005. 
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5.3 Discussion  
Oral delivery of anti-cancer proteins remains a major challenge because of their susceptibility 
to hydrolysis in the GI tract. In this regard, homopolymer based nanoparticles were used for 
drug delivery applications in recent times (Bhumkar et al., 2007). Ceramics such as 
hydroxyapatite and calcium phosphate are safe, biodegradable and have implications in tissue 
engineering and in the delivery of biomacromolecular drugs (Goldberg et al., 2007). 
Homopolymer chitosan is known to act as an enhancer in mucosal penetration of proteins and 
vaccines (van der Lubben et al., 2001). Thus, in the present study calcium phosphate ceramic 
core and chitosan along with alginate were used considering their biocompatibility, chemical 
nature and absorption enhancement properties. It has been observed that when combined with 
NC, bLf helps in increased absorption of released CSC-Lf NC via the intestinal epithelium 
due to its natural ability in iron absorption through the intestine (Mahidhara et al., 2011 ).  
Herein, SurR9-C84A containing a R9 cell penetrating peptide along with Fe-bLf was used in 
a combinatorial approach and was incorporated in the NCs to be able to protect the proteins. 
In total, in the design of the NCs, anti-cancer proteins, SurR9-C84A and Fe-bLf were 
adsorbed on the core formed by ceramic calcium phosphate and embedded in chitosan. SEM 
indicated a stable spherical morphology of ACSC FS NC. DLS spectrometric data represents 
the formation of layers one over other throughout the process of final ACSC formation. The 
size range of Fe-bLf and SurR9-C84A loaded NCs (CSC-FS) was found to increase till the 
formation of the ACSC NCs. Previously it has been shown that the alginate outer layer gets 
fragmented in the intestine releasing CSC inner core, which further will be absorbed in to the 
systemic circulation (un published data). Consequently, alginate covering protects the inner 
CSC nano cores till the intestinal absorption phase (Figure 3.9) so for further experiments for 
the internalization and transcytosis of the NCs, we have used CSC-Sur NCs. 
FTIR spectra confirm the hydrogen bonding and /or electrostatic interaction between positive 
amino groups and negatively charged phosphate groups in calcium phosphate. Thus, the anti-
cancer proteins fits safely in a polymeric matrix formed between calcium phosphate and 
chitosan. Several studies were reported where thermo analytical experiments were used for 
the detection of the differences between the results of TG or DSC measurements of pure 
drugs and their mixtures with various excipients (Drebushchak et al., 2006). It was observed 
in the previous reports that after entrapment in a nanoformulation, melting point and enthalpy 
of melting of the bio molecule was modified (Xie et al., 2011).  Crystal transformation curves 
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proved the arrangement of the alginate and chitosan polymeric layers in the formulation 
along with the ceramic core as depicted by FTIR, as represented in a schematic diagram in 
the Figure 3.1. It was also evident from the DSC finding that the entrapped protein was 
protected by various polymeric layers of the NCs. Sharp peak at 272.170C in case of Fe-bLf 
was absent in NCs loaded with the protein indicating that the entrapped protein is protected 
within the core of the NCs. TGA analysis also further proved these results where, phase 
transistions were absent in case of void NCs compared to polymer and protein loaded NCs. In 
addition to these results, X-ray diffraction spectroscopic data (Section 6) further proved the 
presence of various polymeric and ceramic phases in the NCs.  In order to find out in vitro 
control release profiles of these NC, they were suspended in phosphate buffer saline solution 
and observed for the controlled release of the proteins spectrophotometrically, over a time 
period. Alginate and chitosan being biodegradable polymers, solubilizes in aqueous 
environment and release the loaded SurR9-C84A in a controlled manner. Results (Figure 
5.2a) suggest the controlled release of proteins from the ACSC NCs up to 24 h. Additional 
sustained release of Sur R9-C84A up to 24 h as compared to Fe-bLf could be attributed to the 
presence of cell penetrating arginine (R9) peptide, which binds to the calcium phosphate 
stronger than the Fe-bLf. This controlled release phenomenon was further confirmed 
qualitatively by doing SDS PAGE and immunoblotting (Figure 5.2b). Net positive charge on 
the NCs and their size could be the reasons for the retardation in the stacking gel. Wrapping 
or covering of negatively charged calcium phosphate bound with proteins by positively 
charged chitosan makes the net positive charge on the NC.  Presence of SurR9-C84A and Fe-
bLf specific bands in immunoblot indicates the protection of the native configuration of the 
protein during the formulation procedure. This study was further extended to observe the 
controlled release profiles in the lower pH as discussed in detailed in the chapter 7. Because 
of the pH sensitivity of the alginate gel, lowest release of the protein in the acidic pH was 
observed (only 40% of the protein was released at the end of 24 h) owing to the formation of 
unionized form of the alginate gel. 
Inhibition of apoptosis is a key factor in the carcinogenesis, progression and drug resistance. 
IAPs along with several other proteins such as bcl-2 and bcl-xL play a key role in inhibiting 
apoptosis. As discussed in the previous chapter, it is obvious that Fe-bLf can enhance the cell 
death by inhibiting key molecules involved in the anti-apoptotic pathways. Thus, a 
combination of Fe-bLf and SurR9-C84A shall promote apoptosis by competitively inhibiting 
survivin and/or other anti-apoptotic proteins. To evaluate this finding, terminal deoxy 
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nucleotidyl transferase- mediated dUTP nick end labelling (TUNEL) assay was performed on 
the colon cancer cells, after treatment with CSC-FS along with other combinations, as shown 
in the Figure 5.4. The results indicate the increase in cell apoptosis after treatment with CSC-
FS compared to other combinations, which is important upshot for using these NCs as anti-
cancer therapeutic. These results show that 50 µg/ml of SurR9-C84A along with 100 µg/ml 
of Fe-bLf loaded NCs is essential for showing in vitro cytotoxicity. Flow cytometric analysis 
indicated increase in uptake of the CSC-FS NCs by cells compared to void CSC NCs or 
ACSC FS NCs; this can be because of the encapsulation with SurR9-C84A, which helps in 
improved endocytosis. Cell permeable R9 peptide and Fe-bLf could be the key factor for this 
improved uptake of CSC- FS NCs. It has been suggested that particle size plays a key role in 
the adhesion and uptake of NCs by cells (Chen and Langer, 1998). This can be attributed to 
the reason why ACSC NCs were taken less compared to other nanoformulations. Here, 
decreased uptake of ACSC NCs shall not be confused to affect the overall uptake of NCs by 
cells and/or through intestine. The key notion of using alginate layer is to protect the inner 
core from getting degraded in the GI tract and alginate itself gets fragmented in the process, 
releasing CSC inner core. Thus, the pool of CSC NCs will be abundant in a total population 
of NCs that have reached the final destination, as shown in Figure 3.9. Therefore, minimal 
uptake of ACSC FS NCs that was reported in flow cytometric results adds up to the total 
internalization of the NC. 
Qualitative determination of CSC- FS NCs internalization was assessed with confocal 
microscopy. Internalization of the NCs has been observed by adjusting parameters such as Z 
stack and merge of fluorescence channels. Apoptotic cell morphology was observed in case 
of cells treated with CSC- FS NCs from 6 h, indicating the potential of combinational therapy 
over monotherapy. Mitochondrial membrane depolarization studies also confirm this 
phenomenon, with increase in FITC fluorescence, that corresponding to un aggregated JC-1 
monomers. Mitochondrial membranes were shown to be more depolarized with combination 
of Fe-bLf - SurR9-C84A as well as with CSC – FS NCs indicating combination of these anti-
cancer proteins with enhanced effect. These results are in accordance with previous report 
regarding membrane potential alterations (Das and Sahoo, 2010). In the previous chapters 
transcytosis of nanocarriers was observed. Herein endocytosis of NCs was studied by 
analyzing for the expression of endosomal antibodies. Early endosomal antigen (EEA1) - 
plays an important role in membrane trafficking and is also used as a marker for early 
endosomes (Patki et al., 1997). Similarly, Lysosome associated membrane protein (LAMP -
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1) is an integral part of lysosomes, involved in maintaining the integrity of vesicular 
membrane (Al-Adhami et al., 2005). With this background the study observed the expression 
of these specific markers after treatment of the cells with various combinations of the NCs. 
As shown by flow cytometric analysis, significant increase in the co localization of EEA1 
receptors along with Fe-bLf was observed in combination (CSC – FS) or Fe-bLf loaded NCs 
compared to void NCs, indicating the NCs were internalized by using endosomal pathway. 
Similar result with LAMP-1 co localization with Fe-bLf was observed, which shows 
internalization of CSC- FS NCs/ Fe-bLf alone loaded NCs is much significant than void NCs. 
Furthermore, NCs with the combination of Fe-bLf and SurR9-C84A have showed slight 
increase in EEA1 and/or LAMP1 marker expression, the possible explanation would be the 
combination of the 2 proteins encapsulated in the NCs would increase the cell surface 
receptors for the uptake of these NCs. This might be the reason why there is increased 
augmentation in cell apoptosis with combination therapy compared to other treatments. Thus, 
ACSC NCs loaded with two anti-cancerous proteins show much improved internalization and 
cytotoxicity, which make them impending candidates for biomolecular therapy.     
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Chapter 6: In vivo anti-tumour efficacy of ACSC NCs encapsulating Fe-bLf 
6.1 Introduction  
Bio-inspired hydroxyapatite and calcium phosphate based microporous ceramics have been 
reported to have enhanced bio-availability and biodegradation properties (Paul and Sharma, 
2006). These properties have motivated researchers in developing nano drug delivery 
systems. In spite of the availability of bio-macromolecular therapeutics based on the recent 
developments in genetic engineering field, their use is limited. This is the consequence of 
extreme short plasma half lives of these fragile molecules, imposing cancer patients to suffer 
prolonged parenteral administration (Schoffski et al., 2004). In this regard, oral 
administration would be convenient, cost effective and reduce patient compliances (Gerrits et 
al., 1998a). Anti-cancer proteins and peptides could cover better characteristics like reduced 
side effects and ease of integration on to nanoplatforms (Kanwar et al., 2009b). Native 
configuration of these proteins and peptides can be better conserved when incorporated in 
nanoformulations, to be able to deliver orally. Also, nano structures could have better uptake 
in tumour vasculature based on enhanced permeability and retention (EPR) effect. Thus, 
needle-free systemic delivery of the protein drugs can be achieved by the oral route, which 
offers a convenient alternative for painful regime of targeting anti-cancer bio-
macromolecules against cancer. Polymeric nanocarriers made of carbohydrate and/or 
carbohydrate derivatives are important in anti-cancer and oral drug delivery, as they can be 
efficiently taken up by mucosal membranes in the intestine. Naturally occurring 
polysaccharides like sodium alginate and chitosan have received much attention in drug 
delivery system for their excellent biocompatibility. Chitosan is a weak cationic 
polysaccharide, composed mainly of (1, 4) linked 2-amino-2- deoxy-β-d-glucan, it can be 
subjected to chemical modification to obtain a derivative with the desired characteristics 
(Alves and Mano, 2008). Alginic acid is a linear copolymer of (1, 4) linked-D-mannuronic 
and -L-guluronic acid residues arranged in a non-regular block wise pattern. The amino 
groups in the chitosan molecule and carboxyl groups in the alginate molecule are pH-
sensitive and can be used as drug carrier materials. The interaction between alginate and 
chitosan has been scientifically investigated (Becheran-Maron et al., 2004). Their 
polyelectrolyte complex has been widely used to obtain devices for the controlled release of 
drugs (Murata et al., 2004). 
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Colorectal cancer is a malignancy associated with the incidents of high morbidity and 
mortality. It is the fourth most common form of cancer and the third leading cause of cancer- 
related deaths with approximately around 0.7 million deaths per year worldwide (Xu et al., 
2010). Habitual factors such as diet, lifestyle, food that is rich in fat and carbohydrates that 
were shown to promote colon cancer development as demonstrated by epidemiological 
studies (Weiss et al., 2011). Presently, some naturally occurring compounds such as 
plant/animal derived proteins, flavonoids and polyphenols were shown to potentially prevent 
the development of colon cancer with minimum side effects (Bar-Sela et al., 2010), but need 
enhancement in their bio-availability, which could be achieved by making use of 
aforementioned advances in the nanotechnology. In this regard, bovine lactoferrin (bLf) is a 
pleiotropic protein, which posses above mentioned expectations to be used as an anti-cancer 
nutracuetical agent. It exhibits anti-bacterial activity (Lonnerdal and Iyer, 1995, Valenti and 
Antonini, 2005, Kanwar et al., 2009a, Burrow et al., 2011, Gibbons et al., 2011) along with 
performing key functions such as regulation of cell growth and differentiation (Bi et al., 
1997), myelopoiesis, embryonic growth (Ward et al., 1999),  endothelial cell adhesion 
(Baveye et al., 2000), production of cytokines and chemokines there by implementing 
immune functions (Artym, 2006). It has been observed that bLf induces cellular proliferation 
and cell survival in osteoblasts (Cornish and Naot, 2010). This multi functionality of bLf 
could be attributed to its natural iron metal binding ability.  
Transitional metal elements such as copper, zinc, manganese and selenium were also found to 
bind in the characteristic lobes present in the tertiary structure of bLf protein (Gonzalez-
Chavez et al., 2009). More importantly, siderophilic (iron-loving) nature of the Lf was 
because of a globular structure consisting of two iron-binding sites per molecule (Tsuda et al., 
2010). Recently, iron saturated form of bLf was shown to augment the cancer chemotherapy 
(Kanwar et al., 2008). This study reported for the first time that iron content is a critical 
determinant in the anti-tumour activity of bLf and found that 100% iron-saturated bLf 
(designated as Fe-bLf) acts as a potent natural adjuvant and fortifying agent for augmenting 
cancer chemotherapy, thus has broad utility in the treatment of the cancer. Lf belongs to the 
transferrin (Tf) family and shares 60-80% sequence identity with Tf (Jeffrey et al., 1998). Tf 
is one of the most widely used tumour-targeted ligands because Tf receptors (TfRs) are over 
expressed in several human carcinomas including breast, ovary and brain cancers (Recht et 
al., 1990). Low density lipoprotein receptors (LRP) were found to aid the signalling 
downstream events related to Lf action. LRP receptor specific antibodies were used to show 
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abrogation of Lf internalization in osteoblasts (Grey et al., 2004) and human fibroblast cells 
(Takayama et al., 2003). Mitogen activated lymphocytes were found to express lactoferrin 
receptors (Bi et al., 1994). Lactoferrin was proved to promote the maturation of T 
lymphocytes by activation of p42/44 MAPK (Dhennin-Duthille et al., 2000). However, 
involvement of LRP1 in the internalization of Lf was examined in an interesting study carried 
out to find the Lf-induced enhancement of collagen gel contractile activity in fibroblasts. 
Suppression of LRP expression by using anti-sense oligonucleotides diminished the Lf 
internalization suggesting that LRP1 plays a role in some of the cellular actions of Lf 
(Takayama et al., 2003).  
This chapter demonstrates the formulation of a novel alginate enclosed, chitosan coated anti-
cancer nanocarriers (ACSC NCs) encapsulating the ceramic core formed by Fe-bLf-calcium 
phosphate. Herein, in order to achieve an oral therapeutic systems with 100% Fe-bLf, 
polymeric ACSC nanocarriers were employed for an effective needle free therapeutic. Size, 
surface morphology were analyzed by using additional TEM technique to validate the 
findings of the SEM imaging in the previous chapters. Physicochemical characteristics such 
as X-ray diffraction (XRD) studies and Fourier transform infrared spectroscopy (FTIR) for 
these nanocarriers have been discussed here along with in vivo anti-tumour efficacy. By 
employing human colon cancer xenograft model, oral efficacies of NCs delivering Fe-bLf 
were studied. Further, immunohistochemical data and real time polymerase chain reaction 
(qRT PCR) analysis for internalization of the Fe-bLf loaded in nanocarriers expression of 
LRP receptors and apoptotic genes were evaluated. 
Methodology: A detailed description of methodology involved in the in vivo anti-tumour 
efficacy of ACSC NCs encapsulating Fe-bLf was given in chapter 8, pages 183-201. 
Methodology that corresponds to each specific result sections has been mentioned in the text. 
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6.2 Results 
6.2.1 Physicochemical characterization of Fe-bLf loaded ACSC NCs  
Alginate enclosed chitosan coated ceramic ACSC NCs were generated by combining nano 
precipitation and ionic gelation methods. By utilizing excellent film forming ability of 
chitosan, protein loaded ceramic cores were coated for making biocompatible, crack-free and 
porous hybrid structures (Peniche et al., 2003).  The resulting NCs were well dispersed in 
water and analyzed using DLS spectroscopy (please refer to section 8.6.1, page 188 for a 
detailed methodology). The NCs were found to have a hydrodynamic diameter of 205 ± 15 
nm for CSC inner core. Alginate was used as an additional polymeric layer, in order to 
protect the protein loaded CSC inner core by ionic gelation technique using calcium chloride. 
As predicted by DLS spectrometry, the size of the NCs was increased to 322 ± 27.2 nm after 
enclosing with alginate to form final ACSC-Fe-bLf NCs (Figure 6.1c). TEM results also 
supported the phenomenon of increase in size with additional polymeric layers and attributed 
spherical morphology to the particles (represented in the inset of Figure 6.1a, Figure 6.1b and 
Figure 6.1c). Also, NCs were found to be well-dispersed and shows consistency in their 
particle sizes in aqueous solution at a physiological pH, indicating the thermo dynamical 
stability. Mesoporosity on the calcium phosphate ceramic structures was evident under the 
electron beam (Figure 6.1a) and the inner ceramic core was observed as a dense structure in 
case of alginate enclosed nanocores (Figure 6.1c). Further analysis for the total number of 
NCs per ml of the suspension, indicates that there are 7.2X104 NCs in 1%w/v suspension. An 
amount of 3.55 ng of Fe-bLf was calculated to be present per CSC-Fe-bLf NC, which makes 
a loading efficiency of the protein as 25.8% (Table 6.1). In the same way loading efficiency 
of ACSC NCs was found to be 19.1%, because of the additional dry weight added with the 
incorporation of alginate over the CSC-Fe-bLf NCs.   
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Figure 6.1: DLS spectrometric observation of NCs in various layers predicts the size of (a) Calcium 
phosphate (CaP) ceramic nanocores (160 ± 11 nm) (b) the size was observed to be increased for CSC-
Fe-bLf NCs (205 ± 15 nm) with the additional chitosan layer as predicted and (c) addition of alginate 
layer further seem to increase the size of ACSC-Fe-bLf NCs (322 ± 27.2 nm). The NCs were found to 
have spherical morphology when observed under TEM (figures in inset), scale bars indicates 100 nm. 
 
 
Table 6.1: Characteristics of ACSC NCs 
Samples  Efficiency 
(%)* 
Loading 
content (%) # 
Number of NCs 
per ml (0.1% w/v 
suspension) 
Amount of 
protein per 
NCs 
Size(nm) 
Void ACSC - - 5.5x105 - 322± 27.2 
ACSC Fe-bLf NCs 80.2% 19.5% 5.5x105 2.27ng 322± 27.2 
CSC Fe-bLf NCs 80% 25.6% 7.2x105  3.22ng 205 ± 15  
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6.2.2 Characterization of crystal structure for the ACSC NCs  
In the previous chapter (Section 5.2.3), FTIR, DSC and TGA analysis along with electron 
microscopic observations proved that the NCs obtain a spherical structure with the ceramic 
core and protein residing inside with polymeric layers over it to protect the enclosed protein. 
In this chapter, X-ray diffraction patterns for chitosan coated ceramic encapsulating Fe-bLf 
(CSC-Fe-bLf), ACSC-Fe-bLf NCs and void ACSC NCs were analyzed, to predict the 
crystallinity in the nanoformulations and to analyze more about the interactions between the 
ceramic and polymeric ingredients (please refer to section 8.6.2, page 188 for methodology). 
CaP-FebLf phase with CaP characteristic diffraction at (002) plane and the overlapping 
diffraction at (300), (211), and (112); and Fe+3 characteristic diffraction at (311), (220), (511), 
(440) plane was observed at 2θ = 11.4, 13.6, 22.4, 25.1, 29.7 and 47.2. Broad peaks at 2θ =10.1° 
were observed in the polymeric composite. Figure 6.2 shows the full width half maximum 
(FWHM) of diffraction peak was very broad, which means that the crystallinity of the 
calcium phosphate after the nanopowder formation becomes lower. Diffraction patterns for 
chitosan and sodium alginate were not detected from the XRD patterns, which mean that the 
chitosan and sodium alginate obtained have amorphous structure in the nanocarriers. 
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Figure 6.2: X-ray diffraction patterns of pure calcium phosphate ceramic (CaP - blue), chitosan 
coated ceramic encapsulating Fe-bLf (CSC-Fe-bLf – black), and Alginate encapsulated CSC-Fe-bLf 
(blue) and void ACSC (red). The data indicates the characteristic diffraction pattern for CaP-Lf 
especially at 11.4, 13.6, 22.4, 25.1, 29.7 and 47.2. Interaction between the ceramic and polymeric 
constituents in the nanoformulation was evident from the diffraction pattern obtained for 
nanoformulations, as represented in the figure. Crystallinity of the precipitated CaP was lower after 
encapsulation in the homopolymers. This phenomenon was represented by broad diffraction peaks in 
the nanoformulations prepared by using chitosan and alginate.                                                     
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6.2.3. Cytotoxicity studies of ACSC NCs 
Evaluation of the cytotoxicity with Fe-bLf loaded NCs was represented in the Figure 6.3. The 
ability of the ACSC NCs to deliver Fe-bLf and induce cell death was examined in the human 
colon cancer (Caco-2) cell line in vitro by MTT assay (Section 8.9.1, page 192). The results 
demonstrated that the viability of the Caco-2 cell line was affected by different 
concentrations of the CSC- Fe-bLf as well as ACSC-Fe-bLf NCs, compared to the control 
NCs, without protein (void NCs). CSC-Fe-bLf NCs have exhibited an IC50 value at 1mg/ml 
(2x105) in Caco-2 cell line. Greater cytotoxic activity was observed for almost all doses of 
CSC-Fe-bLf NCs than that of ACSC-Fe-bLf NCs (Figure 6.3). Various concentrations of 
NCs were tested for different time periods at 10 h and 20 h as represented in the Figure 6.3. 
Significant differences between the treatment with void and Fe-bLf loaded NCs were evident 
from the figures. Meager 32 ± 2.8%  cell viability was observed with 3 mg/ml (1.18x106 
NCs) CSC-Fe-bLf NCs treated Caco-2 cells compared to 72.5 ± 4.2% with same 
concentration of void NCs at the end of 10 h (Figure 6.3a). 1 mg/ml (2x105) CSC-Fe-bLf 
NCs have caused 47.9±5.6 % cell death at the end of 10 h whereas it was increased to 52.1 ± 
3.7% is the percentage of cellular death at the end of 20 h. Thus, important observations from 
these experiments were made that the effect on cell viability was concentration and time 
dependent (Figure 6.3b). 
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Figure 6.3: Dose and time dependent cytotoxicity of control and Fe-bLf loaded NCs. The extent of 
growth inhibition was measured by MTT assay, in (a) 10 h and (b) 20 h after the treatment, 
respectively. Increase in cytotoxicity was observed in CSC NCs carrying Fe-bLf, compared to 
controls. It is evident from the figure that CSC-Fe-bLf NCs show increased anti proliferative activity 
at the doses starting from 1.5 mg to 2 mg of the NCs, compared to void or ACSC-Fe-bLf NCs (Data 
represents mean ± SEM. Experiments were repeated 3 times independently with similar results. 
√√P<0.005, √P<0.05). 
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6.2.4 Evaluation of nanotoxicity for Fe-bLf loaded ACSC NCs 
The in vivo anti-tumour efficacies of Fe-bLf loaded ACSC NCs were studied in CaCo-2 
tumour-bearing nude mice (C57BalbC nu/nu). To be able to make oral delivery system, 
ACSC-Fe-bLf NCs were mixed with the mice diet in a ratio of 1.2% w/w protein: diet, mixed 
well and made into pellets for oral delivery. Mice were divided into “control” and 
“treatment” groups, wherein treatment groups receive diet containing Fe-bLf loaded 
nanocarriers (Please refer to section 8.12, page 196 for a detailed explanation for the 
preparation of AIN93G based diets and body condition scoring). The treatment groups were 
again divided in to 2 groups where NCs diet was switched off to the normal diet after the 
second challenge in case of the “2nd control Caco-2”. “Caco-2” represents the treatment group 
that has received the ACSC-FebLf NCs diet till the end of the experiment, up to 65 days after 
the 1st challenge (Table 6.2).  Body weight and behavioral changes in the mice were noted to 
observe any toxicity caused by the nanocarriers. As shown in the Figure 6.4, there was no 
effect in the body weight in treatment groups when compared to controls. In fact, average 
body weight of treatment groups was more than controls and the mice remained healthy. 
Average body weight of all mice before the treatment was found to be 14.22 g. At the end of 
the treatment (9 weeks), the control group showed a 2 g increase in weight, whereas mice 
placed in the NCs diet have gained up to 17.86 g in the body weight. During the process of 
the treatment, behavioral changes such as appearance, food and water intake, natural 
behavior, provoked behavior and clinical signs of respiratory rates, dehydration were 
observed. Body condition score (BCS) calculations were done based on these results in order 
to judge euthanization in accord with animal ethics approval. BCS of 0-4 have indicated that 
the animals were healthy without any of the side effects posed by nanocarrier based therapy. 
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Figure 6.4: Graph showing body weight of mice after treatment. Mice were divided into 3 separate 
groups based on tumour they carried and treatment type (Control, Caco-2 and Caco-2 2nd control – 
see the text for details). Average body weight of the control group remains at 14g at the end of the 
experiment whereas treatment groups have shown an increase in body weight up to 18g.  Data 
represents mean ± SEM (n=5). 
 
Table 6.2 – (a) Experimental design of feeding control and treatment diets in C57BalbC 
nu/nu mice  
Event Caco-2 control  Treatment Caco-2  Treatment Caco-2  2nd 
control 
Challenge 
with Caco-2 
√ 
[14th day after 
acclimatization in 
the control diet] 
√ 
[14th day after treatment 
in the NCs diet] 
√ 
[14th day after treatment 
in the NCs diet] 
Treatment Taxol 
[10th day after the 
1st challenge] 
NCs (1.6x109) 
[NCs diet was fed to 
mice  up to 65th day] 
NCs(1.6x109) 
[NCs diet was fed to mice  
up to 40th day] 
2nd Challenge 
with Caco-2 
√ 
[25th day] 
√ 
[25th day] 
√ 
[25th day] 
Treatment X √ 
[NCs diet up to 65th day] 
X 
[Switched off to the 
control diet after 40th day] 
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6.2.5 Evaluation of nanotoxicity (spectroscopic study)  
In order to evaluate nanotoxicity, Fourier transform infrared spectroscopy was done on mice 
tissues as suggested previously for arsenic induced toxicity in liver of fish (Palaniappan et al., 
2011). Figure.6.5 shows the average FTIR spectra of control and NCs treated tissues of mice 
in the 4000–400 cm–1 range. The data shows no deviation in case of key stretching vibrations 
that corresponds to the biomacromolecules of major organs including liver, brain, intestine, 
heart, kidney and lungs in control and treated tissues, respectively. Major biomacromolecules 
including protein, lipid, nucleic acids, which have characteristic amide (3293 cm–1  and 1543 
cm–1), methyl (CH3 stretching – 2958 cm–1 and CH2 bending- 1451 cm–1) and phosphate 
symmetric stretch (1230 cm–1) vibrations have shown the same frequencies in control as well 
as the treated groups. 
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Figure 6.5: FTIR spectroscopic observation of control (ctrl) vs. treated (tre) tissues shows no toxicity 
with respect to characteristic peaks lying at right positions in control and treated groups in a range of 
wavelength starting from 4000 to 40 cm-1. Amide bond stretching vibration (3293 cm–1  and 1543 cm–
1) corresponding to protein, methyl (2958 cm–1) and methylene (1451 cm–1) that corresponds to lipid 
and phosphate (1230 cm–1) representing nucleic acids were shown in the figure. Same frequencies 
were observed for protein, lipid and nucleic acid constituents among control vs treatment groups in 
heart, intestine, liver, lung and kidney proves that there was no abnormality with respect to the 
biomolecular content in these organs. 
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6.2.6 Anti-tumour efficacy of Fe-bLf loaded ACSC NCs  
In the earlier studies by Kanwar et.al., on abrogation of anti-tumour efficacy of 
chemotherapeutics with the pretreatment of bLf, it was observed a phenomenal anti-tumour 
effect in 1.2%w/w with 100% iron saturated bLf (Fe-bLf).  The bLf diets had inhibited 
tumour growth by 13–31% at the time (day 49) of administration of chemotherapy compared 
to the control diet (Kanwar et al., 2008). Thus, to observe the anti-cancerous efficacy of Fe-
bLf alone, the protein was given in the form of an oral nanoformulation.  Group of 5 mice 
each were fed either with AIN93G diet containing 10%w/w NCs (approximately 3.38x109 
NCs containing 12g Fe-bLf per kg of diet or 1.63 x 109 NCs per kg body weight) or with a 
control AIN 93G diet (Section 8.12, page 196). Colon cancer (Caco-2) cells (1x106) were 
injected subcutaneously (s.c) after the mice had been on the diets for 2 weeks.  Conspicuous 
difference with respect to tumour growth was observed in case of mice, with the 
pretreatments of ACSC Fe-bLf NCs, compared to control group receiving a normal AIN 93G 
diets. The same phenomenon was observed in vitro, when cancer cells treated with Fe-bLf 
loaded NCs. There was substantial increase in anti-cancer efficacy of Fe-bLf when 
incorporated in ACSC NCs. In case of control mice, tumour volume was increased 
periodically with respect to time, whereas this occurrence seemed to be diminished with 
pretreatment. As shown in the Figure 6.6, tumours were regressed by injecting taxol injection 
to mice in control group, when they reached a diameter of ~0.3 cm.  Then the taxol treated 
control and the ACSC-Fe-bLf NCs- alone treatment groups were challenged for the second 
time with 1x 106 Caco-2 cells. Notably, solid tumours appeared in a period of 5 days in case 
of taxol treated control group, whereas treatment groups did not show any tumours. Within a 
time period of 5 weeks, tumours in control group reached ~0.7 cm thus the animals were 
euthanized as per the animal ethics guidelines. More interestingly, throughout the 
experimental period, there were no noticeable tumours observed in NCs based diet fed mice 
groups (Figure 6.6a). However, when one group of mice were shifted to normal diet from a 
NCs diet, after the 2nd challenge,  2 out of 5 mice have shown a mere tumorigenesis with 
tumours ranging <0.1 cm diameter. 
Since the protein loaded NCs were more efficient in comparison to void NCs in cellular 
uptake (Sections 3.2.5, 4.2.4 and 5.2.5) or imposing cytotoxicity  (Sections 6.2.3 and 7.2.4) 
to the cancer cells in vitro, the study was further extended to observe in vivo anti-tumour 
efficacies. In order to observe the in vivo anti-tumour efficacy profiles of the ACSC-Fe-bLf 
NCs in comparison to the void NCs or the mice fed with control diet only, another set of 
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experiments were carried out. Group of 5 mice each were fed either with AIN93G diet 
containing approximately 3.38x109 NCs containing 12 g Fe-bLf per kg of diet or 1.63 x 109 
NCs per kg body weight; or with a same amount of void NCs or a control diet (Figure 6.6). 
After 2 weeks of pretreatments, tumours were induced by injecting s.c injection of 1x106 
Caco-2 cells. Noticeable difference among the 3 groups of mice with respect to tumour 
growth was observed. ACSC-Fe-bLf NCs inhibited tumorigenesis compared to mice 
receiving a void NCs diet or control group receiving a normal diet. Within a period of 20 
days, control group of mice have developed tumours with sizes around 0.432 cm, whereas 
void NCs (showed slight delay in tumourigenesis up to this period with the tumours having 
sizes around 0.21 cm. Nevertheless, a complete abrogation of tumour sizes were observed in 
case of mice treated with ACSC-Fe-bLf NCs.    
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Figure 6.6: (a) In vivo anti-tumour efficacies of NCs as represented with respect to tumour volumes 
of CaCo-2 tumour bearing mice. Tumours (~0.3cm) were developed in control mice with in 1 week 
after the injection of 106 cancer cells, these tumours were regressed by injecting taxol (i.t). When 
challenged for the 2nd time with cancer cells, the mice have shown ~0.7 cm tumours in 4 weeks. In 
neither of the cases (1st challenge or the 2nd challenge) significant tumours were observed in treatment 
groups of mice.  Data represents mean ± SEM. Experiments were repeated for 5 times (b) Graph 
showing the anti-tumour efficacy of the pretreatments of ACSC-Fe-bLf NCs in comparison to the 
Void NCs or mice treated with control diet. Up on s.c challenge with the 106 colon cancer cells, mice 
that were given a diet containing void NCs and control diet have developed tumours (~1cm) in 6 
weeks whereas the ACSC-Fe-bLf NCs treated mice sowed complete abrogation of tumorigenesis. 
Data represents mean ± SEM. Experiments were repeated for 5 times 
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6.2.7. Histopathology studies to analyze tissue integrity after NCs treatment   
Since the reticuloendothelial system (RES) deals with key functions such as formation of new 
red blood cells (RBCs) and white blood cells (WBCs), destruction of old RBCs, WBCs, 
foreign particles and formation of bile pigments in the body. The fate of the key organs 
involved in RES after treatment with NCs was investigated as reported in previous studies 
(Pang et al., 2011) (Section 8.14, page 197). Histological data including H&E staining and 
immunoperoxidase staining for bLf supported the data regarding the non toxicity and 
internalization of nanocarriers. The H&E stained sections of the organs involved in NCs 
internalization, including intestine, brain; organs involved in RES in liver and kidney showed 
no abnormality. The anatomy of controlled versus treated sections retained their integrity, 
showing a minimal damage to these organs with the treatment (Figure 6.7). 
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Figure 6.7: The figure shows H&E staining for observation of tissue integrity in control and 
treatment groups.  6µm thin slices of (a) Control ileum (TS), (b) treated ileum (TS), (c)  Control liver 
(LS), (d)  Treated liver (LS) (e) Control kidney (LS) (f) Treated kidney (LS) (g) Control brain (LS) 
and (h) Treated brain (LS) were stained with haematoxylin and eosin was used as a counter stain. 
Observed under 100X oil immersion objective.  TS- Transverse Section, LS – longitudinal section. 
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6.2.8. Immunohistochemical (IHC) observation of NCs after oral delivery  
In addition to H&E staining, Fe-bLf functionalized on the NCs was used to detect the 
internalization of nanocarriers. Bovine lactoferrin specific antibody was used to bind to 
ACSC-Fe-bLf NCs, dispersed in the tissues and probed with HRP conjugated secondary 
antibody (Section 8.14, page 197). Further addition of HRP substrate DAB shows the 
immunoreactivity corresponding to the distribution of the FebLf NCs in the tissues. In the 
case of treatment groups (Figure 6.8) characteristic immunoreactivity of bLf was seen. As 
represented in the Figure 6.8a, intestine (treatment group) showed intense bLf 
immunoreactivity corresponding to the proposed transcytosis of the NCs. Tumour also 
showed profound immunoreactivity that corresponding to Fe-bLf, followed by mild 
immunoreactivity in the liver and kidney as a function of biodegradability of the NCs. 
Furthermore, in the case of brain tissues a mild immunoreactivity of bLf was observed (Table 
6.3). In addition to IHC, Western blotting of the tissue homogenates (Figure 6.8b), from 
intestine, spleen, liver, kidney, brain, bone, muscle and eye from control as well as treatment 
groups confirmed the lactoferrin specific immunoreactivity as observed with IHC in the 
tissue homogenates from the treatment group. Densitometric analysis of the Western blots 
showed heightened localization of Fe-bLf in the tumour tissue (2.3 ± 0.02 fold increase) 
followed by intestine (1.5 ± 0.02 fold). More interestingly mild immunoreactivity in case of 
bone and eye were observed. 
 
Table 6.3: Tabulation of the immunochemical reactivity 
Tissue Tumour Intestine  Kidney Liver Brain 
Tissue 
distribution 
Control - - - - - 
Treatment +++ +++ ++ ++ + 
* (-) - no immunoreactivity ; (+++) - high immunoreactivity ; (++) – moderate immunoreactivity; (+) – mild immunoreactivity   
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Figure 6.8: (a) Immunohistochemical localization of ACSC-Fe-bLf NCs with lactoferrin antibody. 
Tumour, Ileum (TS), Kidney (LS), Liver (LS) and Brain (LS) sections from control (a-e) and 
treatment (f-j) groups (lower panel) were shown. Images were represented as observed under 100X oil 
immersion objective. (b) Discrete bands of Fe-bLf were observed in case of intestine and tumour 
tissues and faint bands in brain, kidney, bone, eye and liver tissues from treated mice whereas control 
groups showed no immunoreactivity. Lanes 1-5 (kidney, liver, brain, tumour, intestine- treated), lanes 
6-10 (control tissues), lane 11-13 (treated bone, muscle, and eye) and lane 14-16 represent the 
corresponding controls. (c) Densitometric analysis for the confirmation of internalization by Western 
blotting for the detection of endogenous levels of FebLf NCs after tissue homogenization suggests 
preservation of tertiary structure of Fe-bLf. 
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6.2.9. Enhanced permeability and retention efficacy of NCs  
Significant amount of Fe-bLf loaded NCs was still clearly observed around vascular region of 
the tumour and brain tissue slices (Figure 6.9) using Prussian blue and CD31 double staining 
(More comprehensive methodology was given in the section 8.15, page 197). At high 
magnification (100X), NCs were observed to be located in intracellular regions, which was 
corresponding to our previous observations for nuclear transport of CSC-Fe-bLf NCs in vitro, 
in colon cancer cells (data not shown). Consistently, poor immunohistochemical reactivity in 
case of control tissues was verified using the same staining method as a comparison.  
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Figure 6.9: CD-31 and Prussian blue double staining further confirms internalization of NCs (a,b) in 
brain– inset shows internalization of Fe-bLf loaded ACSC NCs near CD-31 stained area (c) control 
tumour shows no Prussian blue staining and d) treatment tumour showing double staining of CD-31 
and Prussian blue indicating the internalization of the NCs via blood vasculature.(e) intestine control 
and (f) transcytosis of NCs via intestinal villi. 
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6.2.10. Analysis for the percentage of RBCs after NCs treatment 
As it was mentioned in the section, 2.10 various factors regulate the iron homeostasis, 
followed by the depletion of RBCs. It has been observed that chemotherapy causes 
hematologic suppression and anaemia.  In the previous studies it was observed that oral 
feeding of Fe-bLf completely restored the numbers of peripheral red and white blood 
cells of mice treated with the combination of paclitaxil and doxorubicin, such that blood 
cell numbers were up to 50% greater than those of healthy control mice. Immune cells, in 
the spleen including CD4+, CD8+, NK, IFN γ expressing and dendritic cell numbers in 
the spleen were significantly increased in the treatment group compared to control. Since 
iron absorption was increased in the key organs such as brain, liver and intestine, as 
discussed in the previous and in the subsequent sections (Section 7.2.8), this study was 
aimed at the calculation of RBC numbers in the control vs treatment mice groups 
(Section 8.12, page 196). In order to perform this, whole blood from mice was collected 
and analyzed in flow cytometry. As it is represented in the Table 6.4, there was no 
reduction of RBC numbers after the treatment. Moreover, there was a slight increase in 
the RBC count confirming the non toxicity of the NCs treatment.     
Table 6.4: Hematologic profiles of tumour bearing mice after NCs treatments  
Treatment Total hematologic 
cell count  
RBC* WBC* 
Control  7.06 ± 0.62 7.3 ± 1.13 7.42 ± 1.14 
Void NCs 7.42 ± 1.14 7.3 ± 0.62 7.95 ± 1.23 
ACSC-Fe-
bLf NCs 
8.71 ± 1.93 8.6 ± 1.91 8.71± 1.93 
* -Mean values of whole blood cells including RBCs (* x 109 cells/ml) and WBCs (* x 106 
cells/ml) counts were recorded flow cytometrically for the blood samples collected directly from 
the heart at the time of autopsy. The heparinized samples were analyzed after dilution with PBS.   
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6.2.11. Real time analysis for the mechanism of endocytosis and apoptosis 
Previous studies have shown that lactoferrin is a LRP as well as transferrin ligand (Strickland 
et al., 2002). Thus, this receptor was detected by RT-PCR analysis in tumours and in other 
organ tissues (Section 8.19, page 199). RT-PCR analysis indicated that LRP1 receptor 
mRNA was overexpressed in colon cancer cell lines compared to GAP3DH controls (Figure. 
6.10). Although LRP1 mRNA was overexpressed in all treated tissues, the level of LRP2 in 
tumour tissues as well as in brain and intestine was elevated much higher (Figure. 6.10). It 
was observed that LRP2 mRNA was elevated 3.4 ± 0.06 (P<0.005) folds in liver, and 1.8 ± 
0.01 fold in brain whereas 4.9 ± 0.05 (P<0.005) fold in the intestine compared to Caco-2 cells 
treated with NCs. Furthermore, real time analysis of various anti-tumour genes in control vs. 
treated tissues indicated down regulation of anti-apoptotic factors including survivin, Bcl-2 
family and upregulation of pro-apoptotic Bax, Fas and caspases as represented in Figure 6.11. 
Anti-apoptotic factor survivin was down regulated in treatments as compared to control cells 
and tumours from treatment groups by 0.46 ± 0.1 fold. Other anti-apoptotic gene BclX was 
down regulated by 0.2 ± 0.03 fold. NCs treatment had also increased the expression of pro-
apoptotic genes including caspase 3 (19.01 ± 0.01fold) caspase 8 (5.7 ± 0.1fold) and caspase 
9 (8.2 ± 0.6 fold) in case of treated tumour tissues compared to control tumour. These results 
were thus used to draw a functional mechanism of action for the ACSC-Fe-bLf NCs as 
represented in the Figure 9.1. 
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Figure 6.10: Real time PCR analysis for LRP receptor shows a) elevated expression of the receptors 
in treated tissues compared to control tissues. LRP1 expression is high in brain (1.6 fold), liver (1.8 
fold) compared to NCs treated Caco-2 cells. LRP2 mRNA levels were elevated by 3.4 fold in liver, 
1.7 fold in brain 4.9 fold in intestine and 1.8 fold in treated tumour tissue. Data represents mean ± 
SEM. Experiments were repeated 3 times independently with similar results. √√P<0.005 b) gel 
images shows qualitative determination of amplified product in various tissues as represented in 
figure. Lane 1- Caco-2 cells; lane 2 – Caco-2 cells + CSC-Fe-bLf; lane 3 – brain control; lane 4 – 
brain treatment; lane 5 – liver treatment; lane 6 – liver control; lane 7 – intestine control; lane 8 – 
intestine treatment; lane 9 – tumour control; lane 10 – tumour treatment.  
 
 
145 
 
  
Figure 6.11: Real time analysis of up/down regulation of apoptotic genes. The levels of gene 
expression in the homogenates of Caco-2 cells (designated as cell), 1.25 mg/ml NCs treated cells 
under in vitro conditions (cell + tre) were measured by qRT PCR and normalized with respect to 
GA3PDH housekeeping gene. Gene expression was also measured in control (designated as tumour) 
and tumours from NCs treated mice (designated as tumour + tre) as represented in Figure 6. Anti-
apoptotic genes including survivin, Bcl-2 families were found to be down regulated whereas pro- 
apoptotic genes such as Bax, caspase3, caspase8, caspase 9, Fas and Fas-L were up regulated. Data 
represents mean ± SEM. Experiments were repeated 3 times independently with similar results 
√√P<0.005; √P<0.05; Caco-2 cells + NCs treatment and tumour from the treatment group compared 
to control cells) Agarose gel images show the qualitative expression of the PCR product. Lane 1- 
colon cancer cells, lane 2 – tumour tissue, lane 3- cells with NCs treatment, lane 4 tumour tisses from 
NCs treated mice.  
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6.2.12 Downregulation of endogenous survivin expression in vivo  
In a similar way as section 4.2.6, endogenous levels of survivin expression in vivo were 
studied (For a comprehensive methodology of Western blotting please refers to section 8.7, 
page 191). Since, survivin plays a crucial role in cellular growth, cancer progression and 
metastasis, inhibition of survivin could promote the apoptosis in cancer cells. As shown 
earlier, the gene expression levels of survivin were found to be downregulated in NCs treated 
cells (Figure 6.11). To confirm this effect, endogenous survivin at the protein levels was 
studied after the treatment with NCs in vivo, taking in vitro assessment in parallel. Decrease 
in survivin levels was observed in the densitometric analysis of the survivin Western blots, as 
a reciprocal of gene analysis. In case of control tumour tissue 1.7 ± 0.03 fold increase in 
survivin was observed when compared to the tumour tissue from treatment group. In case of 
control cells, 1.5 ± 0.03 fold higher survivin was observed compared to the treated cells 
(Figure.6.12). 
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Figure 6.12: Endogenous expression of survivin was analyzed by doing immunoblotting for the 
tissue homogenates. The histogram shows densitometric analysis and the downregulation of survivin, 
in the treatments in comparison to untreated cells or tumour tissue was observed (arbitrary units 
represents the band densities of survivin compared to actin). Western blots showing lane1-tumour 
sample; lane2-tumour + treatment; lane3 untreated cells; lane4-cells treated with NCs. 
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6.2.13. Deregulation of tumour angiogenesis with the NCs treatment 
Previously it was reported that Fe-bLf was shown to reduce the pathological angiogenesis by 
down regulation of resting (CD31) and activated (CD105) blood vessels along with blood 
flow (DiOC7) (Kanwar et al., 2008). In this study measurement of blood vessel density was 
done by counting CD-31(neo angiogenesis - resting) and CD-105 (early angiogenesis - 
activated) blood vessels in the control and treated (tumours from mice fed oral NCs diet) 
tumours (Section 8.16, page 198). Herein, 3 different tumours were analyzed for the degree 
of angiogenic blood vasculature. Control tumour represents the tumours developed in 
untreated mice and void NCs corresponds to the tumours that were developed in mice 
received diet containing void NCs. Angiogenesis in both these controls was compared to the 
degenerative tumour developed in the mice treated with ACSC-Fe-bLf NCs. The CD-31 
average vessel counts were 38.8 ± 4.7 in case of ctrl tumour, whereas it was 23 ± 1.3 in void 
NCs treated tumour. Neo angiogenic vessels were 13 ± 1.3 in control tumour and 4.8 ± 0.5 in 
case of void NCs treated tumours. A significant difference in the mean vessel counts per 
surface area in ACSC-Fe-bLf NCs treated vs. control tumours was observed (Figure 6.12a, 
12b). With the pre treatment CD-31 positive and CD-105 positive blood vessel density was 
reduced by 14.9 ± 0.8 fold and 16.2 ±0.4 fold respectively.   
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Figure 6.13: (a) Visualization of blood vessel density in representative tumour sections was observed 
under confocal microscope. Control tumour (a-f) represents untreated tumour (tumour blood vessels 
in the sections from mice fed with control diet) ; Void NCs represents  tumours developed in mice 
treated with void NCs (g-l); tumours from ACSC-Fe-bLf NCs treated mice were represented as 
ACSC-Fe-bLf NCs (m-r) (Data represents mean ± SEM. Experiments were repeated 3 times and the 
images represent 5 different fields. √√P<0.005; √P<0.05, ACSC-Fe-bLf NCs vs control tumour) (b) 
Histogram representing CD-31 and CD-105 double staining for determination of angiogenesis level in 
control and treatment tumours shows decrease in angiogenesis in case of ACSC-Fe-bLf NCs treated 
mice. 
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6.2.14. Assessment of in vivo apoptosis in the NCs treatment 
It was shown in the previous chapters (Section 3.2.4) that that NCs treatment reduces the 
cancer cell viability in vitro using Annexin-V-PI staining; TUNEL assay; MTT assay. These 
results were reproduced in the in vivo situation, in the prevention studies as represented in 
section 6.2.6 of this chapter. Hence, to further prove the cellular apoptosis in the case of 
treatment group mice, where 2 out of 5 mice have developed a degenerative tumour, in vivo 
apoptosis assessment was done (for a detailed methodology please refer to section 8.17, page 
198). Cellular apoptosis in treated vs. control tumours was observed by performing TUNEL 
assay. A significant number of apoptotic cells were observed in case of tumours developed in 
treatment group, indicating degeneration of the tumour progression in these animals. As 
shown in Figure 6.14 significant numbers of apoptotic cells were observed in ACSC-Fe-bLf 
NCs treatments (61.5 ± 0.4 %) compared to control tumours (3.5 ± 0.3 %).   
 
 
 
 
 
 
 
 
 
 
 
 
 
152 
 
                                       
 
 
Figure 6.14: TUNEL assay performed on the tumour sections as represented in Figure 6.6. 
(a)Significant number of apoptotic cells were observed in NCs treatments compared to control 
tumours. Data represents mean ± SEM. Experiments were repeated 3 times and the images represent 5 
different fields. √√P<0.005; √P<0.05; treatment vs control (b) Confocal observation of in vivo 
TUNEL assay; control 1 represents untreated tumour and control 2 represents taxol injected mice after 
the 2nd challenge and tumours from ACSC-Fe-bLf NCs treated mice.  
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6.3 Discussion  
Previous reports have suggested a synergistic anti-tumour efficacy of 100% iron saturated 
bLf (Fe-bLf) along with the monotherapy or in a combination of the chemotherapeutics, to 
prevent tumorigenesis (Kanwar et al., 2008). This study further reveal that, Fe-bLf could be 
more effective compared to natural bLf in combating tumour. There were reports in relation 
to abrogation of tumorigenesis by recombinant talactoferrin (human lactoferrin) when used in 
combination with cisplatin or radiotherapy in head and neck squamous cell carcinoma 
(Varadhachary et al., 2004). In another study, it was observed that talactoferrin can act as in a 
dual manner to inhibit the growth of head and neck squamous cell carcinoma by direct 
cellular inhibition as well as systemic immunomodulation (Wolf et al., 2007). Talactoferrin 
used in this study was not 100% iron saturated suggesting a further research regarding the 
iron saturation in case of recombinant human lactoferrin in causing anti-cancer cytotoxicity. 
Nevertheless, in case of natural bLf, iron saturation increases the gastrointestinal resistability, 
owing to its enhanced bio-availability for a better outcome of an anti-tumour response. 
Present study used Fe-bLf as a natural anti-cancer agent as bLf is an abundant and easily 
available/ cost effective form compared to its genetically engineered counterpart from human 
source. Taking into account that the rapid renal clearance (Haubner et al., 1999, Noiri et al., 
1996, Sivolapenko et al., 1998) of proteins imposes development of new strategies for 
enhanced bioavailability, this study used the advances in nanotechnology to orally deliver Fe-
bLf.  ACSC nanocarriers have better advantages for encapsulation and delivery of anti-cancer 
proteins. Enhanced delivery could be based on use of leaks in tumour vasculature for 
passive/active delivery of protein drugs. The ACSC NCs were loaded with Fe-bLf and tested 
for the size and morphology to be able to address enhanced permeability and retention effect. 
The nanocarriers were found to have size of 350 nm with alginate coating and obtain a size of 
220 nm for CSC nanocarriers (which would be in significant numbers in the intestine after 
the degradation of alginate layer (Mahidhara et al., 2011 ), making those better candidates for 
oral drug delivery. TEM results have indicated spherical morphology which is highly 
recommended to be able to achieve large surface area and efficient mucoadhesiveness 
(Maysinger, 2007). Also, electron micrographs indicate different intensities in the image, 
which can probably be because of the differences in the electron densities of various layers in 
the nanocarrier. The inner ceramic core was observed as a dense structure in case of alginate 
enclosed NCs. Mesoporosity on the calcium phosphate ceramic structures, which is required 
for physical entrapment of the protein, was evident under the electron beam in the higher 
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magnification of 50 KX. Further, it was shown that the amount of protein loaded in case of 
CSC-Fe-bLf NCs as 3.55 ng per a single particle, thus the loading efficiency of the protein 
was calculated to be 25.8%. NCs with or without the loaded protein have shown almost the 
same sizes and the size distribution was homogeneous with equal dispersion and consistent 
sizes in physiological pH. In the  previous chapter (chapter 5) data demonstrated the linkage 
of amino and phosphate groups (stretching at 1632 cm-1 and presence of PO4 stretching at 
961.6 cm-1 and 3434 cm-1) based on FTIR measurements (Mahidhara et al., 2011 ). The 
organic–inorganic hybrid film formed by using calcium phosphate ceramics and chitosan/ 
alginate could reserve the biocompatibility of the biopolymer and the desirable properties of 
nanostructured materials to a large extent (Kang et al., 2009). XRD analysis of the nano 
delivery systems were performed to determine the crystallographic structure, lattice 
parameters and phase transitions based on the characteristic peaks. The FWHM shows that 
crystallinity of the calcium phosphate after the nanopowder formation becomes lower. 
Diffraction patterns for chitosan and sodium alginate indicates that the chitosan and sodium 
alginate obtain amorphous structure in the nanocarriers. These nanocarriers were lyophilized 
and incorporated in the mice diet, to achieve oral delivery of the anti-cancer protein, Fe-bLf. 
Whilst most of the present study was performed in order to find the anti-cancer efficacy of 
nano-entrapped Fe-bLf, a total of 1.2%w/w of Fe-bLf was incorporated in 1Kg of diet. In 
other words, approximately 3.38x109 NCs containing 12 g Fe-bLf per kg of diet or 1.63 x 109 
NCs per kg body weight were administered to experimental mice. The amount of protein 
supplementation was in accord to the recommendations by the health and food companies to 
sell their bLf products at health and food stores. However, increase in concerns regarding 
nanotoxicity of heavy metal nanoformulations such as iron oxide toxicity on the neuronal 
cells (Pisanic et al., 2007) prompted us to assess any related nanotoxicity for ACSC NCs. It 
has been shown that magnetic nanoparticles that were surface modified with coatings such as 
PEG, TAT peptide results in non specific adsorption to the cell membrane. This was shown 
to accumulate moderate and/or high Fe2O3 nanostructures and finally could lead to acute 
cytotoxicity, cell mobility and alterations in cellular morphology. This could finally lead to 
autonomic nervous system impairment, damage of the cardiovascular system by direct effects 
on endothelial cells and coagulation, direct effects on vascular reactivity. In some cases 
metallic nanoparticles in heart and cardiac myocytes generate reactive oxygen species 
through redox cycling causing oxidative damage to proteins, lipids, and DNA. Nevertheless, 
chitosan and alginate used in this study were proved to be bio-compatible and used in 
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medical applications. Even though, there was evidence regarding mild toxicity of chitosan 
derivatives and solution form of chitosan at low pH and its salts (Baldrick, 2010), careful 
handling of chitosan promises health benefits (Gades and Stern, 2005). Alginate was 
approved by the US Food and Drug Administration (FDA) for its oral use (Tugcu-Demiroz et 
al., 2007). In case of mice treated with diet carrying nanocarriers, there was no abnormality 
with respect to body weight and behavioral changes. Indeed, mice treated with Fe-bLf loaded 
NCs were found to be healthier than control group mostly, because Fe-bLf is a natural 
defense protein with anti-cancer properties. Thus, any questions of nano toxicity (Johnston et 
al., 2010, Vega-Villa et al., 2008) could be nullified and the ACSC nanocarrier system could 
be treated as bio compatible, bio degradable and nutraceutic. Furthermore, to evaluate this 
phenomenon in terms of abnormalities in bio-molecular compositions in various tissues, 
Fourier transform infrared spectroscopy was carried out on vital tissues, that were 
hypothesized to play a key role in absorption and biodegradation of the NCs. The results 
indicated that the stretching and bending vibrations corresponding to proteinaceous, lipid and 
nucleotide components remains the same between control vs. treatment groups, aiding further 
support for the absence of nanotoxicity (Muley et al., 2007). Thus, this bio friendly nature 
could be attributed to the number of biodegradable and bio-active components employed in 
the preparation of ACSC NCs i.e. calcium phosphate, chitosan and alginate. Multi functional 
nature of Fe-bLf, which specifically kills malignancy with absolutely no damage to the 
normal tissues, adds up to the enhanced bio compatibility for the NCs. Taking in to 
consideration that the side effects imposed by anthracyclin based chemotherapeutics, a major 
setback is the deprivation of red blood cell number. Herein, since the main objective of the 
study to overcome these side effects, we have analyzed the number of red blood cell and 
white blood cell population among the various groups compared to control mice. ACSC-Fe-
bLf NCs treated mice were healthy with improved blood cell counts indicating the 
nutraceutical effect of the Fe-bLf in the maintenance of hematologic cell number. Thus, using 
such nanoformulations could help in overcoming a major setback of chemotherapy i.e. 
switching off the chemotherapy over a period to allow the patient’s immune system to 
recover white and red blood cell counts. Hence, a continuous administration of anti-cancer 
therapeutic could be made possible by using a NCs system like ACSC-Lf NCs.  
In order to evaluate the anti-cancer effect, a pretreatment of NCs was given to 5 week old 
mice for a period of 2 weeks followed by tumour induction. As represented in results section, 
there was no significant increase in tumour volume in case of ACSC-Lf NCs treated groups 
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compared to void and untreated controls. These results mimic the in vitro assay that have 
been carried out in order to observe anti-cancerous effects of Fe-bLf loaded NCs by 
observing cancer cell viability in vitro using  MTT assay. The results along with in situ cell 
death detection TUNEL assay suggest Fe-bLf loaded NCs was shown to efficiently kill 
CaCo-2 cells. Also, phenomenal increase in anti-cancer efficacy of Fe-bLf when incorporated 
in ACSC NCs could be attributed to improved delivery and controlled release of the protein 
by NCs (LaRocque et al., 2009, Kanwar et al., 2011b). These results were in accord with 
previous reports in our lab wherein it was observed that nuclear translocation of the Fe-bLf 
NCs in cancer cells occurs in a lesser time frame compared to the free protein alone, which 
could potentiate the action of Fe-bLf for initiating cell death (Mahidhara et al., 2011 ).   
Recent studies have shown that full occupancy of iron in the metal binding pockets in N and 
C lobes in bLf determines the anti-tumour efficacy of the protein (Kanwar et al., 2008). This 
particular phenomenon was attributed to the bioavailability and increased resistance to 
degradation in the digestive tract in case of Fe-bLf. Several studies have supported the 
resistibility of Fe-bLf over 20% iron saturated Lf or the Apo form of bLf in the digestive tract 
because of the iron content (Troost et al., 2001, Kanwar et al., 2008). However, to be able to 
reach a tumour site, Fe-bLf needs an additional protection, which was addressed in this study 
by incorporating the therapeutic protein in to ACSC NCs. Thus, this hypothetical 
phenomenon of the nano-entrapment of the therapeutic protein has shown a significant anti-
cancer efficacy in vitro and in vivo.  Previous data based on the in vitro studies shows 
enhanced anti-cancer ability of these NCs with low doses of Fe-bLf, than that of the free 
protein (Mahidhara et al., 2011 ). When Fe-bLf alone was administered orally, it has 
abrogated tumorigenesis by enhancing anti-tumour immunity via the production of IFN-γ, 
interleukin -18 (Kanwar et al., 2008). This was attributed to the activation of CD4+ and CD8+ 
T cells and NK cells by IL-18 and further production of IFN-γ, which further act as anti-
tumour agent in combination with TNF-α. Herein, untreated control group mice were 
injected with taxol intratumourally and the subsequent secondary challenge of all the mice 
groups with cancer cells had shown no signs of tumorigenesis in the treatment group 
receiving oral delivery of NCs only. However, taxol treated control group developed tumours 
within 5 days after the secondary challenge, owing to unavailability of taxol at the tumour 
site after certain time. Nevertheless, a complete abrogation of tumorigenesis in ACSC-Fe-bLf 
NCs treated mice indicate the possibility of the Fe-bLf acting as dual anti-tumour agent by 
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enhancing indirect anti-tumour immunity as well as acting as a pro-apoptotic enhancer with 
its controlled release from the NCs in the cancer cells.   
Tissue integrity was shown to be preserved in H&E staining of tissue sections including liver, 
spleen, kidney, brain and ileum. This means the nanocarriers do not impose toxicity to these 
organs and open the tight junctions in the intestine in a reversible manner for the transport in 
to the systemic circulation. Further, bLf immuno reactivity was observed in case of liver, 
kidney and spleen, which are the potential sites for reticuloendothelial system. Intestinal 
absorption of the nanocarriers can be confirmed by immunoreactivity in the ileum. 
Neurotoxicity, which could be the side effect of many present day medications could be 
infinitesimal in case of these nanocarriers, which was confirmed by the mild immune 
reactivity in brain tissues. On a positive note, this phenomenon could be employed in brain 
transport of nano drugs with targeting molecules and/or surfactants for the therapeutic use in 
treatment of fiddly disorders like Alzheimer’s disease and multiple sclerosis. The 
immunohistochemical observations were further supported by Western blots for respective 
tissue homogenates. These immunoblots qualitatively as well as quantitatively suggest the 
nanocarrier internalization in the intestine and tumour tissues, including eye and bone.    
Consistent with the findings of immunohistochemical observations and Western blotting for 
the internalization of NCs using the Fe-bLf, the result of Prussian blue staining verified the 
specific internalization of iron on ACSC-Fe-bLf NCs. Colocalization of Prussian blue 
staining along with CD31 positive staining was observed to be accumulated into tumour 
tissues, which indicates enhanced permeability and retention (EPR) effect. In accordance 
with the bLf immunohistochemistry, brain tissue has shown mild reactivity in Prussian blue 
staining. Further, histochemical observations in organs involved in reticuloendothelial system 
such as liver, kidney and spleen have shown positivity, which further supports the bio-
degradability sites for these NCs.  
In addition to the results of both in vitro and in vivo, functional mechanism of internalization 
indicated the up regulation of LRP receptor genes. Previous studies have shown that 
lactoferrin is a LRP as well as transferrin ligand (Strickland et al., 2002). An increased 
expression of Lf receptors (LRP1) in the tissues among the treated comparing to normal 
tissues showed further potential of Fe-bLf for targeting to tumour via intestine when taken 
orally. More importantly, a higher LRP1 level was detected in the intestine and tumour 
tissues compared to control or untreated cells. Thus, based on the surface receptor- ligand 
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chemistry, Lf could guide the NCs into the cells. In order to study bLf induced apoptosis as 
previously reported (Iigo et al., 2009), real time PCR analysis of apoptotic genes in treated 
tumour samples was carried out. Anti-apoptotic genes such as survivin, Bcl family of genes 
has been found to be downregulated with treatment of the NCs, whereas pro apoptotic Bax, 
Fas and caspases indicates promotion of apoptosis in the tumours by the NCs. These reports 
were further supported by the TUNEL assay done on treatment vs. control tumours. The data 
indicates a significant increase in apoptosis in case of small tumours from the treatment 
group, whereas controls including that of taxol treated group (which developed tumours after 
2nd challenge) have shown healthy growing non apoptotic cells in the tumours. By compiling 
these results along with the available literature on the internalization of lactoferrin, it could be 
postulated that CSC-FebLf NCs were internalized using LRP as well as Tfr receptors, as 
represented in the Figure 9.1. The possible explanation of this could be the slow dissolution 
of chitosan in the tumoral acidic environment exposing the epitopes of Fe-bLf to the 
receptors. Taken together, these results give information regarding the mechanism of 
internalization and inducing apoptosis in the cancer cells by ACSC-Fe-bLf NCs. 
Previous reports have shown that the orally administered bLf has significantly suppressed 
3LL cell-induced angiogenesis (Shimamura et al., 2004). This data is in accordance to the 
previous report by Kanwar and coworkers, where Fe-bLf was shown to reduce the 
pathological angiogenesis by downregulation of resting (CD31) and activated (CD105) blood 
vessels along with blood flow (DiOC7)(Kanwar et al., 2008). Thus, measurement of blood 
vessel density was done by counting CD-31(neo angiogenesis - resting) and CD-105 (early 
angiogenesis - activated) blood vessels in control and tumours that were developed in NCs 
treated mice (treated tumours). A significant difference in the mean vessel counts per surface 
area in treated vs. control tumours determined the degree of pathological angiogenesis. Both 
untreated control and void NCs treated control have shown high blood vessel density 
compared to the ACSC-Fe-bLf NCs treated tumours. Anti-angiogenic properties of the 
ACSC-Fe-bLf NCs were confirmed with a significant decrease in blood vessel density as per 
the treatment. Taken together, these results indicate enhancement of anti-tumour efficacy of 
100% iron saturated lactoferrin upon incorporating them in a nanocarrier in order to develop 
an oral therapeutic system for using human colon cancer xenograft model as a proof of 
concept. 
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Chapter7. In vivo oral nutraceutic drug delivery for breast cancer therapy using nano 
Fe-bLf 
7.1 Introduction  
Breast cancer neoplasms are the leading causes of death by cancer, among women in the 
world. More than half of the new cases of breast cancer occur in developed countries in 
comparison to the total number of incidents that were diagnosed worldwide (Evangelista and 
Santos, 2011, Cuzick et al., 2011). Although chemotherapy improves disease-free and overall 
survival in cancer patients, there involves a number of  side effects during the course of the 
treatment or after the completion (Love et al., 1989). The adverse effects such as neuropathy 
and fatigue that occur during the treatment are regarded as short term effects whereas the 
long term effects include leukemia and cognitive dysfunction (Partridge et al., 2001, Shapiro 
and Recht, 2001). Chemotherapeutics that are derived from anthracyclins were reported to 
impose severe problems such as congestive heart failure, ventricular tachycardia, and sudden 
death (Broeyer et al., 2008). Majority of the chemotherapeutics are poorly soluble in water 
due to hydrophobic properties and the solvents used in their formulation induce toxic 
responses, such as hypersensitivity, peripheral neuropathy and can reduce the extent of drug 
delivery to the tumour (Yamamoto et al., 2011). To overcome the aforementioned problems 
recent innovations in genetic engineering and biotechnology could be used as an alternative 
therapeutic strategy (Kanwar et al., 2010b, Liu et al., 2008, Chames and Baty, 2009). 
 In the previous chapter, in vivo data suggested exciting findings that feeding anti-cancer 
nanocarriers loaded with Fe-bLf in xenograft colon cancer model of nude mice as a proof-of-
concept, supported their safe and biocompatible nature with potent anti-tumour efficacy. Bio-
distribution studies using immunohistochemical observations showed enhanced uptake of the 
NCs by intestine and tumour tissues with EPR efficacy of the NCs. In vivo enhancement of 
apoptosis and anti-angiogenic activities opens for the possible new objectives in order to 
carry further studies related to the intense molecular mechanisms in various other cancer 
types, such as breast cancer.  
Since, the orally fed Fe-bLf was shown to augment anti-cancer chemotherapy, herein this 
study tried to further support its gastrointestinal sustainability by incorporating it in the 
polymeric-ceramic nanoformulation. Therefore, the formulation of a novel alginate enclosed, 
chitosan coated calcium phosphate ceramic; anti-cancer nanocarriers (ACSC-FebLf NCs) 
was hypothesized to be more effective than the free protein alone. Taking the previous 
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studies into consideration (Mahidhara et al., 2011 , Kanwar et al., 2011 ), this study further in 
vivo tested the anti-tumour efficacy of ACSC-Fe-bLf NCs. Physicochemical characteristics 
such as size, surface morphology and controlled release profiles of these NCs has been 
discussed here along with in vivo anti-tumour efficacy. Furthermore, immunohistochemical 
data and real time polymerase chain reaction (qRT PCR) analysis for internalization of the 
Fe-bLf loaded in NCs and expression of LRP receptors were evaluated in breast cancer 
xenograft model of nude (C57BalbC nu/nu) mice. 
Methodology: A detailed description of methodology involved in the in vivo oral nutraceutic 
drug delivery for breast cancer therapy using nano Fe-bLf was given in chapter 8. 
Methodology that corresponds to each specific result sections has been mentioned in the text. 
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7.2 Results  
7.2.1 Preparation and characterization of Fe-bLf loaded ACSC NCs 
100% saturated Fe-bLf was loaded on the calcium phosphate ceramic nano cores followed by 
organic–inorganic hybrid film in order to reserve the biocompatibility of the biopolymer 
using some tremendous film forming properties of chitosan (Lu et al., 2006). An average size 
of 205 ± 15 nm for CSC inner core was observed, which was increased to 322 ± 27.2 nm 
after enclosing with alginate to be able to form a final ACSC NCs (Figure 7.1a). These results 
were further confirmed by TEM observation and this attributed a spehricity to the NCs 
(please refer to section 8.6.1, page 188 for a detailed methodology). Mesoporosity on the 
calcium phosphate ceramic structures were evident under the electron beam (Figure 7.1b). A 
sum of 7.2X104 NCs in 1%w/v suspension was observed during the analysis for the total 
number of NCs per ml of suspension. Further, 3.55 ng of Fe-bLf was calculated to be present 
on one NC, which makes a loading efficiency of the protein as 25.8% (Table 6.1).  
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Figure 7.1: Determination of the size of NCs by DLS spectrometric observation of in various layers 
predicts the size of (a) Fe-bLf loaded ceramic nanocores (160 ± 11 nm), CSC-Fe-bLf NCs (205 ± 15 
nm) and ACSC-Fe-bLf NCs (322 ± 27.2 nm ). The NCs were found to have spherical 
morphology when observed under TEM (b) Sphericity and mesoporosity of the CaP (c) chitosan 
coated CaP-FebLf NCs (d) additional alginate layer confirms the hydrodynamic size of ACSC-Fe-
bLfNCs, as done by DLS. Scale bars indicate 100 nm. 
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7.2.2. Release profiles of Fe-bLf in a controlled manner from ACSC NCs in varying pH 
Since the main aim of this study is development of NCs for oral delivery, sustainability of the 
entrapped protein was evaluated. Controlled release profiles of Fe-bLf from ACSC-Fe-bLf 
NCs were analyzed in a range of pH as experienced by NCs in milieu interior, by creating a 
microcosm of theoretical gastrointestinal pH (Section 8.8, page 191). 1% w/v NCs was 
suspended into various buffers under constant stirring and maintained at a temperature of 
37°C. Starting from 1 h till 96 h, the sample was centrifuged, and supernatants were analyzed 
for protein concentration, using spectrophotometrical analysis to be able to observe release of 
Fe-bLf from the NC. The results show that protein release from the alginate encapsulated 
CSC NCs release encapsulated protein in different manner among the buffers of various pH. 
There was an initial burst at the end of 12 h and a sustained release up to 96 h, in a buffer in 
alkaline pH i.e. in pH 8 (Figure 7.2). However, release of the protein was minimal in acidic 
pH, only 55% of the total protein was released by the end of 96 h.  
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Figure 7.2 Controlled release of Fe-bLf from ACSC NC as observed under pH 1.5, pH 2 and 
pH 8 in a range of time starting from 1h to 96 h. 
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7.2.3. Internalization of rhodamine loaded NCs in MDA-MB-231 cells in vitro 
To check the cellular internalization of fluorescently loaded NCs in MDA-MB-231 cells, the 
cells were treated with rhodamine labeled CSC, CSC-Fe-bLf NCs, and ACSC-Fe-bLf NCs, 
for different time intervals ranging from 1 h to 12 h. After every successful treatment, cells 
were trypsinized, washed with PBS several times and permeabilized with 70% ethanol and 
acquired by using BD FACS canto II flow cytometer (Section 8.10.2, page 194). Flow 
cytometric analysis showed an increase in cellular uptake of void CSC NC from 21.8 ± 0.5% 
in 1 h to 59.8 ± 0.9% in 12 h whereas increase was observed to be prominent in Fe-bLf 
loaded CSC NCs, which is 62.5 ± 0.3% initially within 1 h and increases to a massive 85 ± 
1.6% at the time period of 6 h (Figure 7.3d). However, this trend was absent in 12h treatment 
with only 52.4 ± 5.1% of the cells were positive for rhodamine fluorescence. In case of 
ACSC-Fe-bLf NCs, the percentage of endocytosis was less from 1 h- 6 h, however, slight 
increase by the end of 12 h (23%) was observed. To determine qualitative endocytosis, 
rhodamine labeled CSC NCs and CSC-Fe-bLf NCs were treated on to MDA-MB-231 cell 
monolayers grown in 8 well chamber slides. Nuclear staining was done with DAPI (Figure 
7.3). The confocal micrographs indicate cytoplasmic and nuclear localization of NCs. Time 
dependent internalization of NCs was observed. At the end of 12 h treatment, cell layer was 
found to get damaged compared to rhodamine treated control cells. 
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Figure 7.3: (a) Schematic representation for cellular internalization of the rhodamine labeled NCs. 
(b) Confocal microscopy shows the cytoplasmic and nuclear localization of rhodamine labeled CSC-
Fe-bLf NCs. Bright field- cells, red-NCs and blue-nucleus. Scale bars 25 µm. Images were seen with 
100X oil immersion objective. (c) Flow cytometric analysis shows an increase in internalization of 
rhodamine labeled CSC-Fe-bLf NCs from 61% to 83% with time, up to 6 h. Bar diagram shows 
internalization profiles of various NCs, as measured by flow cytometry. Data represents mean ± SEM. 
Experiments were repeated 3 times independently with similar results. √√P<0.005; √P<0.05, CSC-Fe-
bLf NCs vs ACSC FebLf NCs treatment at 1 h.  
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7.2.4. ACSC NCs with loaded Fe-bLf inhibit cellular proliferation in vitro  
Evaluation of the cell proliferation and cytotoxicity with Fe-bLf loaded NCs was represented 
in the Figure 7.4. The ability of the ACSC NCs to deliver Fe-bLf and induce cell death was 
examined in the human breast cancer (MDA-MB-231) cell line in vitro by MTT assay 
(Section 8.9.1, page 192). Cellular viability of the MDA-MB-231 cell line was affected by 
different concentrations of the CSC- Fe-bLf as well as ACSC-Fe-bLf NCs, compared to the 
control NCs, without protein. CSC-Fe-bLf NCs have exhibited an IC50 value at 1mg/ml 
(2.8x105) in MDA-MB-231 cell line. Greater cytotoxic activity was observed for almost all 
doses of CSC-Fe-bLf NCs than that of ACSC-Fe-bLf NCs (Figure 7.4a). Various 
concentrations of NCs were tested for different time periods starting from 10 h till 20 h.  
Significant differences between the treatment with void and Fe-bLf loaded NCs were evident 
from the figures. A sum of 17.6 ± 2.1%  cell viability was observed with 3 mg/ml (1x106 
NCs) CSC-Fe-bLf NC treated MDA-MB-231cells compared to 63.3 ± 2.5% with same 
concentration of void NCs at the end of 10 h (Figure 7.4a). With a concentration of 1mg/ml 
(2.8 x105) CSC-Fe-bLf NCs, 64.8 ± 1.65% of  cell viability was observed at the end of 10 h, 
whereas it was 68.4 ± 3.2% at the end of 20 h. Thus, important observation from these 
experiments made was the effect on cell viability was concentration and time dependent. In 
order to observe cancer cell proliferation after the NCs treatment, in addition to cell viability 
assay like MTT assay, in vitro cell proliferation was measured using CyQUANT assay 
(Section 8.9.3, page 193). Same treatment parameters were analyzed as those were used for 
MTT assay. Figure 7.4b shows inhibition of cellular proliferation at the end of different time 
intervals. The cells treated with CSC-Fe-bLf NCs showed maximum growth inhibition 
compared to void NCs. With 106 CSC-Fe-bLf NCs, cellular proliferation was found to be 
42.8 ± 2.1% at 10 h, whereas at the end of 20 h, it was found to be dropped to15.3 ± 0.8%; 
which means there was a dose and time dependent inhibition of cellular growth by the NCs. 
With the same concentration, void NCs have shown 92.2 ± 1.8% and 72.6 ± 3.6% cell 
proliferation, respectively at the end of 10 h and 20 h respectively, which means the Fe-bLf 
loaded NCs are much efficient in anti-cancer activity compared to the void NCs. Because of 
the outer alginate covering ACSC NCs with Fe-bLf have shown moderate cell proliferation 
inhibition compared to CSC-Fe-bLf NCs.  
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Figure 7.4: (a) Dose and time dependent cell viability of control and Fe-bLf loaded NCs. The extent 
of cell viability was measured by MTT assay, in 10 and 20 h after the treatment, respectively. Increase 
in cytotoxicity was observed in CSC-Fe-bLf NCs, compared to controls. It is evident from the figure 
that CSC-Fe-bLf NCs show decreased cell viability at the doses starting from 1.5 mg to 2 mg of the 
NCs, compared to the same amounts of void or ACSC NCs. (b) Inhibition of cellular proliferation as 
analyzed by CyQUANT assay after treatment with void, ACSC-Fe-bLf and CSC-Fe-bLf NCs. Void 
NCs show increase in cellular proliferation in 10 h and 20 h whereas time and dose dependent growth 
inhibition was observed from the Fe-bLf loaded NCs and the maximum effect was observed at the end 
of 20 h. (Data represents mean ± SEM. Experiments were repeated 3 times independently with similar 
results  √√P<0.005; √P<0.05,CSC-Fe-bLf NCs vs Void NCs treatment). 
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7.2.5. In vivo prevention studies of Fe-bLf loaded ACSC NCs  
 In order to observe the anti-cancerous efficacy of Fe-bLf alone, the protein was given in the 
form of an oral nanoformulation. In order to make oral delivery system, ACSC NCs 
containing Fe-bLf were added to mice diet in a ratio of 1.2% w/w protein: diet, mixed well 
and made into pellets for oral delivery. Similar to the proof of concept study done in colon 
cancer models (Chapter 6), mice were divided into control and treatment groups, wherein 
treatment groups receive diet containing Fe-bLf loaded nanocarriers (Table 7.1). The 
treatment groups were again divided in to 2 groups where NCs diet was switched off after the 
second challenge in case of the treatment MDA 2nd control. Group named treatment MDA 
represents the treatment group that has received the NCs diet till the end of the experiment 
(Section 8.12, page 196).  Group of  mice (n=5) were fed either with AIN93G diet containing 
10%w/w NCs (approximately 3.38x109 NCs containing 12g Fe-bLf per kg of diet or 1.63 x 
109 NCs per kg body weight) or with a normal AIN93G diet.  
Breast cancer (MDA-MB-231) cells (1x106) were injected subcutaneously after the mice had 
been on the diets for 2 weeks.  Conspicuous difference with respect to tumour growth was 
observed in case of mice fed diet containing ACSC Fe-bLf NCs, compared to control group 
receiving a normal diet. There was substantial increase in anti-cancer efficacy of Fe-bLf 
when incorporated in ACSC NCs. In case of control mice, tumour volume was increased 
periodically with respect to time, whereas this occurrence seemed to be diminished with 
pretreatment. As shown in the Figure 7.5, tumours were regressed by injecting taxol injection 
to mice in control group, when they reached a diameter of ~45.6 mm3. Then the taxol treated 
control and the ACSC-Fe-bLf NCs- alone treatment groups were challenged for the second 
time with 1x 106 MDA-MB-231 cells. Notably, solid tumours appeared in a period of 5 days 
in case of control group, whereas treatment groups did not show any tumours. Within a time 
period of 2 weeks, tumours in control group have reached 100.3 mm3 thus the animals were 
euthanized as per the animal ethics guidelines. More interestingly, throughout the 
experimental period, there were no noticeable tumours were observed in NCs treated mice 
groups. In vitro anti-tumour efficacy also correlated with the in vivo data where MDA-MB-
231 cells have shown maximum cytotoxicity and decrease in cell proliferation compared to 
the assays done in colon cancer cells (Section 6.2.3 and section 7.2.4). This could be the 
reason why breast cancer xenografts have not developed tumour at all compared to colon 
cancer xenograft models, where small tumour was seen in one out of 5 mice in the treatment 
groups. 
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Figure 7.5: In vivo anti-tumour efficacy of ACSC-Fe-bLf NCs as represented with respect to tumour 
volumes of MDA-MB-231 tumour bearing mice. Within 1 week after the injection of 107 cancer cells 
tumours (~45.6 mm3) were developed in control diet fed mice and were terminated by injecting taxol 
(i.t) when challenged for the 2nd time, ~100.3 mm3 tumours were observed in 4 weeks. In neither of 
the cases (1st challenge or the 2nd challenge) significant tumours were developed in treatment groups 
of mice.  Data represents mean ± SEM (n=5) 
 
Table 7.1 Breast cancer induction and treatment regime in C57BalbC nu/nu mice 
Event Control  Treatment MDA  Treatment MDA 2nd 
control 
Challenge with 
MDA-MB-231 
√ 
[14th day after 
acclimatization 
in the control 
diet] 
√ 
[14th day after 
treatment in the 
NCs diet] 
√ 
[14th day after treatment 
in the NCs diet] 
Treatment Taxol 
[10th day after 
the 1st 
challenge] 
NCs (1.6x109) 
[NCs diet was fed 
to mice  up to 65th 
day] 
NCs(1.6x109) 
[NCs diet was fed to 
mice  up to 40th day] 
2ndChallenge 
with MDA-MB-
231 
√ 
[45th day] 
√ 
[45th day] 
√ 
[45th day] 
Treatment X √ 
[NCs diet up to 65th 
day] 
X 
[Switched off to the 
control diet after 40th 
day] 
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7.2.6. Evaluation of nanotoxicity for Fe-bLf loaded ACSC NCs 
Assessment of any form of toxicity to the animal after feeding with the NCs diet was 
measured by weight changes and body condition scores in control vs. treated mice.  Scoring 
the body condition of rodents is a non-invasive method for assessing health and establishing 
endpoints for adults. Scores were determined by frequent visual and hands-on examination of 
each animal, by gentle holding from the tail end and by passing the finger over the sacroiliac 
bones (Section 8.12, page 196).  As shown in the Figure 7.6, there was no effect in the body 
weight in controls group that have developed tumours and so is the case with treatment 
group. In fact, average body weight of treatment groups was more in comparison to controls 
and the mice remained healthy. Average body weight of all mice before the treatment was 
found to be 14.41 g. At the end of the treatment (9 weeks), the control group showed 
consistency in weight (16.1 g), whereas mice placed in the NCs diet have gained in the body 
weight up to 17.32 g. During the process of the treatment, behavioral changes such as 
appearance, food and water intake, natural behavior, provoked behavior and clinical signs of 
respiratory rates, dehydration were observed. Body condition score (BCS) calculations were 
done based on these results in order to judge euthanization in accord with animal ethics 
approval. BCS of 0-4 have indicated that the animals were healthy without any of the side 
effects posed by nanocarrier based therapy. 
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Figure 7.6: Body weight of mice with age after treatment with ACSC-Fe-bLf NCs is shown in the 
figure. Three separate groups of mice were pooled based on tumour they carried and treatment type 
(Control, MDA-MB-231 and MDA-MB-231 2nd control – see the text for details). Average body 
weight of the control group remains at 14.41 g at the end of the experiment whereas treatment groups 
have shown an increase in body weight up to 17.32 g.  Data represents mean ± SEM (n=5) 
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7.2.7. Histopathology and bio-distribution studies of the NCs 
In order to observe tissue pathology after the treatment, for further support of non toxicity 
using NCs, haematoxylin and eosin staining was carried out. Organs involved in NCs 
internalization including intestine, brain; key components in reticuloendothelial system (RES) 
including liver and kidney showed no abnormality (Please refer to section 8.14, page 197 for 
a detailed methodology). The anatomy of controlled versus treated sections retained their 
integrity and tissue pathology, showing a minimal damage to these organs with the treatment 
(Figure 7.7a). In addition to tissue pathology, biodistribution of ACSC NCs was done based 
on the Fe-bLf functionalized on the NCs. Bovine lactoferrin specific antibody was used to 
detect exogenous levels of Fe-bLf loaded on the ACSC NCs. In case of treatment groups 
(Figure 7.7b) characteristic immunoreactivity of bLf was seen. As represented, ileum 
(treatment group-) showed intense bLf immunoreactivity corresponding to the proposed 
transcytosis of the NCs. Liver and kidney showed mild immunoreactivity as a function of 
biodegradability of the NCs. Furthermore, in the case of brain tissues a mild 
immunoreactivity of bLf was observed (Table 7.3).                         
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Figure 7.7: (a) Tissue pathology observation after the treatment was represented in the figure. H&E 
staining was carried out in order to observe the tissue integrity in control and treatment groups.  6µm 
thin slices of Intestine (TS), Kidney (LS) and brain (LS) from control (i, iii, v) and treatment (ii.iv,vi) 
were stained with haematoxylin and eosin was used as a counter stain. Observed under 100X oil 
immersion objective. (b) Immunohistochemical localization of ACSC-Fe-bLfNCs using anti-
lactoferrin antibody. Brain (LS) Liver (LS) Intestine (TS) and sections from control (i, iii, v) and 
treatment (i, iii, v) groups were shown. TS- Transverse Section, LS – longitudinal section. 
Table 7.2 Tabulation of the immunochemical reactivity 
Tissue Intestine  Liver Brain 
Tissue 
distribution 
Control - - - 
Treatment +++ ++ + 
* (-) - no immunoreactivity ; (+++) - high immunoreactivity ; (++) – moderate immunoreactivity; (+) – mild immunoreactivity   
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7.2.8. Internalization of Fe-bLf loaded NCs in the tissues 
Since the nano encapsulated Fe-bLf protein was saturated 100% with iron, the amount of iron 
internalized in various tissues was measured as a representative means of bio-distribution 
(For a detailed methodology please refer to section 8.18, page 198). A significant increase in 
iron levels in case of reticuloendothelial organs liver (1.3 ± 0.1), spleen (1.7 ± 0.1) were 
observed corresponding to the result obtained in immunohistochemical observation for Fe-
bLf (Section 7.2.7). Similarly, increased intestinal (1.5 ± 0.03 fold) iron concentration was 
noticed that corresponds to the transcytosis and in case of brain tissue (1.4 ± 0.1 fold) 
compared to control, suggesting the localization of NCs in the brain (Figure 7.8a).  
Furthermore, based on the fact that anti-cancer Fe-bLf showed positive for Prussian blue 
staining, co-localization of NCs along with blood vessels was further investigated (Section 
8.15, page 197). A significant amount of Fe-bLf loaded NCs was still clearly observed 
around vascular region of the brain tissue slices (Figure 7.8c) using Prussian blue and CD31 
double staining. At high magnification (100X), NCs were observed to be located in 
intracellular regions, which was corresponding to the previous observations for nuclear 
transport of CSC-NCs in vitro, in colon cancer/breast cancer cells (Section 3.2.6). 
Consistently, poor immunohistochemical reactivity in case of control tissues was verified 
using the same staining method as a comparison. 
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Figure 7.8: (a) The amount of elevated iron observed in each organ was measured as a function of 
NCs internalization. Significant levels of increased iron in treatment groups (red bars) compared to 
control (blue) in case of spleen, liver, intestine and brain were observed. Data represents ± SEM. 
Experiments were repeated 3 times independently with similar results. Lower panel shows the study 
for internalization of ACSC-Fe-bLf NCs based on CD-31 and Prussian blue double staining using Fe 
saturated bLf loaded in the NCs (b) Control group shows negative for Prussian blue staining  (c) 
Positive staining in treatment group – inset shows internalization of Fe-bLf loaded ACSC NCs near 
CD-31 stained area. This indicates the internalization of the NCs via blood vasculature. 
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7.2.9. Functional mechanism of internalization of the NCs 
Lactoferrin could be internalized by LRP receptors as well as transferrin receptors that are 
expressed on the cell surface (Suzuki et al., 2005, Lopez et al., 2008). However, LRP 
receptors plays important role in the development and growth of cancer metastases (Montel et 
al., 2007). Thus, based on this principle, up/down regulation of LRP receptor mRNA was 
analyzed in various organs that were shown positive for Fe-bLf in IHC, control tissues from 
the untreated group were taken as calibrator (given in detailed in section 8.19, page 199). 
Quantitative RT-PCR analysis indicated that LRP1 receptor mRNA was over expressed in 
breast cancer cell lines relative to GAP3DH controls (Figure. 7.9). Although both LRP1 and 
LRP2 mRNA were over expressed in all samples under consideration, the level of LRP2 in 
brain and intestine was elevated much higher (Figure. 7.9). LRP2 mRNA was elevated 2.2 ± 
0.06 (P<0.005) folds in liver, and 1.8 ± 0.09 fold in brain whereas 0.8 ± 0.09 (P<0.005) fold 
in the intestine compared to corresponding control tissues. LRP1 mRNA was found to up 
regulated 2.2 ± 0.05 fold in MDA-MB-231 cells treated with NCs. Agarose gel images show 
the qualitative representation of q RT-PCR data analysis. Taking in to consideration that 
lactoferrin and transferrin share 60-80% sequence homology as discussed in section 6.1 of 
the dissertation, gene expression levels of transferrin receptors were analyzed along with LRP 
receptors (Figure 7.10). The results indicated an elevated expression of Tfr gene in MDA-
MB-231 cells after the treatment and in the case of liver and brain tissues, compared to their 
respective treatments. Isoforms-Tfr1and Tfr2 was expressed high in intestinal tissue, along 
with treated cells.   
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Figure 7.9: Quantitative real time PCR analysis for LRP receptor shows (a) elevated expression of 
the receptors in treated tissues. mRNA levels from the untreated control tissues were taken as 
calibrator here. LRP1 expression is high in treated cells compared to the untreated cells. LRP2 mRNA 
levels were elevated in liver, brain, intestine and in NCs treated mice tissue compared to tissues from 
the control group. Data represents mean ± SEM. Experiments were repeated 3 times independently 
with similar results.√√P<0.005; √P<0.05 liver, brain and intestine compared to muscle tissue (b) Gel 
images shows qualitative determination of amplified product in various tissues as represented in the 
figure. Lane 1,2- MDA-MB-231 cells, NCs treated MDA-MB-231 cells, lanes 3-7 NCs treated mice 
tissues muscle, intestine, liver, lung and brain; lanes 8-12 control tissues. 
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Figure 7.10: Quantitative real time PCR analysis for transferrin receptor gene in the tissues of 
treatment group shows (a) Elevated expression of the receptors in NCs treated tissues compared to the 
control tissues. Expression of Tfr and its isoform is high in MDA cells, liver, brain and intestine from 
the treatment group compared to the untreated cells or tissues from the control group respectively. 
Data represents mean ± SEM. Experiments were repeated 3 times independently with similar 
results.√√P<0.005; √P<0.05 compared to control cells (b) Gel images shows qualitative determination 
of amplified product. lane 1- MDA cells + NCs; lane 2 - intestine; lane 3 – liver; lane 4 – lung; lane 5 
– brain.  
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7.3 Discussion 
The proof of concept principle used for validation of nano encapsulated Fe-bLf in colon 
cancer was adopted in this study to test its efficacy against breast cancer. Naturally occurring/ 
biodegradable anti-cancerous bio macromolecules are gaining the attention towards an 
alternative therapy for cancer cure (Boon et al., 2007). Thus, the demand of herbal extracts 
and other naturally occurring supplements by cancer patients is incredibly high. Nevertheless, 
imperative scientific investigations are needed in potentiating the clinical proof of activity for 
these fragile medicines. Such a naturally occurring molecule bLf could be regarded as a more 
effective protein, when chemically saturated with iron in combating tumour (Kanwar et al., 
2008). Thus, ACSC-Fe-bLf NCs with 3.55 ng Fe-bLf per a single NC with homogeneous size 
distribution and equal dispersion in the physiological pH were used to test their anti-tumour 
efficacy against MDA-MB-231 breast cancer cells in vitro and in vivo. In the previous 
chapters in vitro control release of bLf in the physiological pH was determined using 
chromatographic techniques (Section 3.2.3). In this study, control release profiles of CSC-Fe-
bLf NCs, were determined at various pH as present in the GI environment and observed for 
the controlled release of the protein colorimetrically Over a time period of 96 h, NCs have 
shown control release profiles of the encapsulated protein in varying range of pH. Lowest 
release of the protein in the acidic pH could be attributed to the pH sensitivity of the alginate 
gel (Moroni et al., 2011). Alginate system maintains its structure without any visible changes 
in morphology, although Ca+2 ions don’t contribute any more to stabilization of the system 
leading to initial burst. Un-ionized form of alginate does allow the protein to diffuse only in a 
slow rate in case of lower pH (Zhang et al., 2008a). When the pH of the buffer is in the 
alkaline range, sodium alginate will be formed releasing the content inside the alginate layer.   
Flow cytometric analysis indicated an increase in uptake of the CSC-Fe-bLf NC by MDA-
MB-231cells compared to void NCs or ACSC-Fe-bLf NCs, as reported in the previous 
sections (Section 3.2.5). Confocal microscopic observation for the internalization of the NCs 
indicated an increment in the internalization of the protein encapsulated NCs. Apoptotic cell 
morphology that was observed in 6 h treatment has indicated enhanced anti-cancer activity of 
the NCs in the breast cancer cells compared to colon cancer cells. 
Main aim of the encapsulation of Fe-bLf in ceramic-polymeric NCs was to make the entire 
system as a bio-active and bio-available. Nevertheless, there were reports in relation to the 
toxicity of chitosan, which is used as one of the ingredients in this study (Ye et al., 2009, 
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Opanasopit et al., 2007). Especially the toxicity studies are targeted towards the chemically 
modified/ metal bound forms of chitosan but pure chitosan seems to be relatively nontoxic 
and bio compatible material. The dietary studies appear to have largely been performed to 
support the safe use of chitosan materials for food use. It was observed that a dosage of 2 
g/kg/day chitosan from gavage dosing and at up to 5% (approximately 3000 mg/kg/day) in 
the diet for durations of up to 3 months have shown no signs of toxicity (Naito et al., 2007). 
In addition, chitosan was employed in the nutritional supplement market as a weight loss aid 
and cholesterol lowering agent (Baldrick, 2010). Since, an amount of approximately 3.38x109 
NCs containing 12 g Fe-bLf per kg of diet or 1.63 x 109 NCs per kg body weight were used 
to administer the experimental mice, any possible nano toxicity on mice was studied. In case 
of mice treated with diet carrying nanocarriers, there was no abnormality with respect to body 
weight and behavioral changes. Indeed, mice treated with Fe-bLf loaded NCs were found to 
be healthier than control group mostly, because Fe-bLf is a natural defense protein with anti-
cancer properties. Because of cachexia tumour bearing mice are generally expected to lose 
body weight with the progression in tumour size over 0.3 cm. Not more than 3% weight loss 
even in the control diet fed animal was observed, which could possibly because of the 
nutritionally balanced, palatable AIN-93G diet.   In the experimental groups, because of the 
bio degradable nature of the Fe-bLf, chitosan and alginate, mice remained healthy and gained 
weight with age within the normal range.  
In addition, since the ultimate goal of the proposed study is to develop and alternative and 
safe oral delivery system enhancing absorption and bioavailability of the Fe-bLf, a 
pretreatment of NCs was given to 5 week old mice followed by tumour induction. Results 
indicated that there was no significant increase in tumour volume in case of treatment groups 
compared to the controls. Thus, the in vivo breast cancer study further confirms the colon 
cancer in vivo findings. These results mimic the in vitro assay that have been carried out in 
order to observe anti-cancerous effects of Fe-bLf loaded NCs by observing cancer cell 
viability in vitro using  MTT assay. The results along with cell proliferation by CyQUANT 
suggest Fe-bLf loaded NCs was shown to efficiently kill MDA-MB-231 cells. Also, 
phenomenal increase in anti-cancer efficacy of Fe-bLf when incorporated in ACSC-Fe-bLf 
NCs could be attributed to improved delivery and controlled release of the protein by NCs. 
Multi functional nature of Fe-bLf, which specifically kills malignancy with absolutely no 
damage to the normal tissues adds up to the enhanced bio compatibility for the NCs.   
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Haematoxylin and eosin staining of tissue sections including liver, spleen, kidney, brain and 
ileum have also shown the preserved tissue integrity. These vital organs once again showed 
normal pathological features which means the NCs does not impose toxicity to these organs 
and open the tight junctions in the intestine in a reversible manner for the transport in to 
systemic circulation. Biodistribution of the NCs based on bLf immunoreactivity was 
observed in case of potential organs for reticuloendothelial system which comprises of liver, 
kidney and spleen. Intestinal absorption of the NCs can be confirmed by immunoreactivity in 
the ileum. Neurotoxicity, which could be the side effect of many present day medications 
could be infinitesimal in case of these NCs, which was confirmed by the mild immune 
reactivity as well as Prussian blue staining in brain tissues. In addition, since the bLf plays a 
crucial role in iron homeostasis (Section 2.10), increased iron uptake in the treatment group 
was analyzed compared to control group of mice. Slight increment in iron levels in the tissues 
including intestine, liver, spleen and brain, supports the novel nutraceutical benefits of using 
Fe-bLf in a nanoformulation.  
Functional mechanism of internalization was validated based on real time analysis of RNA 
levels indicated the up regulation of LRP as well as Tfr receptor genes. Since, lactoferrin is 
shown to be a LRP as well as transferrin ligand (Kawakami et al., 1990, Takayama et al., 
2003), an increased expression of Lf receptors in the tissues from the NCs fed animals 
comparing to control tissues gives a clue for possible internalization using these receptors. 
More importantly, a higher LRP and Tfr levels were detected in the intestine compared to 
control tissue or untreated cells, which suggest when taken orally, intestinal uptake of these 
NCs occur for further targeting to tumour site via the systemic circulation. Thus, based on the 
surface receptor- ligand chemistry, it could be possible that bLf could guide the NCs for 
enhanced internalization. In total, enhancement of bio-availability of 100% iron saturated 
bovine lactoferrin potentiated its anti-tumour efficacy upon incorporating the protein in a 
nanocarrier in order to develop an oral therapeutic system. 
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Chapter 8: Materials and Methods 
8.1. Materials  
Caco-2 and MDA-MB-231 cell lines were obtained from ATCC, Manassas, VA, USA. 
Spectra/Pro dialysis tubing with a molecular weight cut off (MWCO) at 50 kDa was from 
Pacific Laboratory, Nunawading, Victoria, Australia. Glutathione agarose beads for affinity- 
purification of SurR9-C84A was purchased from Sigma-Aldrich, NSW, Australia.  Trypsin-
EDTA, Chitosan with a 20-200 cp viscosity, average molecular weight (MW) of 200 kDa and 
deacetylation degree of 80 %, Sodium tri poly phosphate (STPP), Sodium alginate, potassium 
bromide pellets, HRP conjugated IgG secondary antibody, actin antibody and GenElute™ 
Mammalian Total RNA Purification Kit  were purchased from Sigma-Aldrich, NSW, 
Australia. Formvar with carbon coating on 100 mesh for TEM analysis was from ProSciTech, 
Qld, Australia. PVDF membranes for Western blotting were from Amersham, NSW, 
Australia. Anti-tubulin anti-body and anti-survivin monoclonal antibodies were procured 
from Santa cruz biotechnology inc, Delaware Ave, Santa Cruz, CA, USA. Lissamine 
rhodamine B sulfonyl chloride, CyQUANT® Cell Proliferation Assay kit and Superscript III 
for reverse transcription were purchased from Invitrogen life technologies, Mulgrave, Vic, 
Australia. 8 well chamber slides for the determination of NCs internalization were from BD 
Falcon, North Ryde, NSW, Australia. Vector mounting medium with DAPI, DAB substrate 
for immunoperoxidase staining were obtained from Vector Labs, Burlingame, CA, USA. 
Paclitaxel (Taxol) that was used as a positive control in cell cytotoxicity studies was 
purchased from Biovision, Australia. Annexin V-FLUOS staining kit and in-situ cell death 
detection kit (TUNEL) were purchased from Roche Applied Science, Castle Hill, NSW, 
Australia. TACS-MTT assay kit was purchased from Trevigen (Bio Scientific Pty. Ltd, NSW, 
Australia). Casein free animal diet (AIN93G rodent diet) was purchased from Specialty feeds, 
Glen Forrest, WA. Haematoxylin, eosin and other immunohistochemical reagents were from 
Lomb scientific, Scoresby Vic, Australia. SYBR green super mix for qRT PCR was from 
Bio-Rad, NSW, Australia.  
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8.2 Cell line and culture conditions  
Human breast cancer (MDA-MB-231) cells were grown as a monolayer in Leibovitz’s L-15 
media and Human colon cancer (Caco-2) cells were grown as a monolayer in the Dulbecco's 
Modified Eagle Medium (DMEM) media. Cells were supplemented with 10 % of fetal bovine 
serum (FBS), penicillin (20 units/ml) and streptomycin (20 mg/ml) at 37°C in a saturated 
humid atmosphere. MDA-MB-231 cells were cultured without CO2 and Caco-2 cells were 
grown in 5% CO2. After reaching 80-90% confluency in the culture flasks, cells were 
harvested by a brief (5 min) trypsinization. For cytotoxicity assessment, cells were seeded 
onto 96 well tissue culture plates at concentrations of 1×105 cells/ml. For RNA isolation, 
cells were seeded onto 6 or 12 well tissue culture plates at concentrations of 1×106 cells/ml. 
8.3 Protein preparation methods  
8.3.1 Iron free (apo) bovine lactoferrin (apo-bLf) 
Native bLf solution (10 %( w/v)) was prepared in sterile milliQ and pH was carefully brought 
to 2.06 by addition of 6 M HCl. During this process the solution changed from a murky red 
color to ivory white, indicating the formation of non-iron form of bLf. In order to remove 
unligated metal ions and protein fragments the solution was extensively dialyzed against 0.1 
M citric acid using Spectra/Pro dialysis tubing with MWCO at 50kDa. This was kept 
overnight on a magnetic stirrer at 40C and the dialysis buffer was changed twice more over a 
48 h period. The obtained sample was further used to prepare 100 % iron saturated bovine 
lactoferrin 
8.3.2 Iron saturated bovine lactoferrin (Fe-bLf) 
Apo form of bLf was saturated with ferric [Fe (III)] nonahydrate to form Lf- Fe3+ coordinate 
complexes for the development of deep red colored Fe-bLf. The saturation of bLf with iron 
was achieved by the method described previously (Law and Reiter, 1977, Kanwar et al., 
2008). Ferric nitrilotriacetate (Fe-NTA) was used for iron saturation of bovine lactoferrin and 
was prepared immediately prior to use. Ferric nonahydrate at a molar concentration of 300 
mM was mixed with 600 mM of nitrilotriacetate (NTA) disodium salt in 1:2 ratios, in order 
to obtain a final molar ratio of 1:4. The pH was adjusted to 7.4 with careful addition of 
sodium carbonate. Solid sodium bicarbonate was added to make a final concentration of 0.1 
M in the apo-bLf solution that was prepared as described previously. The pH of the sample 
was then adjusted to 8.0 with the careful addition of 6 M NaOH. Fe-NTA solution was added 
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drop-wise to the apo-bLf sample and mixed on a magnetic stirrer for 1 h at room temperature. 
Following the drop wise addition of Fe-NTA, the pH of the solution was readjusted to 8.0 
with careful addition of 6 M NaOH. To ensure complete metal binding, the solution was 
further stirred for 1 h at room temperature. The color of the sample was noted as maroon red 
indicating the iron bound form of the protein. The sample was then purified by extensive 
dialysis against sterile milli Q using Spectra/Pro dialysis tubing with MWCO at 50 kDa. 
Dialysis was performed over a 48 h period at 40C on a magnetic stirrer. The dialysis buffer 
was changed twice more over the 48 h period. After the dialysis, the sample was stored in -
200C, until further use.  
                                                                     
Figure 8.1: Purified Fe-bLf band at 75kDa in 10% SDS-PAGE 
8.4 Purification of SurR9-C84A from E.coli BL21  
A stretch of 508 nucleotide sequence representing an open reading frame of survivin mutant 
(Sur R9-C84A) containing 9 arginine residues at the N-terminal end of the polypeptide 
sequence (R9 cell permeable peptide carrier) was constructed.  
Sur R9-C84A plasmid was constructed by Dr. Chun Hei Antonio Cheung and Associate 
professor Jagat Kanwar from Department of Molecular Medicine and Pathology, Faculty of 
Medicine and Health science, The University of Auckland. The plasmid was prepared by sub-
cloning the cDNA of a pcDNA3 expression plasmid encoding survivin mutant, which 
contains the entire coding region of mouse survivin (nucleotides 75-583; Genbank accession 
no.NM_009689), into the pGEM-T (Promega Corp.,Madison,WI). Further, it has been 
liberated by digestion with BamHI and cloned into the expression vector pGEX-2T 
(pharmacia biotech, poscataway, NJ) to produce the vector pGEX-2T/ Sur R9-C84A (Figure. 
8.2). 
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Figure 8.2: Map of pGEX-2T vector 
 
8.4.1 Scaling up the culture and purification of SurR9-C84A using glutathione affinity 
chromatography 
Bacteria that had been transformed with the pGEX-2T/ SurR9-C84A plasmid were cultured 
in 4 L of 2x YTA medium at 370C until the optical density at A600 nm reached 0.7. Isopropyl 
thio βD-galactoside (IPTG) at 0.7 nM concentration was added to the culture to induce the 
expression of SurR9-C84A, and the bacteria were cultured for 3 h at 300C. The bacterial 
suspension was centrifuged at 6000Xg for 20 min at 40C and washed several times with PBS. 
The pellet was re-suspended with 50 ml of sodium tris EDTA (STE) buffer containing 1% 
triton X-100, lysozyme (0.1mg/ml), 10 nM dithiothreitol (DTT) and 0.7 % sarkosyl. The 
mixture was sonicated for 2 min and the lysate was centrifuged at 10,000xg for 45 min at 40C 
and the supernatant was harvested. 
 SurR9-C84A was purified from the bacterial lysate on a glutathione-sepharose column. A 2 
ml aliquot of glutathione-sepharose was washed twice with 10 ml of STE containing 1 % 
triton X-100, and mixed with the bacterial lysate on a rotary shaker for 1 h at 40C. The beads 
were transferred to a column and the flow through was collected for further analysis. The 
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beads were then washed with 30 ml of STE and subsequently with 30 ml of 1x PBS. Before 
GST –tagged SurR9-C84A was eluted with 20 ml of elution buffer (100 mM tris, pH 8, 
containing 200 mM NaCl). The purified protein was further concentrated with 30 kDa cut off 
column (GE healthcare). Purified SurR9-C84A was dialyzed twice against 1x PBS at 40C, 
and stored at -800C.  
                                                                
Figure 8.3: Chromatographic separation of purified Sur R9-C84A protein. E1 represents 1st 
elute and the proteins were resolved in 10% SDS PAGE. Prominent band at 16 kDa 
represents monomeric Sur R9-C84A formed because of the denaturation conditions in the 
SDS PAGE, whereas a faint band at 35 kDa denotes GST-tagged Sur R9-C84A dimer. 
8.5 Preparation of alginate enclosed chitosan-calcium phosphate-Lf nanocarriers 
 ACSC-NCs were prepared as previously described with slight modifications (Mahidhara et 
al., 2011 ).  Briefly, calcium phosphate solution was prepared and incubated with 0.1 % w/w 
natural bLf or Sur R9-C84A or Fe-bLf  under pH 8.0 with constant stirring at 40C, for the 
proper adsorption of the protein on the NCs. Obtained solution was centrifuged and washed 
several times to remove traces of unbound protein. 0.01 % w/w chitosan in acetate buffer was 
added to the calcium phosphate under constant stirring and 0.01% of cross linking agent, 
sodium tri polyphosphate (STPP) was added drop wise. Constant stirring has been done to 
ensure this nanoformulation to obtain sizes of 200-250 nm. These nanocores were then coated 
with alginate gel by using 1% w/v alginate solution and calcium chloride, with 0.6% mass 
ratio of Ca/alginate. The finally obtained nanocarriers were washed and lyophilized for 
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further characterization. All these experiments were done at 40C, as to protect the polymeric 
and protein components in the formulation.  
8.6 Physicochemical characterization of ACSC nanocarriers  
8.6.1 Size and morphological determination 
The average size of the NC, in various steps of their preparation viz, calcium phosphate, CaP 
loaded with the protein under investigation (natural bLf or SurR9-C84A, Fe-bLf + SurR9-
C84A or Fe-bLf) , Chitosan formulation and alginate enclosed particles were determined by 
dynamic light scattering (DLS), using zetasizer, after 500 fold dilution with autoclaved 
milliQ water. Surface morphology of these particles was determined by Secondary electron 
microscopy (supra), at an accelerating voltage of 5-10 kV. To prepare samples for SEM; 
CSC, CSC-Lf, CSC-Sur, CSC- FS, CSC-Fe-bLf  and their respective alginate encapsulated 
ACSC NCs were fixed on the stub by a double-sided sticky tape and then coated with gold 
layer by SC7620 sputter coater (Quorum technologies, UK) for 60s. Transmission electron 
microscopy (TEM - JEOL JEM-2100) was used as an additional means to predict surface 
morphology and sphericity of these particles. An accelerating voltage of 100 kV was used to 
analyze the samples that were placed in penta holder (EM-11170 – X Tilt: ±15°), in order to 
visualize in the accelerating electric field. To prepare the samples for TEM; ceramic inner 
core loaded with Fe-bLf (CaP -FebLf), chitosan coated calcium phosphate- Fe-bLf (CSC-Fe-
bLf) and Alginate encapsulated CSC-Lf (ACSC FebLf) NCs in lyophilized form were mixed 
in a polar solvent and fixed on carbon mesh (Formvar with carbon coating on 100 mesh). The 
samples were stained with ruthenium tetroxide and observed in 50,000x magnification.  
8.6.2 X-ray spectrometry  
XRD analysis of the nanodelivery systems were performed to determine the crystallographic 
structure, lattice parameters and phase transitions based on the characteristic peaks obtained 
for the components in nanoformulations. Panalytical XRD instrument is utilized with Bragg-
Brentano parafocusing geometry with copper target X-ray tube with Cu Ka radiations, and 2θ 
range from 100 to 800. 
8.6.3 Fourier Transform Infrared Spectroscopy (FTIR)  
FTIR analysis of the nanosystems were performed utilizing Bio rad FTIR spectrophotometer 
with protocol involving nanosystem mixed with potassium bromide (KBr) powder to obtain 
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nanosystem – KBr pellet. This pellet was then analyzed for the characteristic peaks in the 
range of 1100 – 4000 cm-1 of compounds involved in nanoformulation. Another variant form 
of FTIR analysis involved Bruker Vertex-70 FTIR spectrometer using the ATR mode to 
obtain characteristic peaks of the components in range of 400-4000 cm-1.    
8.6.4. Differential scanning calorimetry (DSC) 
Calorimetric measurements were carried out using DSC-204 (Netzsch) with a standard 
crucible covered with a lid, but not sealed, in an atmosphere of dry nitrogen. Each sample (3 - 
5mg) was heated in an aluminum pan from 25 to 7000C at a flow rate of 10°C/min under dry 
nitrogen. Comparison of the DSC curves provided certain useful information about the 
physical state of ceramic in the carriers and possible interaction between the protein and 
polymer.  
 
8.7 Chromatographic technique used for analysis of the NC characterization and 
cell/tissue lysates  
In order to verify the purity and molecular size of the prepared bLf, SurR9-C84A, protein 
enclosed NCs sample and further cell and tissue lysate samples, proteins were separated by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing and 
denaturing conditions. The mini PROTEAN 3 (BioRad, Gladesville, NSW, Australia) 
apparatus was assembled as per manufacturer’s directions. 
8.7.1 SDS-PAGE  
The Lammeli method (1970) as outlined in Table 8.1 was used to prepare a 1.5 mm thick 10 
% (v/v) polyacrylamide separating gel and a 4 % (v/v) stacking gel. Prior to loading, the 
protein samples were diluted with milli-Q to ensure the final loading range was 
approximately 60 µg per well. 25 µL of sample was mixed with 10 µl of SDS loading buffer 
that contained β-mercaptoethanol which provided the reducing conditions. The samples were 
heated at 950C for 5 min and loaded into the corresponding wells. Alongside samples, 5 µL 
of Intron Biotechnology Prostain (Scientifix, Cheltenham, Victoria, Australia) protein 
molecular weight standard was loaded into the gel to help determine separation efficiency 
and for protein molecular weight determination. Gel was run at 200 volts and 13 watts for 
approximately 40 min. After the completion of electrophoresis, the gel was carefully removed 
from the glass cassette, stacking gel removed and the rest of the gel was placed in a container 
for Coomassie blue staining. 
190 
 
Table:8.1    Reagents used for 10 % separating and 4 % stacking gels for SDS PAGE 
All reagents (except Milli-Q) were purchased from Sigma-Aldrich (Molecular Biology 
Grade) (Sydney, Australia). 
 
8.7.2 Coomassie brilliant blue staining and distaining 
Gels that were run for protein staining were immersed in Coomassie blue stain solution (0.1 
% Coomassie blue R-250) and were left over night with gentle rocking. The stain solution 
was then removed and replaced with 20 % destain solution and left on the shaker for 
approximately 4 h. Gel images were viewed using the BioRad ChemiDoc XRS camera and 
were captured and formatted using Quantity One 1-D Analysis Software (BioRad, 
Gladesville, NSW, Australia). 
 
 
Reagent Separating gel Stacker  
% of the gel 6% 8% 10% 12.5% 15% 4% 
Milli-Q (ml) 4.74 4.32 3.92  3.92 2.92 1.92  
1.5M Tris HCl pH 8.8 
(ml) 
2 2 2 2 2 - 
0.5M Tris HCl pH 6.8 
(ml) 
- - - - - 0.75  
40% Acrylamide Bis 
(ml) 
1.2 1.6 2 2.5 3 0.3  
20% SDS (µl) 40 40 40 40 40 15 
10% APS (µl) 40 40 40 40 40 15 
TEMED (µl) 10 10 10 10 10 10 
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8.7.3 Western blotting 
For Western blotting, prepared protein/ NCs samples were first separated via electrophoresis 
under reducing and denaturing conditions. As per the biological molecule under 
investigation, poly acryl amide gel percentage was chosen from 10-15 %, as described above. 
Bio-Rad precision plus dual colour protein standards or Western blotting standards were used 
to ensure separation efficiency. After electrophoresis, the gel was removed from the glass 
cassette along with the stacking gel intact and immersed in protein transfer buffer for 20 min. 
A PVDF (Polyvinylidene Fluoride) membrane was charged using absolute methanol for a 
period of 30 sec and then transferred into milli-Q water for 10 min. The membrane was 
further equilibrated in the protein transfer buffer for 30 min, prior to transfer. The membrane 
sandwich was then assembled as per manufacturer’s procedure (bio-rad) and the samples 
were transferred for specified time period as per the protein molecular weight (survivin -45 
min, bLf- 90 min, actin -60 min) at 0.35 mA and 100 volts. Following the transfer, membrane 
was removed and rinsed 3 times with 1x Tris Buffer Saline (TBS, pH 7.6) for 5 min each. 
The membrane was then blocked in 5 % (w/v) blocking agent (BSA- for survivin/actin and 
porcine gelatine for bLf) prepared in 1x TBS and incubated for 2 h at room temperature with 
gentle rocking. Subsequently after blocking, the membrane was washed in TBS and 
incubated with primary antibody at an appropriate concentration as per the manufacturer. 
After the incubation, the membrane was washed with TBS containing 0.1 % Tween-20 (TBS-
T) for 10 min each and then incubated for 1 h at 370C with gentle rocking with HRP 
conjugate secondary antibody 1x TBS. After careful washings with TBS, membrane was 
carefully drip dried followed by the addition of ECL developing kit (Amersham Biosciences, 
Sydney, Australia) as per manufacturer’s instructions and incubated for 1 min in order to 
excite the conjugated HRP allowing visualisation of bands. Membrane was viewed with the 
Bio Rad ChemiDoc XRS using the chemiluminescence filter and formatted using Quantity 
One 1-D Analysis Software. 
8.8 Control release and enzymatic sensitivity studies  
In order to obtain the control release profile of the oral drug delivery system, in vitro release 
profile of the nanocarriers entrapped protein was carried out in PBS with a pH 7.2. ACSC Fe-
bLf NCs or ACSC-Sur NCs (1 % w/v) was suspended into phosphate buffer saline under 
constant stirring maintained at a temperature of 37°C. At various time intervals starting from 
1 h to 96 h, the sample was centrifuged, supernatant was collected and the pellets were 
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dispersed in fresh solution. Supernatants were analyzed for protein concentration. To estimate 
the protein concentration, Bradford assay was performed, with suitable standards (Bovine 
serum albumin, Fe-bLf or Sur R9-C84A) as per the protein under investigation.   
ACSC-Fe-bLf NCs, CSC-Fe-bLf NCs, ACSC- Sur NCs and CSC Sur NCs were digested 
with digestive enzyme cocktail mixture using a modified protocol (Kanwar and Kanwar, 
2009). Briefly, the 1% w/v colloidal ACSC, CSC- NC solutions were mixed with 
commercially available enzyme tablet cocktail mixture. The reaction mixture was set in 1:50 
(enzyme: NC solution) ratio and incubated at 370C in a shaker with constant stirring; the 
digests were collected after 1 h to 6 h of incubation. The reaction was stopped by inactivating 
the enzymes at 420C and aliquots were stored at -200C, till further analysis in SDS-PAGE.  
 
8.9. Cell viability assays  
8.9.1. MTT assay  
TACS MTT assay kit was used for cell viability analysis as per manufacturer’s instructions. 
Briefly, human colon cancer cells (Caco-2) and breast cancer cells (MDA-MB-231) were 
grown to confluence in 96 well tissue culture plates in either DMEM or L-15 respectively, 
supplemented with 10% FBS and washed with PBS prior to use. Different formulations of 
protein loaded nanocarriers (void, ACSC-Fe-bLf and CSC-Fe-bLf, ACSC-Sur and ACSC-Lf) 
were used to treat the cells in order to observe the cell viability. Various concentrations (0.05-
3 mg/mL NCs or 5x103 to 106 NCs) were used in order to know the minimum inhibitory 
dosage that is lethal to colon cancer cells in vitro. After 0 min to 10 h and 20 h of incubation, 
the MTT solution (at concentration of 10 % of culture/treatment used) was added to each well 
of the tissue culture plate containing a control or treatment assay and incubated for 3-4 h at 
37ºC, under cell culture conditions. After incubation MTT solvent was added, at an equal 
volume to what was cultured, and allowed to incubate, with occasional gentle pipetting to 
help dissolve crystals. Once crystals were dissolved the plate was measured 
spectrophotometrically (ASYS expert plus UV plate reader) at 550 nm, with reference 
wavelength of 620 nm. 
8.9.2. TUNEL assay 
TUNEL (terminal deoxynucleotidyl transferase mediated dUTP-biotin nick end labeling) 
staining performed using “insitu cell death detection assay” kit (Roche). This assay involves 
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labeling of free 3’ OH ends in genomic DNA with fluorescein-dUTP and measures apoptotic 
cell death by detecting the DNA strand breaks in individual cells. To perform the assay, 
cancer cells were treated with 106 NCs and the cells were fixed with fixation solution (4 % 
paraformaldehyde in PBS, pH 7.4) for 20 min at 15-250C. After fixation, cells were washed 
with PBS and incubated with blocking solution (3 % H2O2 in methanol) for 10 min at 15-
250C. Then the slides were rinsed with PBS and permeabilized with 0.1 % Triton-X-100 for 2 
min. for labeling the slides labeling solution was mixed with enzyme solution to obtain the 
TUNEL reaction mixture. Cells/tissue sections that were pretreated with NCs were treated 
with 100 µl TUNEL reaction mixture and incubated for 60 min at 370C in a humidified 
atmosphere. Then the slides were rinsed and mounted with the mounting medium (Vector 
Labs USA) and analyzed using confocal microscopy. 
For flow cytometric analysis, cultures were seeded at 105 cells per well in multi well plates, 
and were grown for 12 days for expression of oligosaccharide and/or lactoferrin receptors 
After treatment with 106 protein loaded/ void NCs, cells were harvested by brief 
trypsinization and fixed using 4 % PFA and resuspended in TUNEL reaction solution 
containing label solution and enzyme solution, following permeabilization. Cells were later 
washed and observed for fluorescence using flow cytometry, using FITC detector. 
8.9.3. CyQUANT assay 
CyQUANT cell proliferation assay kit was used to assess cellular proliferation of breast 
cancer cells after the treatment with NCs. Briefly, MDA-MB-231 cells were grown to 
confluence in 96 well tissue culture plates in L-15 media without FBS and washed with PBS 
prior to use. Different formulations of nanocarriers (void, ACSC-Fe-bLf and CSC-Fe-bLf) 
were used to treat the cells in order to observe the cell viability. Various concentrations (0.05-
3 mg/mL NCs or 5x103 or 106 NCs) of the NCs were used in order to know the minimum 
dosage that inhibits the proliferation of MDA-MB-231 cells in vitro. After 10 h and 20 h 
incubations, all wells including controls were carefully washed with PBS and carefully kept 
at -700 C, to lyse the cells. CyQUANT GR dye/ cell-lysis buffer were added to each well and 
incubated for 2-5 min at room temperature protected from light and the sample fluorescence 
was measured at 520 nm.   
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8.9.4. Annexin V-FLUOS staining assay for apoptosis 
The detection and quantification of apoptosis and differentiation from necrosis was 
performed with the use of the Annexin V-FLUOS staining kit (Roche Applied Science, 
Castle Hill, NSW, Australia). Assay was based on the theory of plasma membrane alterations 
found in early stages of apoptotic cells, namely the translocation of phosphatidylserine (PS) 
exposed at the external surface of the cell. Annexin V is a Ca2+ dependent phospholipid-
binding protein with high affinity for phosphatidylserine. However, necrotic cells also expose 
PS due to the loss of membrane integrity therefore apoptotic cells are differentiated from 
necrotic cells by the use of propidium iodide that stains DNA of leaky necrotic cells only. 
Assay was carried out as per kit instructions. Caco-2 cells were seeded at a density of 105 
onto 6 well plates and treated with NCs. Following appropriate incubation, cells were 
harvested and 25 μL of Annexin-V-FLUOS labeling solution prepared immediately prior to 
use was added into each chamber and incubated for 15 min at room temperature. The cells 
were further analyzed in flow cytometer, using FITC and PE filters. 
8.10 Endocytosis studies of the nanocarriers 
8.10.1 Protein endocytosis studies of the nanocarriers  
Colon cancer Caco-2 cells were treated with NCs formulation (2.8x105 NC) prepared in 
sterile phosphate buffered saline (PBS pH 7.4). The cells were incubated for 1 h to 6 h, 
washed and lysed by using radio immuno precipitation assay (RIPA) buffer. The obtained 
lysates were preserved for further studies. For immunoblotting, 15 µg of Fe-bLf or natural 
bLf (positive control), lysates from the Caco-2 cells was separated by SDS PAGE, by using 
10% gel. The separated proteins then were transferred to a PVDF membrane after proper 
charging, for 90 min at 0.35 mA and 100 V. Following transfer, the membrane was removed, 
rinsed with TBS and incubated with bLf antibody, and later with anti goat HRP conjugated 
IgG. The membrane was developed by using ECL (GE healthcare) chemiluminescence 
detection kit. 
8.10.2 Flow cytometry and immunofluorescence staining 
Cancer cells (Caco-2 or MDA-MB-231) were grown in 6 well plates for 12 days for the 
expression of the surface oligosaccharide receptors and were treated with 2.8x105 rhodamine 
loaded NCs for different time intervals from 1 h to 12 h. Un treated and rhodamine treated 
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cells were used as controls for comparisons. After every each incubation, cells were 
trypsinized, washed with PBS several times and permeabilized with 90% ethanol. The 
fluorescence was acquired by using BD FACS canto II flow cytometer with 488 nm 
excitation using argon laser and emission under 585 nm using PE filter. For 
immunofluorescence measurements by using confocal microscopy, Caco-2 or MDA-MB-231 
cells were grown in sterile 8 well chamber slides (BD) and treated with rhodamine labeled 
NCs. The cytoskeleton was stained with tubulin antibodies or phalloidin to stain actin 
filaments. Briefly, following treatment with rhodamine labeled NCs, cells were washed 2x 
with PBS and fixed for 15 min with freshly prepared paraformaldehyde and permeabilized 
for 10 min with 0.2 % triton X-100. After 3 more washes with PBS for 3 min each, the slides 
were blocked with 2% rabbit serum for 30 min at RT. Cells were washed 3 times with PBS 
and incubated with actin binding phalloidin-FITC conjugate for 1 h at RT. Slides were 
washed and mounted with Vector mounting media containing DAPI dye (VectorLabs, USA) 
for nuclei staining. The slides were observed under confocal microscopy (Lieca SP5). For 
inter cellular localization of bLf loaded NCs using immunocytochemistry, HRP conjugated 
goat IgG antibody was added to the fixed cells that were pre stained with primary Lf 
antibody. The immuno complexes were detected by using DAB substrate. Haematoxylin was 
used as counter stain. Slides were fixed with permanent mounting media and observed under 
100X oil immersion objective using bright field microscope (Zeiss axioscope 2plus). 
8.10.3 Assessment of in vitro transport of NCs across Caco-2 cell monolayer  
Internalization of NCs was analyzed by trans epithelial electric resistance (TEER) assay. 
Briefly, Caco-2 cells were grown in 6 well transwell inserts (millipore) for 24 days, with 
continuous supply of fresh DMEM for every third day. After formation of monolayer, 
transwell plates were washed with HBSS for removal of unattached and/or dead cells, 
resistance of the monolayer was measured by using millicell ERS instrument (Millipore). 
Monolayers in which TEER values were higher than 500 have been selected for further 
processing. These monolayers were incubated in fresh medium without phenol red, before 
treatment with 2.8x105 fluorescently labeled NCs. TEER values of the monolayers were 
measured for different time intervals ranging from 0 h, 2 h, 6 h, 24 h, 48 h and 72 h. 
Periodically 100 µl of medium from the apical and basolateral sides was withdrawn and fresh 
medium was supplied at various time points (0 h, 2 h, 6 h, 24 h, 48 h and 72 h). Relative 
fluorescent units (RFU) for all the samples after the incubation time were measured using a 
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fluorescence plate reader (MTP 601F, Techomp), at excitation wavelength of 490 nm and 
530 nm of emission wavelength.   
 8.10.4 Mitochondrial potential and endocytosis studies  
Membrane potential changes of mitochondria, as a function of apoptotic progression were 
measured by flow cytometry using JC-1 (cationic dye, which exhibits potential- dependent 
accumulation in mitochondria). Briefly, 106 cells were seeded in 6 well plates and allowed to 
grow to attach and differentiate. Then the cells were treated with 1 ml media each containing 
different nanoformulations including CSC, ACSC, CSC- Fe-bLf and CSC – FS (2x104 NCs) 
for a period of 10 h and 20 h CO2 incubator at 370C. After the treatment, cells were washed 
twice with PBS and collected by trypsinization. The collected cells were then treated with 
JC1 staining solution and incubated at 370C for 20 min. Cells were washed twice with PBS 
and acquired using BD FACS canto II flow cytometer using FITC vs PI dot plot. 
For measurement of endocytosis, the treated cells were washed with PBS and detected for 
expression of early endosomal antigen (EEA1) or lysosomal antigen using LAMP antibody as 
well as goat anti-lactoferrin antibody. Subsequently, FITC labeled anti isotype for EEA / 
LAMP along with anti goat IgG were used to track internalization mechanism of NCs. The 
result was quantified by dot plot of FITC vs PI in BD FACS canto II flow cytometer.  
8.11 Preparation of diet containing ACSC Fe-bLf NCs for oral therapy in vivo 
ACSC NCs were prepared with iron saturated bLf as an anti-cancer cargo to be delivered to 
the cancer site. In order to prepare the mice diet, AIN93G diet was used, which has fortified 
with fixed formulations, including carbohydrate, protein, fat, crude fibre, all vitamins and 
minerals to meet the requirements of breeding laboratory mice. In brief, the ingredients of 
this fixed formula diet are wheat, barley, lupins, soya meal, fish meal, mixed vegetable oils, 
canola oil, salt, calcium carbonate, dicalcium phosphate, magnesium oxide, and a vitamin and 
trace mineral premix. However, the diet free from milk protein casein was used in this study 
to nullify additional anti-cancer properties of casein, if any. The nanocarriers (either ACSC-
FebLf NCs for treatment or void NCs or FebLf protein as controls) were lyophilized and 
mixed with AIN93G diet so as to make 1.2 % w/w of Fe-bLf in the control diet. The diet was 
mixed with appropriate amount of autoclaved milliQ water and made into pellets of suitable 
sizes, to be able to give as a treatment diet.  
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8.12 Induction of tumour and in vivo studies 
For in vivo studies, athymic nude mice at 8 weeks of age were subcutaneously injected with 
1x106 Caco-2 (into the left flank of mice) cells. The mice were divided into control and 
treatment groups, containing 5 animals in each group. Body weight, behavioral changes and 
tumour sizes were observed at regular intervals of 5 days each. Tumour growth was 
determined by measuring two perpendicular diameters, as described previously (Kanwar et 
al., 2003, Kanwar et al., 2001b). Tumour volume was calculated using the formula ½ L(mm) 
X W2, where L is the longest dimension of the tumour and W is the shortest dimension of the 
tumour as measured by a vernier calipers. Animals were euthanized when tumours reached 
1.0 cm in diameter, in accord with Animal Ethics Approval. In case of control group, once 
the tumour reached 200 mm3 volumes, taxol treatment was given in order to test for a second 
challenge. Second challenge was done on both control as well as treatment groups with 1x 
107 Caco-2 cells. After a time period of 9 weeks, different groups of mice were sacrificed and 
tissues including intestine, liver, lungs, spleen, brain, heart, lungs and tumours were 
harvested. Tissues were snap frozen and stored in -800C until further use. Blood was 
collected from the heart and serum was separated. Heparinized blood was used for RBC and 
WBC count. 
8.13 Tissue processing and H&E staining 
Tissues were thawed washed with PBS from the interior lumen (in the case of gut tissue), 
fixed using 4%PFA and frozen in OCT compound stored at -200C and sectioned in to 5 
micron thin cryotome sections. The cryotomic sections were fixed on the slide by using ice 
cold acetone solution. The sections were rehydrated in distilled water, stained with 
haematoxylin and eosin using routine sectioning and staining techniques.  
8.14 Tissue pathology and immunohistochemistry 
For immunohistochemical staining, the sections were fixed, rinsed in distilled water to 
remove OCT compound. The sections were rehydrated with TBS–T and blocked with 3% 
hydrogen peroxide in 0.3 % rabbit serum to overcome endogenous peroxidase activity. Goat 
anti-bovine Lf antibody (Bethyl labs, USA) (1:1000) was used for the detection of exogenous 
Fe-bLf with anti-goat HRP conjugated IgG secondary antibody. The sections were then 
washed in TBS-T and developed with DAB substrate (Sigma- Aldrich) and incubated for 10 
min in dark. After counterstaining with haematoxylin slides were fixed with permanent 
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mounting media and observed under 100X oil immersion objective using bright field 
microscope (Zeiss axioscope 2plus). 
8.15 CD31 and Prussian blue double staining  
 To determine angiogenic vasculature in the tissues of interest, 10 µm frozen sections were 
immunostained with goat anti CD-31 antibody. CD-31 positive blood vessels were detected 
using anti goat IgG secondary antibody. Further, Prussian blue staining was used to visualize 
the iron reactivity and the tissues were incubated for 20 min with Prussian blue stain and the 
slides were counterstained with neutral red stain for 1 min. After serial dehydration in 
gradients of ethanol, the slides were fixed with permanent mounting media and observed 
under the microscope for Prussian blue and CD31 double staining. 
8.16 CD31, CD105 double staining  
For CD31 and CD105 double staining, 10 µm frozen sections were pre-incubated in 1% 
rabbit and horse serum and then incubated for 60 min with goat anti CD-31 and rabbit anti 
CD105 (1:100) antibodies at 370C. After gentle washes, the sections were incubated for 60 
min with donkey anti goat IgG - alexa 488 and goat anti mouse IgG – alexa 568 conjugated 
secondary antibodies. Permanent mounting media was used to fix the cover slips and 
analyzed in confocal microscopy with PMT voltage corresponding to 488 and 568 nm. 
8.17 In vivo TUNEL assay  
TUNEL assay was done with insitu cell death detection kit (Roche) as per the manufacturer’s 
protocol. Briefly, tumour sections were incubated in permeabilization solution (0.1% Triton 
X100 in 0.1% sodium citrate) after being fixed and washed with distilled water to remove 
OCT compound. The slides were then placed in a plastic jar containing 200 ml citrate buffer 
pH 6.0 and microwave irradiation was carried out for 30 sec. The slides were immersed for 
30 min at 15-200C in Tris HCl containing 3% BSA and 50 µl of TUNEL reaction mixture 
was added on to the section after gentle rinsing with PBS at 15-250C. The reaction mixture 
was incubated for 60 min at 370 C in order to develop the reaction and evaluated under 
confocal microscope, soon after mounting with permanent mounting media.  
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8.18 Estimation of intracellular iron by colorimetric method 
Tissues under investigation were lyophilized and lysate was homogenized with the milliQ 
water. The procedure for measuring iron saturation in the tissues was modified from the 
method described. Briefly, to 1ml of tissue homogenate or to the Fe-bLf (positive control), 50 
µl of ascorbic acid was added and mixed well to maintain iron in a reduced state. A sample 
without protein was taken as control and a series of standards were made with ferric 
nonahydrate. 100 µL of 65% trichloroacetic acid was added into each tube after 5 min to 
digest the bound proteins. The tubes were immediately covered with parafilm and shaken 
vigorously for 30 sec and allowed to stand for 10 min and centrifuged at 10,000 rpm for 20 
min. Following centrifugation, 500 µL of supernatant from each sample, iron standards and 
blank, were added into new eppendrof tubes containing 100 µL of alkaline acetate solution 
followed by the addition of 75 µL of tripyridyl solution, to obtain a colored product. The 
samples were mixed well and allowed to stand for a further 10 min. Absorbance was read at 
550 nm with an Asys Expert Plus microplate reader (Asys Hitech, Cambridge, UK). Iron 
concentration was determined by comparing the resulting absorbance values with the 
standard graph. 
8. 19. Real Time analysis of quantitative mRNA levels  
8.19.1 RNA extraction 
Total RNA was isolated from various tissues and cells by using a GenElute™ mammalian 
total RNA purification kit (Sigma-Aldrich), as per the manufacturer’s instructions. Briefly, 
250 µL of lysis solution was added to the cells/ 5 mg of homogenized tissues and mixed 
thoroughly. The lysates were then pipetted into GenElute filtration columns and centrifuged 
at 14000 rpm for 2 min to remove cellular debris. To get rid of debris in the filtrate, ethanol 
was added to each column and vortexed. GenElute binding columns were used to retain RNA 
in the lysates. The column was then washed with wash solution 1 and 2 to remove unwanted 
salts. The columns were then transferred into fresh collection tubes, RNA were eluted by 
adding elution buffer and centrifuged at 14000 rpm for 1 min. The purity of total RNA 
isolated from each treatment was calculated by the ratio of 260/280 nm and the concentration 
was calculated by reading the absorbance at 260 nm using the ASYS expert plus UV plate 
reader. 
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8.19.2. cDNA preparation  
From the calculated concentrations, 5 µg of total RNA having mRNA pool was used to obtain 
cDNA, using SuperScript III first strand synthesis system (Invitrogen) as per manufacturer’s 
instructions. Briefly, 1 µL of 50 µM oligo(dT) and 1 µL of 10 mM dNTP mix were added to 
the total RNA and the mixture was made up to 10 µL with nuclease-free water (Applied 
Biosystems, Scoresby, VIC, Australia). Tubes were incubated in Takara PCR thermal cycler 
(Scientifix, Cheltenham, Victoria, Australia) at 650C for 5 min, to be able to overcome 
secondary structures of the mRNA and then placed in ice for 1 min. The cDNA synthesis 
mixture (containing First strand buffer, DTT, RNase OUT and SuperScript III RT) was 
prepared and 10 µL was added to each tube. Tubes were mixed gently and collected by brief 
centrifugation. They were then incubated in PCR thermal cycler for 50 min at 500C, for the 
reverse transcription. Following incubation, reactions were terminated by incubating the 
tubes at 850C for 5 min and then allowed to chill on ice.  
 
8.19.3. Quantitative real time PCR  
Amplification of cDNA by qRT-PCR was performed according to the protocol given in the 
SybrGreen RT-PCR kit (BioRad). PCR reaction mixture for each cDNA synthesis was 
prepared and placed in the IQ5 Bio-Rad thermal cycler and the cycling started immediately. 
PCR conditions for the genes under investigation involved an annealing temperature as per 
Tm of the nucleotide sequences of the primers (Table 8.2). Samples were run in triplicate and 
a mean Ct value for triplicate samples was used for further calculations. The amount of 
mRNAs was normalized to an endogenous reference gene (GA3PDH) and expressed as n-
fold mRNA levels relative to the calibrator. The calibrator used was control tissue sample 
from the tissue collection, which is under study that was analyzed on every assay plate with 
unknown sample. Furthermore one specific normal tissue sample was included in each run as 
a control of the reproducibility among the experiments performed at different times. The 
amount of the target was defined by delta delta Ct method, where the target amount was 
represented by 2ln (-∆∆Ct). 
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Table: 8.2    Primer sequences for amplified genes 
Name Forward primer sequences  Reverse primer sequences Annealing
temp 
Reference 
LRP1 5’ATCGTGCCGCGAGTATGC
CG3’ 
5’GTGTGGCGCGTGATGGTGG
A 3’ 
52 (Demeule et al., 
2008) 
LRP2 5’CCAAGTTGCTATTCGTGG
G 3’ 
5’GCACCCAGTCTCCAGTCAG 
3’ 
52 (Demeule et al., 
2008) 
GA3PDH 5’CCATCACCATCTTCCAGGA
G3’ 
5’CCTGCTTCACCACCTTCTTG3
’ 
52 (Demeule et al., 
2008) 
Survivin 5’CCACCGCATCTCTACATTC
A 3’ 
5’TATGTTCCTCTATGGGGTCG 
3’ 
50 (Kim et al., 2011) 
Bax 5’GGCCCACCAGTCCTGAGC
AGA 3’ 
5’GCCACGTGGGCGTCCCAAA
GT 3’ 
55 (Nilkaeo and 
Bhuvanath, 2006) 
Bcl2 5’TTCTTTGAGTTCGGTGGG
GTC 3’ 
5’TGCATATTTGTTTGGGGCAG
G 3’ 
57 (Zhang et al., 2011) 
Caspase 3 5’CTCGGTCTGGTACAGATG
TCG 3’ 
5’GGTTAACCCGGGTAAGAAT
GTGCA3’ 
55 (Deligezer et al., 
2006) 
Caspase 8 5’GGGACAGGAATGGAACA
CAC 3’ 
5’CAGCAAGGGAAGGGCACTT
C3’ 
52 (Yu et al., 2008) 
Caspase 9 5’CTGCGAACTAACAGGCAA
GC 3’ 
5’CTAGATATGGCGTCCAGCT
G3’ 
52 (Yu et al., 2008) 
Fas 5’GAAGGACATGGTTTAGAA
GTG 3’ 
5’ACTTAGTGTCATGACTCCAG
C3’ 
55 (Roh et al., 2002) 
Fas-L 5’GGATTGGGCCTGGGGATG
TTTCA 3’ 
5’TTGTGGCTCAGGGGCAGGT
TGTTG3’ 
57 (Ryan et al., 2006) 
Tfr 5’TGTAGGCTGCCCATTGTA
AC-3’ 
5’CAGAATTCCCACACATCCAC
T-3’ 
52 (Herbison et al., 
2009) 
Tfr 1 5’CTC ACT TTA GAC AAT 
GCT GC 3’ 
5’CTCATGACACGATCATTGAG 
3’ 
50 (Kollia et al., 2003) 
Tfr 2 5’GGAGTGGCTAGAGGGCT
ACCTCA 3’ 
5’GGTCTTGGCATGAAACTTGT
CA 3’ 
53 (Kollia et al., 2003) 
 
8. 20 Statistical analysis 
Results are expressed as mean values ± S.D. of at least three experiments unless otherwise 
stated. For the statistical evaluation of numerical data, student’s t-test was used for evaluating 
the significance. The value of √ P<0.05 denotes statistical significance, whereas √√ P<0.005 
denotes results that are highly significant. 
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Chapter 9: Conclusions and future research options 
9.1 Conclusions  
Somatic or germinal cells with an altered expression of multiple genes and inflammatory 
modulators will be naturally selected as a cancer malformation, with increased survival 
advantage and an unreduced proliferative potential. With the current and predicted increase in 
cancer causalities and lack of solid impact in the mainstay cancer therapeutics, it is becoming 
increasingly important for scientists to find safe and effective alternative therapies. With the 
heightened evidence regarding the possible intervention of dietary nutraceuticals for anti-
cancer therapy in the recent past, is fascinating to use this natural, cost effective and safe 
medical care which warrants greater attention. Since the chronic inflammation is tightly 
linked with cancer, dietary agents that can suppress the inflammation could help in the 
prevention and treatment of cancer. Multiple cell signaling pathways that are affected during 
carcinogenesis could be effectively tackled using dietary agents that are derived from plant or 
animal origin such as curcumin and milk proteins to control several of these pathways. 
Nevertheless, quite a number of questions regarding the bioavailability and safety as well as 
the precise molecular targets of these dietary agents should be answered before using these 
nutraceuticals as part of cancer prevention or a treatment regime in the clinic. Moreover, 
combinatorial approach is an ideal method to combat the multi faced malice of 
carcinogenesis, which could be achieved by integration of various scientific fields such as 
advances in genetic engineering, bio-technology and nanotechnology. In this regard 100% 
iron saturated bovine lactoferrin, a chemically modified natural milk protein along with a 
genetically engineered dominant negative mutant of survivin have gained attention for use as 
anti-cancer therapeutics. Thus, the baseline of experiments in this study points towards 
feasibility for testing oral bio-availability of the aforementioned anti-cancer protein drugs 
using nanotechnology. Short comings of using these protein drugs were addressed by using 
nanotechnology.  
Oral drug delivery is the most preferred route of administration but a challenging area 
especially to deliver fragile biomolecules, which were implicated as alternative therapy. 
Thus, using nanomedical approach, oral administration of 100% Fe-bLf and Sur-R9-C84A, 
which are otherwise sensitive in the interior milieu, were tested for their efficiency towards 
the abolition of cancer. The major purpose of this study that was addressed in the dissertation 
is to test the bio-availability and anti-tumour efficacy of Fe-bLf after encapsulating it in the 
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ACSC NCs. This proof of concept was successfully tested in nude mice bearing colon and 
breast cancer xenograft tumours from human origin.  Along with Fe-bLf, Sur-R9-C84A, 
which was promised in cancer therapy, was tested for its in vitro anti-cancer efficacy after 
incorporated in the calcium phosphate ceramic cores coated with biodegradable chitosan and 
alginate polymers. To be able to address their bio-availability, a series of experiments 
involving in vitro and in vivo testing of the bio-activity of the protein loaded NCs were 
evaluated.  
Three main conclusions of this study are as follows:  
1. Fe-bLF/Sur R9-C84A retains their nativeness and structural configuration in the core 
of alginate encapsulated chitosan coated NCs after the formulation procedure. 
2. NCs loaded with therapeutic proteins show enhanced internalization and anti-cancer 
efficacy in the colon and breast cancer cell lines in vitro. 
3. Orally administered NCs in nude mice demonstrate 
i. In vivo anti- cancer ability as a proof-of-concept 
ii. No nanotoxicity and 
iii. Enhanced permeability and retention efficacy. 
Mechanism of internalization and induction of programmed cell death in the cancer cells by 
ACSC-Fe-bLf NCs is shown in the Figure 9.1. Therefore, these findings support the 
impending use of ACSC NC system as a step forward in the search of new generation 
nutraceutic system towards cancer therapy. More detailed conclusions from each study, 
which were subdivided in to 5 different chapters in this dissertation could be drawn as 
follows: 
1. Preparation and characterization of ACSC NC with native Lf  
Saturation of bLf with transition metal ions was shown to enhance its anti-cancerous 
properties. This could be attributed to the fact that fully saturated bLf was more stable 
than the native/ half saturated bLf, in the digestive tract. Thus, anti-cancerous efficacy 
of native bLf could be enhanced if it is encapsulated in the bio-degradable 
nanoformulations. Taking this into account, this study discussed some fundamental 
work that has been carried out in order to develop a novel nano delivery platform, 
which can carry native bLf saturated with moderate metal ions. In order to protect the 
protein, various biodegradable polymer layers were integrated on to the ceramic 
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cores, that was saturated with bLf, which was confirmed by DLS spectrometry and 
SEM. Various parameters were changed in order to obtain NCs with desired spherical 
morphology to lodge therapeutic proteins. In vitro protein release profiles over a time 
period and pH sustainability measurements indicated the protection of the cargo by 
alginate and chitosan polymers. This designates their use in providing a nanoplatform 
for the controlled release and a proper shielding of the protein drug under varying pH. 
The NCs were found to undergo endocytosis and transcytosis as indicated by flow 
cytometry and millicell experiments. Cell viability and apoptotic studies by annexin-v 
–PI staining and TUNEL assay have proved the proposed hypothesis that the native 
bLf loaded on to the NCs show an enhanced anti-cancer efficacy. Thus, this study has 
generated the hypothetic basis for the remaining chapters.  
2. Validation of bio-availability of the Sur R9-C84A after encapsulation in ACSC 
NCs  
The survivin mutant was found to play a role in promotion of apoptosis and its 
function and mechanism have been studied in various tumour types. The data suggest 
that the use of Sur R9-C84A deserves further investigation as a useful approach to 
cancer therapy, using polymeric ACSC NCs. Size of the NCs was further reduced by 
protocol modifications with altered concentrations of chitosan and alginate as 
confirmed by DLS spectrometry and SEM with the sizes of NCs ranging from 322.1± 
22.6 nm. In vitro protein release profiles over a time period and enzymatic 
sustainability measurements proved the protection of encapsulated protein by alginate 
matrix in the microcosm of gastrointestinal milieu. The NCs were found to undergo 
endocytosis within 1 h as indicated by flow cytometry and confocal microscopy, 
which contribute towards their enhanced cytotoxicity. Downregulation of endogenous 
survivin at gene level as well as the protein level suggest the possible mechanism of 
action by enhancing the intrinsic pathway of apoptosis. However, a clear-cut 
mechanism of downregulation of endogenous survivin by using Sur R9-C84A or Fe-
bLf is not clear and needs to be explored further. These findings indicate the potential 
of using these SurR9-C84A nanocarriers as a new therapeutic strategy for cancer 
treatment. 
3. Combination Sur R9-C84A and Fe-bLf loaded on ACSC NCs 
The anti-cancer proteins Fe-bLf and SurR9-C84A were known for their role in 
promotion of apoptosis and its benefits when used in combinatorial therapy. Fe-bLf 
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and SurR9-C84A, adsorbed on the ceramic cores were entrapped in ACSC NCs to 
boost their bio-availability. In vitro protein release profiles over a time period showed 
controlled release profiles; FTIR and DSC experimental data indicated the structure 
and chemical bonding pattern in the NCs with chitosan and alginate forming a coat 
over the inner ceramic core. TGA analysis further confirmed the arrangement of 
various polymeric layers in the nanocarriers by means of phase transformations. CSC-
FS NCs with a combination of proteins have shown enhanced cytotoxicity to the 
cancer cells. This enhanced cytotoxicity could be attributed to improved endocytosis 
profiles, where the NCs were internalized more competently as indicated by flow 
cytometry and confocal microscopy. Endocytosis studies using early and late 
endosomal markers (EEA1 and LAMP1) have indicated the functional mechanism of 
internalization for CSC-FS NCs in the cancer cells by means of endosomal pathway. 
Furthermore, mitochondrial membrane depolarization studies showed an altered 
membrane potential with the use of CSC-FS NCs, which indicates the activation of 
intrinsic mitochondrial pathway for a mechanistic action for the promotion of cell 
death. Thus, the use of Fe-bLf and survivin R9-C84A deserves further investigation as 
a useful approach to cancer therapy, using polymeric ACSC NCs. 
4. In vivo anti-tumour efficacy of ACSC NCs with Fe-bLf in human colon cancer 
model 
This chapter is the theme for the entire dissertation and is a continuation for a 
previous patented study, wherein 100% iron saturated bLf was shown to potentiate 
anti-tumour efficacy of chemotherapeutics. Fe-bLf can be incorporated in suitable 
edible consumer products such as ice creams, yoghurts, muesli bars and cheeses 
(Kanwar, 2010). Various protecting aids such as anti-oxidants can be employed in 
order to defend the protein configuration for the storage. Herein, to be able to further 
enhance anti-tumour efficacy and bioavailability of Fe-bLf, nanotechnology was used 
as an innovative tool. In order to protect the protein, various biodegradable polymer 
layers were integrated on to the Fe-bLf loaded ceramic nano cores, which was 
confirmed by the spectroscopic and microscopic techniques. In vitro cytotoxicity 
indicates the enhanced and more efficient anti-cancer activity. As a proof of concept, 
this nanoformulation was tested in C57BalbC nu/nu xenograft bearing human colon 
cancer cells. In vivo data with respect to nanotoxicity, using a xenograft model of 
nude mice, FTIR and tissue pathology designate a safe and biocompatible nature of 
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these NCs. Bio-distribution studies showed enhanced uptake of the NCs by intestine 
and tumour tissues along sides a sparse presence in RES organs indicating the 
biodegradability of the NCs. EPR efficacy of the NCs was observed in tumour tissues 
as observed by Prussian blue and CD-31 double staining. In vivo promotion of 
apoptosis and anti-angiogenic nature opens for the possible new objectives in order to 
carry further studies related to the profound molecular mechanisms that could be 
manipulated by this NCs. LRP receptor mRNA was shown to be upregulated in the 
tissues of treatment group, showing a possible internalization using these receptors. 
Furthermore, down regulation of anti-apoptotic genes were observed in treatment 
group in comparison to the control group. Future experiments related to insights of 
up/down regulation of angiogenic mediators and inhibitors could suggest a clear 
mechanistic view of the anti-cancerous nature of these novel nanocarriers.  
5. In vivo oral nutraceutic drug delivery for breast cancer therapy using nano Fe-
bLf  
With current and predicted increase in breast cancer causalities, it is becoming 
increasingly important for scientists to find safe and effective alternative therapies. 
Gastro intestinal resistibility of Fe-bLf was improved by incorporating it in the ACSC 
nanoformulation and successfully tested in a proof of concept study using colon 
cancer xenograft mice model. Further, building on the previous work, this study 
innovatively addressed combination of potential therapies which includes 
nanotechnology and alternative medicine to combat breast cancer. Fe-bLf loaded 
ACSC NCs were evaluated for their in vitro anti-cancerous nature in the MDA-MB-
231 breast cancer cell line, along sides testing the internalization of the NCs. There 
was a phenomenal increase in the anti proliferative efficacy of the ACSC- Fe-bLf 
NCs as reported by CyQUANT and MTT cell proliferation and cell viability assays, 
respectively. In vivo data with respect to nano toxicity, using the xenograft model of 
human breast cancer in nude mice, and tissue pathology designate safe and 
biocompatible nature of these NCs. The NCs were proved to be incredibly anti- 
tumorigenic based on the fact that none of the mice injected with breast cancer cells 
developed tumours. Biodistribution profiles based on immunohistochemical studies 
prove the bio-degradability of the NCs in the different tissues of the body. Iron uptake 
studies in various organs was analyzed based on spectroscopic and Prussian blue 
methods demonstrated a slight increase in iron in the organs including liver, spleen, 
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intestine and brain. Quantitative real time study for the gene expression showed a 
noticeable increase in the expression levels of LRP and Tfr receptors in case of 
intestine, liver and brain tissues.  Finally, a novel new generation targeted approach 
could enhance further anti-tumour efficacy alongside benefiting Australian 
agricultural and dairy sectors as a nanoformulation therapy by inflating the raw 
material for industrial production. 
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Figure 9.1: Functional mechanism of Fe-bLf loaded ACSC NCs based on the findings in the 
proof of concept study with colon cancer xenograft. Since bLf is a ligand for transferrin and 
LRP receptors, the CSC-Fe-bLf NCs that are released from ACSC-Fe-bLf NCs in the 
intestine are endocytosed in to the cancer cells, after binding to these receptors. This could be 
possible by using Fe-bLf epitopes that are partially exposed from the chitosan layer, by its 
slow dissolution in the acidic pH offered by the tumour tissue. Further control release of Fe-
bLf from the NCs executes the anti-tumour efficacy by interfering with molecular 
mechanisms involved in the cellular apoptosis. Downregulation of anti-apoptotic genes and 
up regulation of pro-apoptotic genes are found to be the profound mechanisms as described in 
the chapter 6 and chapter 7. Since Fe-bLf could act as immunomodulatory molecule, 
integration of extrinsic and intrinsic pathways of apoptosis leads to enhanced cytotoxicity in 
the cancer cells.       
 
 
 
209 
 
 
Salient characteristics of various NCs are tabulated as below. 
Table 9.1 Comparison of physicochemical and biological characters among various NCs. 
Characteristics ACSC Lf NCs 
(with native bLf) 
ACSC Sur 
NCs 
ACSC FS NCs ACSC – FebLf 
NCs 
Size 379 ± 27.2nm 322 ± 22.6nm 318 ± 23.3nm 322± 27.2nm 
Encapsulating 
efficacy 
80% 87% 82% 80% 
Loading efficacy 19.3% 22.3% 21.5% 19.5% 
Cytotoxicity 
(20h with 1x106 
NC)  
44.7% 64.83% 65.8% 68% 
Internalization 
efficacy(2.8x105 
NCs) 
72.2 ± 7.2% 82 ± 2.7 % 83± 4.7 % 86.6 ± 2.25 % 
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9.2 Recommendations for future research: 
This study has addressed a few important observations which could be used for a variety of 
disorders other than just cancer. In chapter 6 (Section 6.2.8) bio-distribution profiles have 
shown that there was NC internalization in the brain, bone tissue and eye, as represented by 
mild immunoreactivity along with the other organs including kidney, liver, tumour and 
intestine, in the Western blots. On a positive note, this phenomenon could have implications 
in treatment of disorders that are particular to these organs. For example,   neurodegenerative 
disorders are a group of disorders associated with abnormalities in the brain. These diseases 
pose serious challenges as they represent nearly 35% of the burden about all other general 
disorders (Heemels, 2006).  Chemotherapeutic drugs have been in use for neurodegenerative 
diseases (NDDs) such as Alzheimer’s and Parkinson’s disease. However, they are far from 
being ideal in the sense that 98% of these drugs are unable to cross the blood brain barrier 
(BBB) efficiently and a promising technique is required further for efficient therapy of these 
diseases (Pardridge, 2003). In this regard, nanotechnology provides a new hope in designing 
new therapeutics by using colloidal carriers (Bhaskar et al., 2010). As discussed in chapter 1, 
nanocarrier drug delivery involves targeting drugs enclosed in a particular polymer and/or 
amphiphilic lipids, with advantages such as controlled release, nanoplatform availability for 
combinatorial therapy and tissue specific targeting by using advanced technologies such as 
molecular trojan horse (MTH) technology (Kanwar et al., 2009b). Furthermore, anti-cancer 
protein SurR9-C84A, that has been discussed in this study has previously been tested for its 
dual role with an additional neuroproliferative effect in vitro (Baratchi et al., 2010a), which 
could offer potential benefits to treat NDDs, when incorporated in the nanoformulations. 
Thus, ACSC NCs encapsulating therapeutic moieties could be surface modified with 
surfactants such as polyvinyl alcohol, polyethylene glycol or polybutyrate cyanoacrylates in 
order to increase their internalization in the BBB. The same technology could be used to 
cross blood retinal barrier to cure disorders related to eye such as retinoblastoma and corneal 
haze (Kanwar et al., 2010c).  
Similarly, as the study was aimed at using nutraceuticals for combating cancer to tackle the 
chronic inflammation, other  chronic inflammatory diseases such as arthritis could be 
targeted. Ongoing study in our lab has suggested that the bovine lactoferrin could induce 
chondro proliferative, anti-inflammatory and signaling pathways (unpublished data). Taking 
these results together with localization of the NCs in bone joints, a targeted anti-arthritic 
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nanoformulation could be achieved. As represented in Fig 9.2, integration of more bio 
macromolecules on the nanocarriers make the system more esteemed for anti-cancer therapy.  
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Figure 9.2: Diagrammatic representation of trancytosis and absorption of orally delivered ACSC- 
Fe-bLf NCs and antibody to cancer specific ligand targeted CPP- siRNA –ACSC NCs (Left panel).  
Right panel shows internalization of (a) Fe-bLf Loaded ACSC NCs (b) CPPs linked to SurR9-C84A, 
survivin siRNA, oncogenic antisense microRNA-27a loaded on to ACSC NCs; along with (c) 
Nutraceutical loaded targeted NCs with antibody to cancer specific ligand and (d) Aptamer loaded 
NCs – into cancer cells. The figure shows ACSCs were protected from various gastric enzymes in 
vitro and in vivo based on surface modification by chitosan (yellow) and alginate (orange). After 
transcytosis from the gut cells and subsequent endocytosis into the tumour tissue, anti-cancer bio-
macromolecules embedded in the nanocore silences key cell cycle regulators there by eliminating the 
tumour. 
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The functional mechanism of internalization for the NCs seems to be mediated by 
LRP/transferrin receptors in vivo as suggested by real time PCR analysis. However, more 
detailed insights into the molecular targets and the pathway of apoptotic responses could be 
deeply investigated to be able to draw clear mechanistic insights into the anti-tumour efficacy 
of the NCs. Although, passive targeting was successful in case of anti-cancerous 
nanoformulations based on EPR effect, active targeting enhances drug retention in the target 
of interest. Thus, these NCs could further be used as targeted delivery vehicles with 
combinatorial addition of anti-cancer miRNA/siRNA along with active targeting moieties by 
labeling with tumour specific ligands such as antibodies or aptamers.  
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